# VaccineNation

> Generated by All in One SEO v5.0.2.1, this is an llms.txt file, used by LLMs to index the site.

Strategy & Innovation in Vaccines

## Sitemaps

- [XML Sitemap](https://vaccinenation.org/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Microneedle technology wins Gates grants of $6.6 million](https://vaccinenation.org/technology/microneedle-technology-wins-gates-grants-of-6-6-million/): The University of Connecticut (UConn) announced in October 2024 that associate Professor Thanh Nguyen’s research has received “significant”
- [IFFIm: $1 billion to support global vaccine programmes](https://vaccinenation.org/global-health/iffim-1-billion-to-support-global-vaccine-programmes/): In October 2024 the International Finance Facility for Immunisation (IFFIm) priced a US$1 billion, 3-year fixed-rate bond to fund “critical vaccine
- [Study: vaccinating children against mpox “most efficient”](https://vaccinenation.org/global-health/study-vaccinating-children-against-mpox-most-efficient/): A study in The Lancet Global Health sought to provide counterfactual scenarios to evaluate the short-term effects of different vaccination strategies
- [UK begins Phase III trial of mRNA norovirus vaccine](https://vaccinenation.org/technology/uk-begins-phase-iii-trial-of-mrna-norovirus-vaccine/): The National Institute for Health and Care Research (NIHR) announced in October 2024 that the first Phase III randomised trial of an investigational
- [WHO declares Egypt malaria-free after 100-year effort](https://vaccinenation.org/global-health/who-declares-egypt-malaria-free-after-100-year-effort/): In October 2024 WHO certified Egypt as malaria-free after a “nearly 100-year effort” by the government and people to end the disease. WHO described
- [Bacterial vectors for precision cancer vaccine development](https://vaccinenation.org/therapeutic/bacterial-vectors-for-precision-cancer-vaccine-development/): Research in Nature in October 2024 leverages evidence that bacteria “naturally home in on tumours and modulate antitumour immunity” to explore
- [Global Polio Eradication Initiative faces challenges](https://vaccinenation.org/global-health/global-polio-eradication-initiative-faces-challenges/): The Global Polio Eradication Initiative (GPEI) announced the “difficult decision” to extend the timelines needed to achieve polio eradication.
- [The Vaccine Group and APHA secure animal vaccine grant](https://vaccinenation.org/technology/the-vaccine-group-and-apha-secure-animal-vaccine-grant/): In October 2024 the Animal and Plant Health Agency (APHA) and The Vaccine Group (TVG) announced that Innovate UK has awarded them a Smart
- [Valneva and LimmaTech secure Shigella vaccine fast track](https://vaccinenation.org/technology/valneva-and-limmatech-secure-shigella-vaccine-fast-track/): Valneva and LimmaTech Biologics announced in October 2024 that they have been granted Fast Track designation by the United States FDA for Shigella4V
- [Modelling study: 100 Days Mission demands vaccine equity](https://vaccinenation.org/global-health/modelling-study-100-days-mission-demands-vaccine-equity/): A study in The Lancet Global Health estimates the impact that the 100 Days Mission could have had on the COVID-19 pandemic. The authors
- [Parliamentarians support Pandemic Agreement efforts](https://vaccinenation.org/global-health/parliamentarians-support-pandemic-agreement-efforts/): In October 2024, parliamentarians from across the world met at the UNITE Global Summit in Berlin to sign a statement in support of the WHO Pandemic Agreement
- [CEPI and NRC work on safe protein antigens, faster](https://vaccinenation.org/technology/cepi-and-nrc-work-on-safe-protein-antigens-faster/): CEPI announced in October 2024 that it is working with experts at the National Research Council of Canada (NRC) to bioengineer a “commonly
- [NeoDisc pipeline enables personalised cancer immunotherapy](https://vaccinenation.org/technology/neodisc-pipeline-enables-personalised-cancer-immunotherapy/): A paper in Nature Biotechnology in October 2024 presents an “end-to-end clinical proteogenomic pipeline” to address the challenges associated
- [Panthera joins Parexel’s Site Alliance Vaccine Network](https://vaccinenation.org/technology/panthera-joins-parexels-site-alliance-vaccine-network/): In October 2024, Panthera Biopartners announced that Parexel has confirmed its inclusion in the Parexel Site Alliance Vaccine Network.
- [Study highlights facial palsy link to COVID-19 vaccines](https://vaccinenation.org/global-health/study-highlights-facial-palsy-link-to-covid-19-vaccines/): A study in Emerging Infectious Diseases explores the association between COVID-19 vaccination and facial palsy (FP) in South Korea. The authors
- [“Promising” Rift Valley vaccine enters Phase II in Kenya](https://vaccinenation.org/global-health/promising-rift-valley-vaccine-enters-phase-ii-in-kenya/): Phase II trials of a “promising” human vaccine candidate against Rift Valley fever are beginning in Kenya with CEPI support. CEPI reported in October 2024
- [Transgene shares “disappointing” TG4001 study update](https://vaccinenation.org/therapeutic/transgene-shares-disappointing-tg4001-study-update/): Transgene announced in October 2024 that the primary objective of its randomised Phase II study of TG4001 has not been met. The study was evaluating
- [EIB Global supports Akagera Medicines with €2 million](https://vaccinenation.org/global-health/eib-global-supports-akagera-medicines-with-e2-million/): In October 2024 the European Investment Bank (EIB Global) announced €2 million financing for early-stage vaccine development in Rwanda by Akagera Medicines
- [SK bioscience announces $3 million investment in FinaBio](https://vaccinenation.org/technology/sk-bioscience-announces-3-million-investment-in-finabio/): SK bioscience announced in October 2024 that it has signed an agreement to acquire a stake in Fina Biosolutions (FinaBio) with a $3 million investment.
- [CEPI and CIDRAP advance coronavirus vaccine R&D roadmap](https://vaccinenation.org/technology/cepi-and-cidrap-advance-coronavirus-vaccine-rd-roadmap/): CEPI announced in October 2024 that the Centre for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota is to receive US$3.2
- [NIH funding for Orlance Enhanced Seasonal Influenza Vaccine](https://vaccinenation.org/technology/nih-funding-for-orlance-enhanced-seasonal-influenza-vaccine/): Orlance, Inc., announced in October 2024 that it has been awarded a National Institutions of Health (NIH) Fast Track Small Business Innovation Research
- [Study: TCV protects children against typhoid but declines](https://vaccinenation.org/global-health/study-tcv-protects-children-against-typhoid-but-declines/): A study in The Lancet in October 2024 finds that a single dose of typhoid conjugate vaccine (TCV) offers safe and effective protection against typhoid two
- [AMR report: vaccines could reduce antibiotics needed by 22%](https://vaccinenation.org/global-health/amr-report-vaccines-could-reduce-antibiotics-needed-by-22/): A WHO report in October 2024 suggests that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% every year.
- [WHO, IMF, and WBG agree on pandemic preparedness principles](https://vaccinenation.org/global-health/who-imf-and-wbg-agree-on-pandemic-preparedness-principles/): In October 2024, WHO announced an agreement with the International Monetary Fund (IMF) and the World Bank Group (WBG) on “broad principles
- [Wellcome funding to overcome AMA capacity challenges](https://vaccinenation.org/global-health/wellcome-funding-to-overcome-ama-capacity-challenges/): The African Union Development Agency – New Partnership for Africa’s Development (AUDA-NEPAD) announced in October 2024 that Wellcome
- [Three human cases of H5 bird flu reported in California](https://vaccinenation.org/infection/three-human-cases-of-h5-bird-flu-reported-in-california/): In October 2024, the United States CDC reported a third human case of H5 bird flu in the state of California. This announcement followed the identification
- [GSK’s Arexvy offers protection for 3 RSV seasons](https://vaccinenation.org/global-health/gsks-arexvy-offers-protection-for-3-rsv-seasons/): GSK announced in October 2024 that data from the AreSVI-006 (Adult Respiratory Syncytial Virus) Phase III trial of Arexvy indicate that a single dose
- [CEPI funding for University of Sheffield’s RNAbox process](https://vaccinenation.org/technology/cepi-funding-for-university-of-sheffields-rnabox-process/): In October 2024, CEPI announced that it is awarding funding of up to £3.7 million to support researchers at the University of Sheffield as they seek
- [Adult vaccination in the EU: report finds disparities](https://vaccinenation.org/global-health/adult-vaccination-in-the-eu-report-finds-disparities/): A report from Coalition for Life Course Immunisation (CLCI) considers the financial and policy frameworks of various National Immunisation Programmes
- [WHO mpox update: 14 countries in “active” outbreaks](https://vaccinenation.org/infection/who-mpox-update-14-countries-in-active-outbreaks/): A recent WHO situation report on the mpox PHEIC reveals that 14 countries on the continent have reported mpox cases in the last six weeks and are
- [Study: cancer vaccine could tackle lesions if used early](https://vaccinenation.org/therapeutic/study-cancer-vaccine-could-tackle-lesions-if-used-early/): A study in the Journal for ImmunoTherapy of Cancer finds that vaccination in a clinically relevant genetic cancer mouse model generated a population
- [Gavi celebrates life-saving efforts in 2023 Progress Report](https://vaccinenation.org/global-health/gavi-celebrates-life-saving-efforts-in-2023-progress-report/): Gavi shared the 2023 Annual Progress Report in October 2024, highlighting that more than 1.3 million future deaths were averted in 2023 through
- [WHO confirms HPV vaccine Cecolin for single-dose schedule](https://vaccinenation.org/technology/who-confirms-hpv-vaccine-cecolin-for-single-dose-schedule/): In October 2024, WHO announced that a fourth WHO-prequalified human papillomavirus (HPV) vaccine product, Cecolin, has been confirmed
- [DRC begins mpox vaccination drive with donated doses](https://vaccinenation.org/global-health/drc-begins-mpox-vaccination-drive-with-donated-doses/): WHO Africa reported in October 2024 that the Democratic Republic of the Congo (DRC) has started a vaccination campaign as part of outbreak
- [Rallying around Rwanda: Marburg vaccines delivered](https://vaccinenation.org/global-health/rallying-around-rwanda-marburg-vaccines-delivered/): A week after the declaration of a Marburg outbreak in Rwanda in September 2024, Sabin Vaccine Institute announced that it is providing doses
- [Vaxart initiates sentinel cohort for Phase IIb study](https://vaccinenation.org/technology/vaxart-initiates-sentinel-cohort-for-phase-iib-study/): In September 2024, Vaxart announced the initiation of the sentinel cohort of its Phase IIb clinical trial evaluating the oral pill COVID-19 vaccine
- [OvarianVax project secures Cancer Research UK funding](https://vaccinenation.org/global-health/ovarianvax-project-secures-cancer-research-uk-funding/): The University of Oxford announced in October 2024 that scientists working on ‘OvarianVax’ a vaccine to encourage the immune system to “recognise and attack
- [WHO launches SPRP for Aedes-borne arboviruses](https://vaccinenation.org/global-health/who-launches-sprp-for-aedes-borne-arboviruses/): WHO announced in October 2024 that it is launching the Global Strategic Preparedness, Readiness, and Response Plan (SPRP) to tackle dengue
- [As Rwanda’s Marburg outbreak worsens, Hamburg sounds alarm](https://vaccinenation.org/infection/as-rwandas-marburg-outbreak-worsens-hamburg-sounds-alarm/): After the announcement of an outbreak of Marburg virus in Rwanda in September 2024 and the initiation of response efforts, reports of suspected
- [SK bioscience completes IDT Biologika acquisition](https://vaccinenation.org/technology/sk-bioscience-completes-idt-biologika-acquisition/): In October 2024, SK bioscience announced the successful completion of its acquisition of a controlling stake in IDT Biologika. This follows the announcement
- [Lassa fever study expands disease symptoms investigation](https://vaccinenation.org/global-health/lassa-fever-study-expands-disease-symptoms-investigation/): In October 2024, CEPI announced the expansion of research into Lassa fever in West Africa in a “pioneering study” to explore the variation in disease symptoms
- [Gritstone’s data “encouraging”, but are they enough?](https://vaccinenation.org/therapeutic/gritstones-data-encouraging-but-are-they-enough/): Interim Phase II data from Gritstone bio’s study evaluating GRANITE in September 2024 are described as “encouraging” in a company statement.
- [DNA vaccines show promise against multiple myeloma](https://vaccinenation.org/therapeutic/dna-vaccines-show-promise-against-multiple-myeloma/): In an article for npj vaccines in October 2024, researchers present their investigation into the efficacy of a combination of DNA vaccine encoding mouse GPRC5D
- [Study of mRNA transfer programme hub finds weaknesses](https://vaccinenation.org/global-health/study-of-mrna-transfer-programme-hub-finds-weaknesses/): A study in PLOS Global Health in September 2024 compares the WHO and Medicines Patent Pool (MPP) mRNA technology transfer programme
- [Money matters at UNGA: Gavi’s funding updates](https://vaccinenation.org/global-health/money-matters-at-unga-gavis-funding-updates/): Gavi announced two major funding updates at the United Nations General Assembly High-level week 2024, revealing that it is making progress
- [Grant to support leptospirosis vaccine development efforts](https://vaccinenation.org/global-health/grant-to-support-leptospirosis-vaccine-development-efforts/): The University of Connecticut announced in September 2024 that a $3.8 million R01 grant from the National Institute of Allergy and Infectious Diseases (NIAID)
- [Rwanda reports its first Marburg outbreak with six deaths](https://vaccinenation.org/infection/rwanda-reports-its-first-marburg-outbreak-with-six-deaths/): In September 2024 WHO’s Regional Office for Africa announced that Rwandan health authorities are “intensifying outbreak control efforts” after detecting Marburg
- [UK and US urge vaccination as influenza data revealed](https://vaccinenation.org/global-health/uk-and-us-urge-vaccination-as-influenza-data-revealed/): In response to recent data on influenza-associated deaths in the United Kingdom and United States, experts from the UKHSA and the CDC are urging
- [An unlikely duo? WHO and TikTok partner on health content](https://vaccinenation.org/global-health/an-unlikely-duo-who-and-tiktok-partner-on-health-content/): WHO and TikTok announced a year-long collaboration to provide “reliable, science-based health information” in September 2024. The partnership
- [Study explores waning MMR immunity and measles outbreaks](https://vaccinenation.org/global-health/study-explores-waning-mmr-immunity-and-measles-outbreaks/): A study in The Lancet Public Health in September 2024 evaluates the measles dynamics in England between 2010 and 2019 to understand the effects
- [$4.2 million grant supports CMV vaccine development](https://vaccinenation.org/global-health/4-2-million-grant-supports-cmv-vaccine-development/): A $4.2 million Programme Project Grant renewal from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID)
- [Vaccine delivery vehicle to improve access in Samoa](https://vaccinenation.org/technology/vaccine-delivery-vehicle-to-improve-access-in-samoa/): UNICEF announced in September 2024 that it is working with Australia and Samoa to improve access to vaccinations in Samoa. To this end, an innovative
- [IAVI and Africa CDC sign MoU to protect against disease](https://vaccinenation.org/global-health/iavi-and-africa-cdc-sign-mou-to-protect-against-disease/): In September 2024 Africa CDC and IAVI announced the signing of a Memorandum of Understanding (MoU) to enhance the continent’s capacity to fight
- [Thought leader: CEPI steps up with new Biosecurity Strategy](https://vaccinenation.org/global-health/thought-leader-cepi-steps-up-with-new-biosecurity-strategy/): At the United Nations General Assembly High-Level Week in September 2024, CEPI launched a new Biosecurity Strategy to bolster global health security
- [Anixa plans Phase II study for breast cancer vaccine](https://vaccinenation.org/therapeutic/anixa-plans-phase-ii-study-for-breast-cancer-vaccine/): Anixa Biosciences announced a strategic plan for a Phase II study of its breast cancer vaccine in September 2024. The proposed trial follows a Phase I
- [Study shows PCPs struggle to change patient vaccine beliefs](https://vaccinenation.org/global-health/study-shows-pcps-struggle-to-change-patient-vaccine-beliefs/): A study in Patient Education and Counselling explores the experiences of primary care physicians (PCPs) with vaccine-hesitant patients in the hope
- [MSD Animal Health expands NOBIVAC NXT platform for cats](https://vaccinenation.org/technology/msd-animal-health-expands-nobivac-nxt-platform-for-cats/): MSD Animal Health announced in September 2024 that it is expanding the newly USDA-approved NOBIVAC NXT vaccine platform to include a best-in-class
- [Evaxion launches enhanced AI-Immunology platform](https://vaccinenation.org/technology/evaxion-launches-enhanced-ai-immunology-platform/): Evaxion Biotech announced the launch of an enhanced version of its clinically validated AI-Immunology platform in September 2024, with an update
- [WHO and partners launch AAM for mpox countermeasures](https://vaccinenation.org/global-health/who-and-partners-launch-aam-for-mpox-countermeasures/): In September 2024 WHO announced the establishment of an access and allocation mechanism for mpox medical countermeasures, including vaccines
- [WHO: progress on pandemic agreement negotiations](https://vaccinenation.org/global-health/who-progress-on-pandemic-agreement-negotiations/): In September 2024, WHO described “significant progress” on government-led negotiations on a pandemic agreement after another round of discussions.
- [Next-gen vaccines: Vicebio announces financing and study](https://vaccinenation.org/technology/next-gen-vaccines-vicebio-announces-financing-and-study/): Vicebio announced $100 million Series B financing and the initiation of a Phase I clinical study of RSV/hMPV bivalent vaccine in September 202
- [Self-administered FluMist secures FDA approval](https://vaccinenation.org/technology/self-administered-flumist-secures-fda-approval/): In September 2024 the United States FDA announced the approval of FluMist for self- or caregiver-administration. It is approved for active immunisation
- [EMA expansion of MVA-BN has implications for global response](https://vaccinenation.org/global-health/ema-expansion-of-mva-bn-has-implications-for-global-response/): In September 2024, the European Medicines Agency (EMA) announced its recommendation to extend the indication of the smallpox and mpox
- [Japan and DRC agree on Lc16 mpox vaccine donations](https://vaccinenation.org/global-health/japan-and-drc-agree-on-lc16-mpox-vaccine-donations/): In September 2024, Africa CDC offered congratulations to the Governments of Japan and the Democratic Republic of the Congo (DRC) for their agreement
- [Chikungunya in India has a “notorious edge this year”](https://vaccinenation.org/infection/chikungunya-in-india-has-a-notorious-edge-this-year/): The Times of India reported in September 2024 that cases of chikungunya in children were symptomatic of a “shift” in epidemiology. Case numbers
- [Brenus Pharma raises funds for STC cancer research](https://vaccinenation.org/therapeutic/brenus-pharma-raises-funds-for-stc-cancer-research/): In September 2024, Brenus Pharma announced the completion of a $25 million Series A financing round and receipt of non-dilutive funding to take the STC-1010
- [Study pits recombinant DNA against IVT mRNA technologies](https://vaccinenation.org/technology/study-pits-recombinant-dna-against-ivt-mrna-technologies/): An article in Scientific Reports in September 2024 uses Digital Shadows to facilitate a comparison of recombinant DNA and in vitro (IVT) mRNA
- [Global Fund to support DRC with $9.5 million against mpox](https://vaccinenation.org/global-health/global-fund-to-support-drc-with-9-5-million-against-mpox/): The Global Fund to Fight AIDS, Tuberculosis, and Malaria (the Global Fund) announced in September 2024 that it is responding to a request from the government
- [PharmaJet and Scancell partner on Stratis for DNA vaccine](https://vaccinenation.org/technology/pharmajet-and-scancell-partner-on-stratis-for-dna-vaccine/): PharmaJet announced in September 2024 that it has entered a long-term license and supply agreement with Scancell Holdings to use PharmaJet’s
- [Gavi funds APA for 500,000 MVA-BN doses for Africa](https://vaccinenation.org/global-health/gavi-funds-apa-for-500000-mva-bn-doses-for-africa/): In September 2024, Gavi and Bavarian Nordic announced an advance purchase agreement (APA) to secure 500,000 doses of MVA-BN mpox vaccine
- [MinervaX and Wacker Biotech collaborate on GBS vaccine](https://vaccinenation.org/technology/minervax-and-wacker-biotech-collaborate-on-gbs-vaccine/): MinervaX and Wacker Biotech announced a collaboration to manufacture active protein ingredients for MinervaX’s Group B Streptococcus (GBS) vaccine
- [NHS urges childhood vaccination as data show low coverage](https://vaccinenation.org/global-health/nhs-urges-childhood-vaccination-as-data-show-low-coverage/): A statistical report from UKHSA and NHS England in September 2024 reveals a drop in childhood vaccination coverage in England in 2023-2024.
- [Polio campaign in Gaza reaches around 560,000 children](https://vaccinenation.org/global-health/polio-campaign-in-gaza-reaches-around-560000-children/): The first round of an emergency polio vaccination campaign in the Gaza Strip reached around 560,000 children under ten between 1st and 12th September 2024.
- [Plug-and-play: PROVIDENT consortium receives NIAID funding](https://vaccinenation.org/technology/plug-and-play-provident-consortium-receives-niaid-funding/): Albert Einstein College of Medicine announced receipt of a five-year grant worth $14 million a year from the National Institute of Allergy and Infectious Diseases
- [HPV vaccines: Angola arms itself against cervical cancer](https://vaccinenation.org/global-health/hpv-vaccines-angola-arms-itself-against-cervical-cancer/): WHO Africa announced in September 2024 that more than 1,400,000 doses of human papillomavirus (HPV) vaccine have arrived in Angola as part
- [IO Biotech: "promising” Phase II data for cancer candidate](https://vaccinenation.org/therapeutic/io-biotech-promising-phase-ii-data-for-cancer-candidate/): In September 2024, IO Biotech announced “promising” data from its Phase II basket trial of IO102-IO103 in combination with Merck’s anti-PD-1
- [“Deliberate ignorance” predicted vaccine refusal in study](https://vaccinenation.org/global-health/deliberate-ignorance-predicted-vaccine-refusal-in-study/): A paper in npj vaccines in September 2024 explores the significance of “biased processing” of information relating to vaccines in addressing vaccine hesitancy
- [Investigational mRNA vaccine has promise in cancer trial](https://vaccinenation.org/therapeutic/investigational-mrna-vaccine-has-promise-in-cancer-trial/): King’s College London shared in September 2024 that an mRNA cancer immunotherapy (mRNA-4359), targeted for patients with lung cancer,
- [WHO prequalification for Bavarian Nordic’s MVA-BN](https://vaccinenation.org/technology/who-prequalification-for-bavarian-nordics-mva-bn/): In September 2024, WHO announced that the MVA-BN vaccine, manufactured by Bavarian Nordic, is the first vaccine against mpox to be put on the prequalification
- [Pancreatic cancer vaccine trial launches in Birmingham](https://vaccinenation.org/therapeutic/pancreatic-cancer-vaccine-trial-launches-in-birmingham/): Researchers at the University of Birmingham announced the launch of a trial to study the use of an mRNA cancer vaccine in the treatment of pancreatic
- [COVID-19 in LAC region: up to 2.61 million deaths averted](https://vaccinenation.org/global-health/covid-19-in-lac-region-up-to-2-61-million-deaths-averted/): A study in Open Forum Infectious Diseases in September 2024 estimates the number of deaths averted through vaccination in Latin America and the Caribbean Region
- [Bavarian Nordic shares mpox vaccine supply update](https://vaccinenation.org/global-health/bavarian-nordic-shares-mpox-vaccine-supply-update/): Bavarian Nordic issued an update on its supply and manufacturing activities in support of mpox response efforts in September 2024. The company
- [HPV vaccine GARDASIL 9 meets endpoints in Phase III trial](https://vaccinenation.org/global-health/hpv-vaccine-gardasil-9-meets-endpoints-in-phase-iii-trial/): In September 2024, Merck (MSD) announced positive top-line results from its pivotal Phase III trial evaluating the company’s 9-valent Human Papillomavirus
- [Study: need for clinical surveillance of patients with C-VAM](https://vaccinenation.org/global-health/study-need-for-clinical-surveillance-of-patients-with-c-vam/): An FDA-funded study in eClinical Medicine explores the clinical characteristics, myocardial injury, and longitudinal outcomes of COVID-19 vaccine-associated
- [GSK’s herpes candidate fails to meet trial objective](https://vaccinenation.org/therapeutic/gsks-herpes-candidate-fails-to-meet-trial-objective/): GSK announced in September 2024 that it has completed the primary objective data analysis from the Phase II part of its TH HSV REC-003 trial.
- [15,460 additional mpox vaccine doses arrive in DRC](https://vaccinenation.org/global-health/15460-additional-mpox-vaccine-doses-arrive-in-drc/): Gavi announced in September 2024 that a shipment of 15,460 doses of mpox vaccine has arrived in the Democratic Republic of the Congo (DRC)
- [OSE Immunotherapeutics launches ‘Artemia’ cancer trial](https://vaccinenation.org/therapeutic/ose-immunotherapeutics-launches-artemia-cancer-trial/): In September 2024, OSE Immunotherapeutics announced the launch of an international Phase III clinical trial of its off-the-shelf neoepitope-based
- [Evaxion’s topline data show EVX-01 has promise](https://vaccinenation.org/therapeutic/evaxions-topline-data-show-evx-01-has-promise/): In September 2024, Evaxion Biotech announced positive topline data from a Phase II trial of EVX-01. This is part of a one-year interim analysis
- [Cancer Research UK funds Oxford’s ‘LynchVax’ efforts](https://vaccinenation.org/global-health/cancer-research-uk-funds-oxfords-lynchvax-efforts/): The University of Oxford’s Centre for Cancer Early Detection and Prevention announced in September 2024 that Cancer Research UK has awarded a team
- [Study: cost-effectiveness of RSV vaccination in Canada](https://vaccinenation.org/global-health/study-cost-effectiveness-of-rsv-vaccination-in-canada/): A study in CMAJ in September 2024 evaluates the cost-effectiveness of different age cut-offs for RSV adult vaccination programmes, with or without
- [Vaccines Europe: supply chain resilience needs collaboration](https://vaccinenation.org/technology/vaccines-europe-supply-chain-resilience-needs-collaboration/): A paper from Vaccines Europe in September 2024 reveals “key vulnerabilities” in the vaccine supply chain and offers strategies to strengthen resilience.
- [CDC: confirmed human avian influenza case in Missouri](https://vaccinenation.org/infection/cdc-confirmed-human-avian-influenza-case-in-missouri/): The United States CDC confirmed in September 2024 that a human case of avian influenza A(H5) has been reported by the state of Missouri. The case was identified
- [Use of suppressive bluetongue vaccines permitted in UK](https://vaccinenation.org/global-health/suppressive-bluetongue-vaccines-permitted-in-uk/): The UK Department for Environment, Food, and Rural Affairs (DEFRA) announced in September 2024 that the Secretary of State has permitted
- [Partnership to protect pigs awarded government funding](https://vaccinenation.org/global-health/partnership-to-protect-pigs-awarded-government-funding/): The Vaccine Group (TVG) announced in September 2024 that its partnership with the University of Plymouth and the University of Cambridge has been
- [mRNA vaccine shows potential against mpox in study](https://vaccinenation.org/technology/mrna-vaccine-shows-potential-against-mpox-in-study/): A paper in Cell in September 2024 presents a promising mRNA vaccine candidate against mpox disease. The mRNA-lipid nanoparticle (LNP) vaccine
- [Phase 1 of Gaza polio vaccination conducted “successfully”](https://vaccinenation.org/global-health/phase-1-of-gaza-polio-vaccination-conducted-successfully/): WHO announced in September 2024 that the first phase of a polio vaccination campaign has been “successfully” concluded in Gaza. Over 187,000 children
- [First mpox vaccine doses arrive in DRC from Bavarian Nordic](https://vaccinenation.org/global-health/first-mpox-vaccine-doses-arrive-in-drc-from-bavarian-nordic/): Bavarian Nordic announced in September 2024 that the first doses of its mpox vaccine, MVA-BN (JYNNEOS), have arrived in the Democratic Republic of Congo
- [WHO: cholera cases increase and OCV stockpile under pressure](https://vaccinenation.org/infection/who-cholera-cases-increase-and-ocv-stockpile-under-pressure/): In September 2024 WHO published the global cholera statistics for 2023, revealing an increase in cases and deaths. The current global risk from
- [WHO and Africa CDC: mpox preparedness and response plan](https://vaccinenation.org/global-health/who-and-africa-cdc-mpox-preparedness-and-response-plan/): In response to the mpox outbreak, declared a PHEIC by WHO and a PHECS by Africa CDC, the two organisations announced that they are co-leadin
- [Paper details H5N1 detection in Antarctic Region](https://vaccinenation.org/infection/paper-details-h5n1-detection-in-antarctic-region/): A paper in Nature communications in September 2024 reports on the detection H5N1 high pathogenicity avian influenza virus (HPAIV) in the Antarctic,
- [Rokote and 3PBIOVIAN partner on FINCoVac 2.1 vaccine](https://vaccinenation.org/technology/rokote-and-3pbiovian-partner-on-fincovac-2-1-vaccine/): 3PBIOVIAN announced in September 2024 that it has been selected by Rokote Laboratories Finland Ltd. as CDMO partner for GMP manufacturing
- [Study: structural inequities to vaccine access in India](https://vaccinenation.org/global-health/study-structural-inequities-to-vaccine-access-in-india/): A study in Vaccine in August 2024 explores the role of “structural and historical inequities” in shaping access to COVID-19 vaccines for the transgender
- [Vaxcyte reports positive topline results in study of VAX-31](https://vaccinenation.org/technology/vaxcyte-reports-positive-topline-results-in-study-of-vax-31/): Vaxcyte announced in September 2024 that its Phase I/II study of VAX-31, the 31-valent pneumococcal conjugate vaccine (PCV), has produced
- [Personalised therapy: XPO1 identified as “bona fide” antigen](https://vaccinenation.org/therapeutic/personalised-therapy-xpo1-identified-as-bona-fide-antigen/): A paper in Science Advances in August 2024 describes XPO1 (Exportin-1/CRM1) as a “bona fide tumour antigen” recognised by natural killer (NK) cells.
- [Mpox public perception study highlights need for knowledge](https://vaccinenation.org/global-health/mpox-public-perception-study-highlights-need-for-knowledge/): A study in Vaccine X presents a “comprehensive view of people’s opinions, fears, and behaviours” about mpox. The authors searched various
- [Positive booster data for Valneva and Pfizer Lyme candidate](https://vaccinenation.org/technology/positive-booster-data-for-valneva-and-pfizer-lyme-candidate/): In September 2024, Valneva and Pfizer announced positive immunogenicity and safety data from the VLA15-221 Phase II study investigating a second
- [Childhood vaccination approach shows promise against HIV](https://vaccinenation.org/global-health/childhood-vaccination-approach-shows-promise-against-hiv/): In August 2024 researchers at Weill Cornell Medicine shared that their strategy to provide protection against HIV has shown promise in a study.
- [Poliovirus detection in Gaza prompts vaccination campaign](https://vaccinenation.org/infection/poliovirus-detection-in-gaza-prompts-vaccination-campaign/): The detection of poliovirus environmental samples from Khan Younis and Deir al-Balah in July 2024 has led to the initiation of an inoculation campaign
- [DEFRA launches TB eradication strategy with Field Force](https://vaccinenation.org/global-health/defra-launches-tb-eradication-strategy-with-field-force/): In August 2024 the UK Department for Environment, Food, and Rural Affairs announced the launch of a new tuberculosis (TB) eradication strategy
- [UNICEF issues emergency tender for mpox vaccine procurement](https://vaccinenation.org/global-health/unicef-issues-emergency-tender-for-mpox-vaccine-procurement/): UNICEF announced in August 2024 that it has issued an emergency tender for the procurement of mpox vaccines amid the public health emergency
- [APPC data shows US vaccine willingness is decreasing](https://vaccinenation.org/global-health/appc-data-shows-us-vaccine-willingness-is-decreasing/): The Annenberg Public Policy Centre (APPC) shared a report in August 2024, revealing that the number of Americans believing COVID-19 vaccination
- [Emergent secures FDA mpox expansion for ACAM2000](https://vaccinenation.org/technology/emergent-secures-fda-mpox-expansion-for-acam2000/): In August 2024, Emergent BioSolutions announced that the US FDA has approved the supplemental Biologics License Application (sBLA) for the expansion
- [Study explores COVID-19 vaccine as hyperglycaemia treatment](https://vaccinenation.org/therapeutic/study-explores-covid-19-vaccine-as-hyperglycaemia-treatment/): Research in Nature communications in August 2024 reports a non-human primate model of metabolic post-acute sequelae of SARS-CoV-2 to identify
- [Mental health condition disparities in HPV vaccination](https://vaccinenation.org/global-health/mental-health-condition-disparities-in-hpv-vaccination/): A study in The Lancet Public Health by researchers at Karolinska Institutet finds “disparities’ in cervical cancer prevention among girls with mental health
- [Workflow to detect falsified vaccines validated in study](https://vaccinenation.org/technology/workflow-to-detect-falsified-vaccines-validated-in-study/): Researchers from the University of Oxford shared their work in npj vaccines in August 2024, addressing the threat of “substandard and falsified vaccines”
- [Lassa vaccine in West Africa would save lives and money](https://vaccinenation.org/global-health/lassa-vaccine-in-west-africa-would-save-lives-and-money/): Research in Nature Medicine in August 2024 presents the importance of a safe and effective Lassa vaccine deployed across 15 countries of continental
- [Bharat Biotech launches HILLCHOL against cholera](https://vaccinenation.org/technology/bharat-biotech-launches-hillchol-against-cholera/): Bharat Biotech announced the launch of HILLCHOL in August 2024, describing the novel single-strain oral cholera vaccine (OCV) as a “significant
- [Exploring myocarditis after infection or vaccination](https://vaccinenation.org/global-health/exploring-myocarditis-after-infection-or-vaccination/): A study in JAMA Network in August 2024 explores the link between myocarditis and COVID-19 infection or vaccination. The nationwide cohort study
- [Gates Foundation grant for Immorna RSV vaccine efforts](https://vaccinenation.org/technology/gates-foundation-grant-for-immorna-rsv-vaccine-efforts/): Immorna Biotherapeutics announced that it has received a grant, worth $3,800,000, from the Bill & Melinda Gates Foundation in support of the clinical
- [Tonix partners with Bilthoven Biologics on mpox vaccine](https://vaccinenation.org/technology/tonix-partners-with-bilthoven-biologics-on-mpox-vaccine/): Tonix Pharmaceuticals announced in August 2024 that it is collaborating with Bilthoven Biologics (BBio) to advance TNX-801. TNX-801 is Tonix’s mpox
- [Optimised synthetic DNA: CEPI funds Afrigen access efforts](https://vaccinenation.org/technology/optimised-synthetic-dna-cepi-funds-afrigen-access-efforts/): CEPI announced in August 2024 that it is providing US$2.05 million to researchers at Afrigen Biologics to support their work on synthetic DNA.
- [WHO launches mpox strategic plan after PHEIC declared](https://vaccinenation.org/global-health/who-launches-mpox-strategic-plan-after-pheic-declared/): In August 2024 WHO launched a global Strategic Preparedness and Response Plan (SPRP) to address the mpox public health emergency of international concern
- [WHO shares mpox update: newly affected countries](https://vaccinenation.org/infection/who-shares-mpox-update-newly-affected-countries/): In August 2024 WHO shared a disease outbreak update on the mpox situation in Africa, presenting information on the latest countries that are reporting cases.
- [UCLH lung cancer patient receives novel vaccine in trial](https://vaccinenation.org/therapeutic/uclh-lung-cancer-patient-receives-novel-vaccine-in-trial/): University College London Hospitals (UCLH) announced in August 2024 that a patient with lung cancer at UCLH is the first to receive a novel cancer
- [Partnership to transform intradermal injection technology](https://vaccinenation.org/technology/partnership-to-transform-intradermal-injection-technology/): The Pandemic Institute announced in August 2024 that it has signed a Memorandum of Understanding (MoU) with Pharma Latch after attending
- [Everest launches personalised mRNA cancer vaccine trial](https://vaccinenation.org/therapeutic/everest-launches-personalised-mrna-cancer-vaccine-trial/): In August 2024 Everest Medicines announced the launch of an Investigator-Initiated Clinical Trial (IIT) assessing the safety, tolerability, immunogenicity,
- [Gonorrhoea antibody study supports vaccine development](https://vaccinenation.org/technology/gonorrhoea-antibody-study-supports-vaccine-development/): Amid a rise in cases of antibiotic-resistant gonorrhoea, authors of a paper in Nature Communications present their research into the immune response gonorrhoea
- [Ebola epidemic study finds vaccine "highly” protective](https://vaccinenation.org/global-health/ebola-epidemic-study-finds-vaccine-highly-protective/): A paper in The Lancet Infectious Diseases in August 2024 presents the results of an observational study during the Ebola epidemic in the Democratic
- [Touchlight supports Zika vaccine development with dbDNA](https://vaccinenation.org/technology/touchlight-supports-zika-vaccine-development-with-dbdna/): In August 2024 Touchlight announced that it is supplying its proprietary dbDNA to the University of Nottingham in support of the research and development
- [WHO calls for action to protect children with vaccines](https://vaccinenation.org/global-health/who-calls-for-action-to-protect-children-with-vaccines/): At WHO South-East Asia Regional Director Saima Wazed’s inaugural address to the 15th Meeting of the WHO South-East Asia Regional Immunisation Technical
- [Africa CDC report highlights threat of AMR on continent](https://vaccinenation.org/global-health/africa-cdc-report-highlights-threat-of-amr-on-continent/): A report shared by Africa CDC in August 2024 finds that the threat presented by treatment-resistant diseases has increased in Africa, with children
- [Economic cost: putting a price on HPV vaccine programmes](https://vaccinenation.org/global-health/economic-cost-putting-a-price-on-hpv-vaccine-programmes/): In Vaccine X researchers from PATH address a “dearth” of evidence on determinants of vaccine delivery costs for human papillomavirus (HPV)
- [Cryptosporidiosis: vaccine approved for protection of cattle](https://vaccinenation.org/global-health/cryptosporidiosis-vaccine-approved-for-protection-of-cattle/): MSD Animal Health announced in August 2024 that it has received Veterinary Medicines Directorate (VMD) approval for the first vaccine in Great Britain
- [Emergent pledges ACAM2000 doses for mpox response](https://vaccinenation.org/technology/emergent-pledges-acam2000-doses-for-mpox-response/): Emergent BioSolutions announced in August 2024 that it is “proactively” working with WHO and the US government in response to the outbreak
- [Shigella4V: the long journey and road ahead](https://vaccinenation.org/technology/shigella4v-the-long-journey-and-road-ahead/): Earlier this month, Valneva (NASDAQ: VALN) and LimmaTech Biologics announced a strategic partnership to accelerate the development of a quadrivalent vaccine
- [Aga Khan Foundation: nutrition and immunisation in Pakistan](https://vaccinenation.org/global-health/aga-khan-foundation-nutrition-and-immunisation-in-pakistan/): The Aga Khan Foundation (AKF) announced in August 2024 that it is launching a $7.2 million nutrition and immunisation programme in Pakistan
- [Tonix shares mpox vaccine update after PHEIC declared](https://vaccinenation.org/technology/tonix-shares-mpox-vaccine-update-after-pheic-declared/): In August 2024 Tonix Pharmaceuticals “reiterated its commitment” to advancing the development of its live attenuated virus vaccine TNX-801 for
- [PAHO and SLIPE cooperate against disease in children](https://vaccinenation.org/global-health/paho-and-slipe-cooperate-against-disease-in-children/): In August 2024 the Pan American Health Organisation (PAHO) and the Latin American Society of Paediatric Infectious Diseases (SLIPE) signed
- [SARS-CoV-2 “molecular dance” insights for vaccine efforts](https://vaccinenation.org/technology/sars-cov-2-molecular-dance-insights-for-vaccine-efforts/): A study by researchers at Yale School of Medicine (YSM), Northeastern University, and Rice University in Science (not open access) in August 2024
- [Sweden reports case of mpox clade 1 after PHEIC declared](https://vaccinenation.org/infection/sweden-reports-case-of-mpox-clade-1-after-pheic-declared/): In August 2024 the Public Health Agency of Sweden announced that a person who sought care at Region Stockholm has been diagnosed with mpox
- [UKHSA data shows resistant gonorrhoea rising in England](https://vaccinenation.org/infection/ukhsa-data-shows-resistant-gonorrhoea-rising-in-england/): Data from the UK Health Security Agency (UKHSA) shared in August 2024 reveals a “concerning rise” in antibiotic-resistant gonorrhoea infections
- [CureVac advances CVGBM in glioblastoma trial](https://vaccinenation.org/therapeutic/curevac-advances-cvgbm-in-glioblastoma-trial/): In August 2024 CureVac announced the start of the dose-confirmation Part B in its ongoing Phase I study of CVGBM in patients with resected glioblastoma.
- [ASEAN health ministers pledge immunisation investments](https://vaccinenation.org/global-health/asean-health-ministers-pledge-immunisation-investments/): Gavi announced in August 2024 that health ministers from the Association of Southeast Asian Nations (ASEAN) have pledged to increase investments
- [WHO declares “worrying” mpox outbreak a PHEIC](https://vaccinenation.org/infection/who-declares-worrying-mpox-outbreak-a-pheic/): After a meeting of an International Health Regulations (IHR) Emergency Committee on 14th August 2024, WHO Director-General Dr Tedros Adhanom
- [“Suboptimal” vaccine uptake in pregnancy needs interventions](https://vaccinenation.org/global-health/suboptimal-vaccine-uptake-in-pregnancy-needs-interventions/): An article in npj vaccines in August 2024 describes vaccine uptake for COVID-19 and influenza vaccines in pregnancy as “suboptimal”. The authors
- [ICMR and Panacea initiate DengiAll vaccine trial in India](https://vaccinenation.org/technology/icmr-and-panacea-initiate-dengiall-vaccine-trial-in-india/): The Indian Council of Medical Research (ICMR) and Panacea Biotec announced in August 2024 that they have initiated the first-ever Phase III
- [Africa CDC declares mpox PHECS and prepares for vaccines](https://vaccinenation.org/infection/africa-cdc-declares-mpox-phecs-and-prepares-for-vaccines/): In August 2024 Africa CDC declared the mpox outbreak a Public Health Emergency of Continental Security (PHECS), which enables the organisation
- [ABRYSVO: Pfizer's positive safety and immunogenicity data](https://vaccinenation.org/technology/abrysvo-pfizers-positive-safety-and-immunogenicity-data/): In August 2024 Pfizer announced positive top-line safety and immunogenicity results from substudy B of its ongoing Phase III clinical trial MONeT
- [COVID-19 vaccine rollout and mental health in US adults](https://vaccinenation.org/global-health/covid-19-vaccine-rollout-and-mental-health-in-us-adults/): Research in The Lancet Regional Health Americas in August 2024 evaluates the effect of various COVID-19 vaccine rollout phases on “trends and prevalence”
- [EU Study: COVID-19 vaccines saved at least 1.6 million lives](https://vaccinenation.org/global-health/eu-study-covid-19-vaccines-saved-at-least-1-6-million-lives/): A paper in The Lancet Respiratory Medicine presents results from a WHO Europe study that suggest that COVID-19 vaccines saved at least 1.6 million
- [Before mpox emergency meeting WHO prepares for vaccine EUL](https://vaccinenation.org/infection/before-mpox-emergency-meeting-who-prepares-for-vaccine-eul/): In August 2024 WHO issued an invitation for manufacturers of mpox vaccines to submit an Expression of Interest for Emergency Use Listing (EUL).
- [Funding for methane emissions vaccine collaboration](https://vaccinenation.org/global-health/funding-for-methane-emissions-vaccine-collaboration/): The Pirbright Institute announced in August 2024 that a “global quest” to cut methane emissions in cattle through vaccination is supported by $9.4 million
- [LASSARAB vaccine a “worthy candidate” for development](https://vaccinenation.org/technology/lassarab-vaccine-a-worthy-candidate-for-development/): An article in npj vaccines in August 2024 presents research into the efficacy of a deactivated rabies virus (RABV)-based vaccine encoding the glycoprotein
- [CEPI to support Boost Biopharma vaccine development](https://vaccinenation.org/technology/cepi-to-support-boost-biopharma-vaccine-development/): CEPI announced in August 2024 that it is providing a $5 million cash injection to Boost Biopharma to advance its “cutting-edge” rapid antigen design process
- [CDC report highlights childhood vaccination benefits](https://vaccinenation.org/global-health/cdc-report-highlights-childhood-vaccination-benefits/): A report from US CDC Morbidity and Mortality Weekly Report (MMWR) in August 2024 explores the health and economic benefits of routine childhood
- [UKHSA’s whooping cough warning as cases exceed 10,000](https://vaccinenation.org/infection/ukhsas-whooping-cough-warning-as-cases-exceed-10000/): Data from the UK Health Security Agency (UKHSA) released in August 2024 reveal that 10,493 laboratory confirmed cases of pertussis in England
- [Understanding how BCG destroys bladder cancer cells](https://vaccinenation.org/therapeutic/understanding-how-bcg-destroys-bladder-cancer-cells/): In August 2024 a paper in Disease Models and Mechanisms presents research that uncovers the earliest cellular mechanisms involved in tumour
- [US places $156.8 million JYNNEOS order from Bavarian Nordic](https://vaccinenation.org/technology/us-places-156-8-million-jynneos-order-from-bavarian-nordic/): Bavarian Nordic announced in August 2024 that the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration
- [Nanoparticle platform boosts range of vaccine candidates](https://vaccinenation.org/technology/nanoparticle-platform-boosts-range-of-vaccine-candidates/): Researchers in Science Advances present their work developing a “highly modular saponin-based nanoparticle platform”. The platform incorporates
- [Phylex “on track” with Nipah virus vaccine research](https://vaccinenation.org/technology/phylex-on-track-with-nipah-virus-vaccine-research/): In August 2024 Phylex Biosciences announced the publication of a preprint presenting research into the immunogenicity of its Nipah mRNA nanoparticle
- [Study finds vaccination “crucial” to koala protection](https://vaccinenation.org/global-health/study-finds-vaccination-crucial-to-koala-protection/): An article in npj vaccine in August 2024 presents an evaluation of a 10-year assessment of a Major Outer Membrane Protein-based vaccine in wild koalas
- [ANKTIVA and AdHER2DC trial tackles endometrial cancer](https://vaccinenation.org/therapeutic/anktiva-and-adher2dc-trial-tackles-endometrial-cancer/): ImmunityBio announced in August 2024 that a clinical trial to study ANKTIVA and the investigational AdHER2DC vaccine in individuals with HER2-expressing
- [ULCA launches paediatric brain cancer vaccine trial](https://vaccinenation.org/therapeutic/ulca-launches-paediatric-brain-cancer-vaccine-trial/): In August 2024 researchers at the University of California, Los Angeles (UCLA) announced the launch of a “first-of-its-kind" clinical trial to evaluate
- [Ultimovacs: UV1 combination does not meet endpoints](https://vaccinenation.org/therapeutic/ultimovacs-uv1-combination-does-not-meet-endpoints/): In August 2024 Ultimovacs announced topline data from the FOCUS Phase II trial combining UV1 and pembrolizumab in patients with metastatic
- [Badger vaccination project in Cornwall shows promise](https://vaccinenation.org/global-health/badger-vaccination-project-in-cornwall-shows-promise/): A paper in People and Nature presents a 4-year badger vaccination initiative, which suggests that badger vaccination could be a “technically effective
- [PAHO alert warns of growing Oropouche virus danger](https://vaccinenation.org/infection/paho-alert-warns-of-growing-oropouche-virus-danger/): The Pan American Health Organisation (PAHO) issued an epidemiological alert in August 2024 that urged Member States to “strengthen surveillance
- [Anivive secures NIAID contract for Valley Fever vaccine](https://vaccinenation.org/global-health/anivive-secures-niaid-contract-for-valley-fever-vaccine/): Anivive Lifesciences announced in August 2024 that it has been awarded a contract worth up to $33 million by the National Institute
- [AAHI and Afrigen partner on adjuvants for sub-Saharan Africa](https://vaccinenation.org/technology/aahi-and-afrigen-partner-on-adjuvants-for-sub-saharan-africa/): In August 2024 the Access to Advanced Health Institute (AAHI) announced an expanded partnership with Afrigen Biologics to develop effective
- [PrEPVacc HIV vaccine trial finds no infection reduction](https://vaccinenation.org/global-health/prepvacc-hiv-vaccine-trial-finds-no-infection-reduction/): In July 2024 PrEPVacc, an African-led, European-supported HIV prevention study, announced that the results of the HIV vaccine trial
- [PrEPVacc trial stops with “little or no chance” for vaccines](https://vaccinenation.org/technology/prepvacc-trial-stops-with-little-or-no-chance-for-vaccines/): In December 2023 the PrEPVacc HIV prevention study announced that vaccinations in the study have stopped due to “little or no chance” that
- [Study considers vaccine interventions across countries](https://vaccinenation.org/global-health/study-considers-vaccine-interventions-across-countries/): A paper in Nature Human Behaviour (not open access) in August 2024 presents a meta-analysis examining different types of vaccination
- [WHO and CEPI call for “broader” pandemic research approach](https://vaccinenation.org/global-health/who-and-cepi-call-for-broader-pandemic-research-approach/): In August 2024 WHO and CEPI shared a joint release calling on researchers and governments to “strengthen and accelerate”
- [Cape Town considers seal vaccination amid rabies concern](https://vaccinenation.org/infection/cape-town-considers-seal-vaccination-amid-rabies-concern/): The City of Cape Town, South Africa, shared the results of an expert scientific workshop convened in partnership with the Department of Forestry
- [Valneva and LimmaTech partner on Shigella vaccine](https://vaccinenation.org/technology/valneva-and-limmatech-partner-on-shigella-vaccine/): In August 2024 Valneva and LimmaTech announced that they have entered a strategic partnership and exclusive licensing agreement
- [WHO prequalification status for Biological E’s nOPV2](https://vaccinenation.org/technology/who-prequalification-status-for-biological-es-nopv2/): Biological E announced in July 2024 that WHO has granted prequalification status to the company’s Novel Oral Polio Vaccine type 2 (nOPV2).
- [Africa CDC shares update on mpox situation in Africa](https://vaccinenation.org/infection/africa-cdc-shares-update-on-mpox-situation-in-africa/): Africa CDC shared a situation update on mpox on the African continent in July 2024. This reveals that between January 2022 and July 2024
- [Equity and security: RVMC 3-year strategy launches](https://vaccinenation.org/global-health/equity-and-security-rvmc-3-year-strategy-launches/): In July 2024 the Regionalised Vaccine Manufacturing Collaborative (RVMC) shared its strategy for 2024-2027, launched by Dr Frederik Kristensen,
- [Study compares complications after COVID-19 vaccines](https://vaccinenation.org/global-health/study-compares-complications-after-covid-19-vaccines/): A paper in Nature Communications in July 2024 explores the effect of COVID-19 vaccines on cardiovascular diseases by examining
- [ApiJect Injector shows favourable environmental profile](https://vaccinenation.org/technology/apiject-injector-shows-favourable-environmental-profile/): ApiJect announced in July 2024 that a peer reviewed study comparing the environmental footprint of the company’s prefilled injection
- [BioNTech announces positive results in melanoma trial](https://vaccinenation.org/therapeutic/biontech-announces-positive-results-in-melanoma-trial/): In July 2024 BioNTech announced positive topline data from its ongoing Phase II trial in patients with unresectable stage III or IV melanoma
- [GSK and Flagship announce portfolio collaboration](https://vaccinenation.org/technology/gsk-and-flagship-announce-portfolio-collaboration/): GSK and Flagship Pioneering announced in July 2024 that they have entered a collaboration to discover and develop a portfolio of “transformational”
- [Airfinity suggests US RSV vaccine market will fall by 2030](https://vaccinenation.org/global-health/airfinity-suggests-us-rsv-vaccine-market-will-fall-by-2030/): In July 2024 Airfinity announced a reduction in its sales projections for vaccines against Respiratory Syncytial Virus (RSV) for older adults in the US.
- [SMART trial to assess post-exposure mpox vaccine protection](https://vaccinenation.org/global-health/smart-trial-to-assess-post-exposure-mpox-vaccine-protection/): CEPI announced in July 2024 that a clinical trial to assess if an mpox vaccine can protect against mpox after contact with the infection
- [Study suggests Shingrix has reduced risk of dementia](https://vaccinenation.org/global-health/study-suggests-shingrix-has-reduced-risk-of-dementia/): A study in Nature Medicine (not open access) in July 2024 explores “emerging evidence” that Shingrix offers protection against dementia.
- [Sinergium Biotech to lead mRNA avian influenza project](https://vaccinenation.org/technology/sinergium-biotech-to-lead-mrna-avian-influenza-project/): In July 2024, WHO announced that Argentine manufacturer Sinergium Biotech is to lead a new project that aims to accelerate the development
- [“It’s time for action” on World Hepatitis Day 2024](https://vaccinenation.org/global-health/its-time-for-action-on-world-hepatitis-day-2024/): On 28th July 2024 WHO marked World Hepatitis Day with the theme “it’s time for action”, calling for increased awareness of viral hepatitis
- [Empowering healthcare workers to address misinformation](https://vaccinenation.org/global-health/empowering-healthcare-workers-to-address-misinformation/): Researchers in Vaccine share their design of a training programme intended to enhance the skills and confidence of healthcare workers
- [Gavi’s Big Catch-Up: millions of doses allocated](https://vaccinenation.org/global-health/gavis-big-catch-up-millions-of-doses-allocated/): Gavi announced in July 2024 that it has allocated nearly 200 million additional vaccine doses to contribute to the vaccination of around 50% of children
- [UK COVID-19 Inquiry demands “fundamental change”](https://vaccinenation.org/global-health/uk-covid-19-inquiry-demands-fundamental-change/): The first report from the UK COVID-19 Inquiry was released in July 2024, concluding that the UK was “ill prepared” to deal with the pandemic,
- [Vaccine trial innovation for improved pandemic preparedness](https://vaccinenation.org/technology/vaccine-trial-innovation-for-improved-pandemic-preparedness/): An article in Infection in July 2024 summarises discussions held at a VACCELERATE Consortium workshop, which explored the applicability
- [Diakonos announces FDA Fast Track designation for DCV](https://vaccinenation.org/therapeutic/diakonos-announces-fda-fast-track-designation-for-dcv/): Diakonos Oncology Corporation announced in July 2024 that the US FDA has granted Fast Track designation for its dendritic cell vaccine
- [Chandipura virus detected in India “needs more research”](https://vaccinenation.org/infection/chandipura-virus-detected-in-india-needs-more-research/): In July 2024 Indian news outlets reported cases and deaths of suspected Chandipura virus (CHPV) in Gujarat. 8 children are said
- [Court: EU Commission gave poor purchase agreement access](https://vaccinenation.org/global-health/court-eu-commission-gave-poor-purchase-agreement-access/): In July 2024 the Court of Justice of the European Union found that the EU Commission “did not give the public sufficiently wide access”
- [UK announces national RSV vaccination programme](https://vaccinenation.org/global-health/uk-announces-national-rsv-vaccination-programme/): The UK Department of Health and Social Care announced in July 2024 that the UK will become the first country in the world to offer a national vaccination
- [A zoonotic web: mapping zoonotic relationships in Austria](https://vaccinenation.org/global-health/a-zoonotic-web-mapping-zoonotic-relationships-in-austria/): A paper in Nature Communications in July 2024 presents the concept of a “zoonotic web”, describing the “complex relationships” between zoonotic
- [Report calls for support of GPs in vaccine delivery](https://vaccinenation.org/global-health/report-calls-for-support-of-gps-in-vaccine-delivery/): In July 2024, Grattan Institute shared a report on the importance of GPs in providing vaccination services. The authors, Peter Breadon and Anika Stobart,
- [“Unconventional” immune response offers TB vaccine path](https://vaccinenation.org/technology/unconventional-immune-response-offers-tb-vaccine-path/): Researchers at the Hackensack Meridian Centre for Discovery and Innovation (CDI) shared in July 2024 that their paper in Cell Reports
- [Making malaria history: Côte d’Ivoire deploys R21/Matrix-M](https://vaccinenation.org/global-health/making-malaria-history-cote-divoire-deploys-r21-matrix-m/): Côte d’Ivoire, the first country to roll-out the R21/Matrix-M vaccine, began vaccinations in July 2024 with the first child vaccinated in Abidjan
- [Sabin launches Phase II trial of Sudan ebolavirus vaccine](https://vaccinenation.org/technology/sabin-launches-phase-ii-trial-of-sudan-ebolavirus-vaccine/): Sabin Vaccine Institute announced in July 2024 that it has launched a Phase II clinical trial for its vaccine against Sudan ebolavirus
- [5 human cases of avian influenza identified in Colorado](https://vaccinenation.org/infection/5-human-cases-of-avian-influenza-identified-in-colorado/): The Colorado Department of Public Health and Environment announced in July 2024 that, in coordination with the Colorado Department of Agricultur
- [Data show global childhood immunisation “stalled” in 2023](https://vaccinenation.org/global-health/data-show-global-childhood-immunisation-stalled-in-2023/): In July 2024 WHO and UNICEF shared that data on global childhood immunisation from 2023 reveals that 2.7 million additional children were left
- [Understanding the effects of Long COVID on the workforce](https://vaccinenation.org/global-health/understanding-the-effects-of-long-covid-on-the-workforce/): A study in PLOS One in June 2024 explores the “ongoing workforce issues” caused by a “significant incidence of Long COVID” in the population.
- [Oxford teams launch Marburg trial of ChAdOx1 vaccine](https://vaccinenation.org/technology/oxford-teams-launch-marburg-trial-of-chadox1-vaccine/): Oxford’s Pandemic Sciences Institute announced in July 2024 that a clinical trial to test a vaccine against Marburg virus has been launched.
- [UKHSA whooping cough warning: cases continue](https://vaccinenation.org/infection/ukhsa-whooping-cough-warning-cases-continue/): In July 2024 the UKHSA shared data revealing that cases of whooping cough are still increasing with 2,591 cases confirmed in May.
- [Orlance awarded NIH grant for needle-free RNA platform](https://vaccinenation.org/technology/orlance-awarded-nih-grant-for-needle-free-rna-platform/): Seattle-based biotech Orlance announced in July 2024 that it has been awarded a Phase I Small Business Innovation Research (SBIR)
- [CEPI on H5N1: taking a “calm urgency” approach](https://vaccinenation.org/global-health/cepi-on-h5n1-taking-a-calm-urgency-approach/): In July 2024 CEPI shared a blog post about the outbreak of H5N1 bird flu in cattle in the US, offering insight into its approach towards this growing threat.
- [As elephants fight EEHV, vaccine hope appears](https://vaccinenation.org/global-health/as-elephants-fight-eehv-vaccine-hope-appears/): In July 2024, days after announcing the death of two elephants from Elephant Endotheliotropic Herpesvirus (EEHV), Dublin Zoo announced
- [Fighting TB: a multi-epitope-based subunit vaccine](https://vaccinenation.org/technology/fighting-tb-a-multi-epitope-based-subunit-vaccine/): An article in Scientific reports in July 2024 describes the “pressing need” for novel and safe vaccines that provide “robust immune
- [WHO update on mpox in South Africa: 3 deaths reported](https://vaccinenation.org/infection/who-update-on-mpox-in-south-africa-3-deaths-reported/): In July 2024, WHO shared a disease outbreak news update on the mpox situation in South Africa. It stated that, between 8th May and 2nd July 2024
- [Study finds increase in STD diagnoses in the US](https://vaccinenation.org/infection/study-finds-increase-in-std-diagnoses-in-the-us/): A study from FAIR Health in July 2024, presented as an infographic, shows that the percentage of commercially insured patients with sexually
- [Study suggests RSV vaccination in pregnancy is safe](https://vaccinenation.org/global-health/study-suggests-rsv-vaccination-in-pregnancy-is-safe/): A study in Jama Network Open in July 2024 explores the possibility of association between nonadjuvanted bivalent respiratory syncytial
- [WHO introduces global open access MeDevIS platform](https://vaccinenation.org/technology/who-introduces-global-open-access-medevis-platform/): WHO announced in July 2024 that its online open access clearing house, MeDevIS (Medical Devices Information System), is being
- [mRNA in Japan: Moderna and Mitsubishi Tanabe join forces](https://vaccinenation.org/technology/mrna-in-japan-moderna-and-mitsubishi-tanabe-join-forces/): Moderna and Mitsubishi Tanabe Pharma Corporation announced in July 2024 that they have entered a joint agreement regarding
- [Targeting IL-10 to improve vaccine efficacy for S. aureus](https://vaccinenation.org/global-health/targeting-il-10-to-improve-vaccine-efficacy-for-s-aureus/): A study in JCI Insight in July 2024 presents work from researchers at Trinity College Dublin who sought to improve vaccine responses
- [CEPI to support Apriori Bio’s Octavia AI platform](https://vaccinenation.org/technology/cepi-to-support-apriori-bios-octavia-ai-platform/): In July 2024 CEPI announced an award of US $1.1 million to support Apriori Bio in advancing its biology-informed artificial intelligence
- [HilleVax to discontinue infant norovirus vaccine development](https://vaccinenation.org/technology/hillevax-to-discontinue-infant-norovirus-vaccine-development/): HilleVax announced in July 2024 that topline data results from NEXT-IN1, a Phase IIb trial of HIL-214, reveal a failure to meet primary
- [HOOKIPA Pharma announces start of therapeutic vaccine trial](https://vaccinenation.org/therapeutic/hookipa-pharma-announces-start-of-therapeutic-vaccine-trial/): In July 2024, HOOKIPA Pharma announced that the first person has been dosed in a Phase Ib clinical trial of HB-500, an investigational
- [Nipah virus roadmap to “move ball forward” against disease](https://vaccinenation.org/global-health/nipah-virus-roadmap-to-move-ball-forward-against-disease/): In July 2024 the Centre for Infectious Disease Research and Policy (CIDRAP) announced an updated roadmap for Nipah virus (NiV) research and development.
- [Merck and Afrigen announce mRNA technology MoU](https://vaccinenation.org/technology/merck-and-afrigen-announce-mrna-technology-mou/): Merck’s Life Science business sector and Afrigen Biologics announced in July 2024 that they have entered a non-binding Memorandum of
- [CDC confirms fourth human case of avian influenza in the US](https://vaccinenation.org/infection/cdc-confirms-fourth-human-case-of-avian-influenza-in-the-us/): The US CDC stated in July 2024 that another human case of highly pathogenic avian influenza (HPAI) A(H5) virus infection has been identified
- [Shifting the regulatory paradigm in the “age of calamity”](https://vaccinenation.org/global-health/shifting-the-regulatory-paradigm-in-the-age-of-calamity/): Writing in response to a 2023 lecture “Regulation in the Age of Calamity” by CEPI’s Dr Richard Hatchett, authors in Clinical and Translational Science
- [WHO report on therapeutic HPV vaccine development](https://vaccinenation.org/therapeutic/who-report-on-therapeutic-hpv-vaccine-development/): A report shared by WHO in July 2024 presents the importance of designing therapeutic human papillomavirus (HPV) vaccines for use
- [GSK and CureVac announce mRNA licensing agreement](https://vaccinenation.org/technology/gsk-and-curevac-announce-mrna-licensing-agreement/): In July 2024, GSK and CureVac announced that they have “restructured” an existing collaboration into a new licensing agreement
- [“Substantial” HSV burden demands “crucial” vaccine efforts](https://vaccinenation.org/global-health/substantial-hsv-burden-demands-crucial-vaccine-efforts/): A study in BMC Global and Public Health in July 2024 explores the economic consequences of herpes simplex virus (HSV)-2 and –1
- [HHS provides $176 million for Moderna mRNA influenza efforts](https://vaccinenation.org/technology/hhs-provides-176-million-for-moderna-mrna-influenza-efforts/): The US Department of Health and Human Services (HHS) announced that through BARDA, part of the Administration for Strategic
- [PAHO and World Bank launch PROTECT pandemic project](https://vaccinenation.org/global-health/paho-and-world-bank-launch-protect-pandemic-project/): The Pan American Health Organisation and World Bank launched the PROTECT Project in July 2024 at an event attended virtually
- [NIH-sponsored trial to evaluate nasal COVID-19 vaccine](https://vaccinenation.org/technology/nih-sponsored-trial-to-evaluate-nasal-covid-19-vaccine/): In July 2024, the US National Institutes of Health (NIH) announced the beginning of a Phase I trial to test the safety of a nasal vaccine
- [CTIBIOTECH’s SAFESKIN3D project secures Sanofi support](https://vaccinenation.org/technology/ctibiotechs-safeskin3d-project-secures-sanofi-support/): In June 2024 it was announced that CTIBIOTECH has launched the SAFESKIN3D project to produce flexible 3D bioprinted human skin
- [PharmaJet technology selected for polio immunisation efforts](https://vaccinenation.org/technology/pharmajet-technology-selected-for-polio-immunisation-efforts/): In June 2024, PharmaJet announced that the Tropis Intradermal (ID) Needle-free System will be used for a house-to-house polio immunisation
- [EMA experts consider myocarditis and vaccination](https://vaccinenation.org/global-health/ema-experts-consider-myocarditis-and-vaccination/): In an article for npj vaccines in June 2024, experts from the European Medicines Agency (EMA) provide a “concise overview” of the epidemiology
- [Child health dashboard upates to track "critical factors”](https://vaccinenation.org/global-health/child-health-dashboard-updates-to-track-critical-factors/): In June 2024 WHO announced that the Child Health and Wellbeing Dashboard has been updated to include the latest data, downloadable datasets
- [Fighting fusions: a mAb for measles protection efforts](https://vaccinenation.org/technology/fighting-fusions-a-mab-for-measles-protection-efforts/): Researchers at La Jolla Institute for Immunology (LJI) Centre for Vaccine Innovation are exploring ways to prevent the fusion of measles
- [USDA calls for “good biosecurity” to fight H5N1](https://vaccinenation.org/global-health/usda-calls-for-good-biosecurity-to-fight-h5n1/): The US Department of Agriculture shared a release from Agriculture Secretary Tom Vilsack in June 2024, in which the importance
- [IDT Biologika and SK bioscience announce partnership](https://vaccinenation.org/technology/idt-biologika-and-sk-bioscience-announce-partnership/): IDT Biologika and SK bioscience announced a strategic partnership in June 2024, with SK bioscience to acquire 60% of IDT Biologika’s
- [New mpox strain causes concern: “most dangerous yet”](https://vaccinenation.org/infection/new-mpox-strain-causes-concern-most-dangerous-yet/): In June 2024 health officials shared concerns about a new mpox strain that is moving along the eastern border of Democratic Republic
- [Exploring COVID-19 vaccination and menstruation patterns](https://vaccinenation.org/global-health/exploring-covid-19-vaccination-and-menstruation-patterns/): A paper in npj vaccines in June 2024 seeks to “unravel” the direct effect of the COVID-19 vaccine on granulosa cells (GCs), endocrine
- [USDA approval: Merck Animal Health canine influenza vaccine](https://vaccinenation.org/global-health/usda-approval-merck-animal-health-canine-influenza-vaccine/): In June 2024 Merck Animal Health (known as MSD Animal Health outside the US and Canada) announced that the USDA has approved
- [ILiAD and Emmes to conduct Phase III pertussis studies](https://vaccinenation.org/technology/iliad-and-emmes-to-conduct-phase-iii-pertussis-studies/): ILiAD Biotechnologies announced in June 2024 that Emmes Group has been chosen to conduct Phase III studies of its lead pertussis
- [EU Council adopts vaccine-preventable cancer recommendation](https://vaccinenation.org/global-health/eu-council-adopts-vaccine-preventable-cancer-recommendation/): The European Council announced in June 2024 that it has adopted a recommendation seeking to address vaccine-preventable cancers
- [Defence Therapeutics’ ARM-X anti-cancer vaccine effective](https://vaccinenation.org/therapeutic/defence-therapeuticss-arm-x-anti-cancer-vaccine-effective/): In June 2024, Defence Therapeutics announced that its second-generation ARM-X anti-cancer vaccine is “therapeutically effective”
- [Osivax completes enrolment for OVX033 Phase I trial](https://vaccinenation.org/technology/osivax-completes-enrolment-for-ovx033-phase-i-trial/): Osivax announced in June 2024 that it has completed enrolment for its Phase I trial of OVX033, a broad-spectrum vaccine candidate
- [Vaxxinity announces “beacon of hope” for Parkinson’s disease](https://vaccinenation.org/therapeutic/vaxxinity-announces-beacon-of-hope-for-parkinsons-disease/): In June 2024 Vaxxinity announced the publication of “groundbreaking exploratory data” from a Phase I clinical trial of UB-312 in patients
- [AstriVax takes novel vaccine platform to clinical trial](https://vaccinenation.org/technology/astrivax-takes-novel-vaccine-platform-to-clinical-trial/): AstriVax announced in June 2024 that the first participants have been dosed in a Phase I clinical study to investigate the safety and efficacy
- [Gavi launches AVMA and outlines immunisation plans](https://vaccinenation.org/global-health/gavi-launches-avma-and-outlines-immunisation-plans/): In June 2024, Gavi co-hosted the Global Forum for Vaccine Sovereignty and Innovation with the African Union and the French Republic.
- [Sanofi and Biovac partner on polio vaccines in Africa](https://vaccinenation.org/global-health/sanofi-and-biovac-partner-on-polio-vaccines-in-africa/): Sanofi and Biovac announced in June 2024 that they are partnering to produce inactivated polio vaccines (IPV) in Africa. The agreement
- [Analysis finds global infectious disease outbreaks “surging”](https://vaccinenation.org/infection/analysis-finds-global-infectious-disease-outbreaks-surging/): Analysis by Airfinity and Bloomberg News, reported in June 2024, suggests that at least 13 infectious diseases are showing a resurgence. A study compiling
- [CEPI and NTI launch Bio Funders Compact for biosecurity](https://vaccinenation.org/global-health/cepi-and-nti-launch-bio-funders-compact-for-biosecurity/): In June 2024 CEPI announced the launch of the international Bio Funders Compact (BFC) in partnership with the Nuclear Threat Initiative
- [Team Europe announces pledge of over €750 million to AVMA](https://vaccinenation.org/global-health/team-europe-announces-pledge-of-over-e750-million-to-avma/): In June 2024, the European Commission (EC) announced that the European Union and its Member States will contribute over €750 million
- [Funding for promising UQ cattle tick vaccine trials](https://vaccinenation.org/global-health/funding-for-promising-uq-cattle-tick-vaccine-trials/): The University of Queensland (UQ) is making progress on a “highly effective” vaccine to address one of the “top cattle pests”.
- [IVI announces agreements for public health and access](https://vaccinenation.org/global-health/ivi-announces-agreements-for-public-health-and-access/): In June 2024 the International Vaccine Institute (IVI) announced the signing of two Memoranda of Understanding (MoU): with the Pasteur Network
- [Realising “underutilised” vaccine potential against AMR](https://vaccinenation.org/global-health/realising-underutilised-vaccine-potential-against-amr/): A paper in Vaccine in June 2024 considers how vaccines can be used to reduce the growing threat of antimicrobial resistance (AMR). The authors
- [Study explores variables associated with COVID-19 recovery](https://vaccinenation.org/global-health/study-explores-variables-associated-with-covid-19-recovery/): A study in JAMA Network Open in June 2024 investigates different variables associated with time to recovery from SARS-CoV-2 infection.
- [NextGen funding for GeoVax’s dual-antigen COVID-19 vaccine](https://vaccinenation.org/technology/nextgen-funding-for-geovaxs-dual-antigen-covid-19-vaccine/): GeoVax announced in June 2024 that it has received an award to advance development of GEO-CM04S1 in a Phase IIb clinical trial. GEO-CM04S1
- [Meeting you where you're at: BARDA's Dr Kumiko Lippold](https://vaccinenation.org/technology/meeting-you-where-youre-at-bardas-dr-kumiko-lippold/): At The World Vaccine Congress in Washington VaccineNation conducted a series of conversations with some of our experts. In this interview we meet BARDA's
- [RAY CRO's Ahmed Hamouda: taking pride in services](https://vaccinenation.org/technology/ray-cros-ahmed-hamouda-taking-pride-in-services/): In a throwback to the Barcelona Congress in October 2023 we are sharing a conversation with RAY CRO's Ahmed Hamouda, who joined us to share
- [FDA approval for Merck’s 21-valent CAPVAXIVE in adults](https://vaccinenation.org/technology/fda-approval-for-mercks-21-valent-capvaxive-in-adults/): In June 2024 Merck (known as MSD outside the US and Canada) announced that the FDA has approved CAPVAXIVE for the prevention of invasive
- [Fiocruz and SINOVAC partner for research and development](https://vaccinenation.org/technology/fiocruz-and-sinovac-partner-for-research-and-development/): In June 2024, the Oswaldo Cruz Foundation (Fiocruz) announced that SINOVAC is to invest $100 million in the development of cell therapy, vaccine
- [NextGen funding for Vaxart’s oral pill COVID-19 vaccine](https://vaccinenation.org/technology/nextgen-funding-for-vaxarts-oral-pill-covid-19-vaccine/): In June 2024 Vaxart announced that it has received a project award valued at up to $453 million to conduct a Phase IIb comparative study to evaluate
- ["Driving" research with EmVenio Research's Thad Wolfram](https://vaccinenation.org/technology/driving-research-with-emvenio-researchs-thad-wolfram/): Our next interview from The World Vaccine Congress in Washington is with EmVenio Research's President Thad Wolfram, who joined us to present
- [NextGen funding for CyanVac intranasal vaccine study](https://vaccinenation.org/technology/nextgen-funding-for-cyanvac-intranasal-vaccine-study/): In June 2024 CyanVac announced that it has received a funding award under Project NextGen to support a Phase IIb study of CVXGA, the company’s
- [Infectious disease insights: AHCC's Dr Jerry Brown](https://vaccinenation.org/infection/infectious-disease-insights-ahccs-dr-jerry-brown/): Next in our series of interviews with experts at The World Vaccine Congress in Washington is a conversation with Absolute Health Care Centre's Dr Jerry Brown
- [Gavi and partners announce support for rabies PEP](https://vaccinenation.org/global-health/gavi-and-partners-announce-support-for-rabies-pep/): In June 2024 Gavi announced its support for human rabies vaccines for post exposure prophylaxis (PEP) within routine immunisation.
- [South Africa announces second mpox death among six cases](https://vaccinenation.org/infection/south-africa-announces-second-mpox-death-among-six-cases/): In June 2024 South Africa’s Minister of Health, Dr Joe Phaahla, announced an additional laboratory-confirmed case of mpox and a second death
- [Study compares vaccines against otitis media hearing loss](https://vaccinenation.org/global-health/study-compares-vaccines-against-otitis-media-hearing-loss/): A study in PLOS Medicine in June 2023 compares otitis media (OM)-related hearing loss in children randomised to one of two pneumococcal conjugate vaccine
- [Update from WHO on avian influenza case in Mexico](https://vaccinenation.org/infection/update-from-who-on-avian-influenza-case-in-mexico/): In June 2024, shortly after a notification of a fatal case of human infection with avian influenza in Mexico, WHO shared a disease outbreak news update
- [WHO: outbreaks of Oropouche virus in Cuba present risk](https://vaccinenation.org/infection/who-outbreaks-of-oropouche-virus-in-cuba-presents-risk/): In June 2024, WHO shared a disease outbreak news update stating that it has been notified of outbreaks of Oropouche virus disease in two provinces of Cuba
- [Study finds protection against pertussis in mRNA platform](https://vaccinenation.org/technology/study-finds-protection-against-pertussis-in-mrna-platform/): A study in npj vaccines in June 2024 presents the mRNA vaccine platform as a potential solution to bacterial infections. Immunogenicity and challenge
- [Study links COVID-19 vaccine side effects to nAB responses](https://vaccinenation.org/global-health/study-links-covid-19-vaccine-side-effects-to-nab-responses/): A study in Annals of Internal Medicine in June 2024 suggests that short-term systemic side effects of SARS-CoV-2 mRNA vaccination “are associated
- [EU arms itself against avian influenza with CSL Seqirus](https://vaccinenation.org/global-health/eu-arms-itself-against-avian-influenza-with-csl-seqirus/): In June 2024 the European Commission announced that the Health Emergency Preparedness and Response Authority (HERA) has signed a joint
- [Nykode’s mRNA-LNP platform has “significant advantages”](https://vaccinenation.org/therapeutic/nykodes-mrna-lnp-platform-has-significant-advantages/): In June 2024 Nykode Therapeutics announced updates to its mRNA platform, highlighting the “significant advantages” of its APC-targeted neoantigen
- [Pneumococcal disease vaccines: impact and cost-effectiveness](https://vaccinenation.org/global-health/pneumococcal-disease-vaccines-impact-and-cost-effectiveness/): A study in Vaccine presents a comparison of the impact and cost-effectiveness (CE) of vaccination against pneumococcal disease in England.
- [Study to investigate Ebola booster vaccination efforts](https://vaccinenation.org/technology/study-to-investigate-ebola-booster-revaccination-efforts/): A study by the Institute of Tropical Medicine Antwerp (ITM) and the National Institute for Biomedical Research (INRB) in the Democratic Republic
- [A safer and healthier Africa: Dr Yewande Alimi of Africa CDC](https://vaccinenation.org/global-health/a-safer-and-healthier-africa-dr-yewande-alimi-of-africa-cdc/): Our next conversation from The World Vaccine Congress welcomed Africa CDC's Dr Yewande Alimi to our interview zone. Dr Alimi joined us during
- [ACT EU launches advice pilots to improve clinical trials](https://vaccinenation.org/technology/act-eu-launches-advice-pilots-to-improve-clinical-trials/): In June 2024 the European Medicines Agency (EMA) announced that the Accelerating Clinical Trials in the EU (ACT EU) initiative is launching
- [Moderna: influenza and COVID-19 combination vaccine data](https://vaccinenation.org/technology/moderna-influenza-and-covid-19-combination-vaccine-data/): In June 2024 Moderna announced that its Phase III trial of mRNA-1083 has met primary endpoints, eliciting a higher immune response than the
- [FDA approval of GSK’s RSV vaccine in adults 50-59](https://vaccinenation.org/technology/fda-approval-of-gsks-rsv-vaccine-in-adults-50-59/): GSK announced in June 2024 that the US FDA has approved its RSV vaccine, Arexvy, for the prevention of RSV lower respiratory tract disease
- [Gavi: decisions to accelerate global immunisation](https://vaccinenation.org/global-health/gavi-decisions-to-accelerate-global-immunisation/): In June 2024 the Board of Gavi, the Vaccine Alliance, shared a series of decisions to “provide a framework for the acceleration of global immunisation”
- [No link between COVID-19 vaccine in pregnancy and stillbirth](https://vaccinenation.org/global-health/no-link-between-covid-19-vaccine-in-pregnancy-and-stillbirth/): A study in Obstetrics and Gynaecology in June 2024 examines the association between COVID-19 vaccination during pregnancy and stillbirth
- [Preprint: Nipah vaccine found safe and immunogenic in study](https://vaccinenation.org/technology/preprint-nipah-vaccine-found-safe-and-immunogenic-in-study/): A study shared as a The Lancet preprint in May 2024 presents the results of an evaluation of a potential Nipah virus (NiV) vaccine. The recombinant
- [Study: need for vaccination “nuances” at local level](https://vaccinenation.org/global-health/study-need-for-vaccination-nuances-at-local-level/): In May 2024, Pennsylvania State University shared that their research, published in Vaccine, reveals the importance of considering “nuances at
- [Mexico reports fatal case of human avian influenza A(H5N2)](https://vaccinenation.org/infection/mexico-reports-fatal-case-of-human-avian-influenza-ah5n2/): In June 2024 WHO shared a disease outbreak news update stating that the Mexico International Health Regulations (IHR) National Focal Point (NFP)
- [Novel vaccine platform induces long-lasting COVID immunity](https://vaccinenation.org/technology/novel-vaccine-platform-induces-long-lasting-covid-immunity/): In June 2024 a team from Monash University shared that a collaboration with the Yong Loo Lin School of Medicine at the National University of Singapore
- [US adults still believe false MMR vaccine autism claim](https://vaccinenation.org/global-health/us-adults-still-believe-false-mmr-vaccine-autism-claim/): A study from the Annenberg Public Policy Centre (APPC) in June 2024 reveals that a quarter of US adults are unaware that “claims that the MMR
- [Study investigates Facebook vaccine misinformation](https://vaccinenation.org/global-health/study-investigates-facebook-vaccine-misinformation/): A study in Science in May 2024 explores the link between social media misinformation and vaccination intentions in the US. The researchers consider
- [£2.5 million contract for hVIVO’s Omicron study](https://vaccinenation.org/technology/2-5-million-contract-for-hvivos-omicron-study/): In June 2024, hVIVO announced that it has signed a £2.5 million contract with a mid-sized pharmaceutical company to initiate an Omicron characterisation study
- [Sustained improvement in Moderna and Merck 3-year data](https://vaccinenation.org/therapeutic/sustained-improvement-in-moderna-and-merck-3-year-data/): In June 2024 Moderna and Merck announced the first presentation of results from a planned analysis from the Phase IIb randomised KEYNOTE-
- [WHO dengue update: over 7.6 million cases this year](https://vaccinenation.org/infection/who-dengue-update-over-7-6-million-cases-this-year/): In May 2024 the WHO shared a disease outbreak news update on the global dengue situation, stating that by 30th April 2024 over 7.6 million dengue
- [First enrolment in Transgene head and neck cancer trial](https://vaccinenation.org/therapeutic/first-enrolment-in-transgene-head-and-neck-cancer-trial/): Transgene announced in June 2024 that the first patient has been enrolled in the Phase II part of a randomised Phase I/II clinical trial of TG4050
- [World Health Assembly progress: IHR and Pandemic Agreement](https://vaccinenation.org/global-health/world-health-assembly-progress-ihr-and-pandemic-agreement/): WHO shared in June 2024 that at the annual meeting of its 194 member countries, the World Health Assembly (WHA), a “historic” agreement was
- [US FDA approval for Moderna’s mRESVIA in older adults](https://vaccinenation.org/technology/us-fda-approval-for-modernas-mresvia-in-older-adults/): Moderna announced in May 2024 that the US FDA has approved mRESVIA (mRNA-1345), its mRNA respiratory syncytial virus (RSV) vaccine
- [CEPI and Bavarian Nordic partner on children’s mpox vaccine](https://vaccinenation.org/technology/cepi-and-bavarian-nordic-partner-on-childrens-mpox-vaccine/): In May 2024, CEPI and Bavarian Nordic announced a partnership to advance the development of Bavarian Nordic’s mpox vaccine in children in Africa.
- [Truly novel technology with AstraZeneca's Dr Antu Dey](https://vaccinenation.org/technology/truly-novel-technology-with-astrazenecas-dr-antu-dey/): Next from our series of conversations with experts at The World Vaccine Congress in Washington is an interview with Dr Antu Dey from Icosovax,
- [NHS patients access personalised cancer vaccine trials](https://vaccinenation.org/therapeutic/nhs-patients-access-personalised-cancer-vaccine-trials/): NHS England announced in May 2024 that “thousands” of cancer patients across the country will get “fast-tracked” access to trials of personalised
- [US: another human avian influenza case but risk “low”](https://vaccinenation.org/infection/us-another-human-avian-influenza-case-but-risk-low/): In May 2024 the US CDC announced that a second human case of highly pathogenic avian influenza (HPAI) A (H5) virus infection had been identifie
- [Synthetic biology produces QS-21 adjuvant in yeast](https://vaccinenation.org/technology/synthetic-biology-produces-qs-21-adjuvant-in-yeast/): Researchers from University of California, Berkeley, shared research in Nature that demonstrates the complete biosynthesis of QS-21 in engineered
- [Gavi and CEPI expand partnership for vaccine access](https://vaccinenation.org/global-health/gavi-and-cepi-expand-partnership-for-vaccine-access/): In May 2024, Gavi and CEPI announced the expansion of their partnership to “enhance the rapid development, deployment, and access to vaccines
- ["Follow the science", says GWU's Dr Anita Patel](https://vaccinenation.org/global-health/follow-the-science-says-gwus-dr-anita-patel/): Our next interview from The World Vaccine Congress in Washington features George Washington University's Dr Anita Patel, who joined us at the Congress
- [Preparing for pandemics: influenza A virus vaccines](https://vaccinenation.org/global-health/preparing-for-pandemics-influenza-a-virus-vaccines/): A paper in Human Vaccines & Immunotherapeutics in May 2024 presents a review of pandemic preparedness for avian influenza viruses, which
- [Creating a "ripple effect" with UIC's Dr Katrine Wallace](https://vaccinenation.org/global-health/creating-a-ripple-effect-with-uics-dr-katrine-wallace/): Our next interview guest from The World Vaccine Congress in Washington is Dr Katrine Wallace from the University of Illinois, Chicago. Dr Wallace
- [CEPI and BioNTech expand African ecosystem partnership](https://vaccinenation.org/technology/cepi-and-biontech-expand-african-ecosystem-partnership/): In May 2024 CEPI announced that it is expanding its strategic partnership with BioNTech to contribute to “building a sustainable and resilient end-to-end
- [Launching into the future with AstraZeneca's Dr Bret Sellman](https://vaccinenation.org/technology/launching-into-the-future-with-astrazenecas-dr-bret-sellman/): In our series of conversations conducted with experts at The World Vaccine Congress in Washington this April we were able to meet AstraZeneca's Dr Bret Sellman,
- [Aerosol vaccine to protect poultry from bacterial disease](https://vaccinenation.org/technology/aerosol-vaccine-to-protect-poultry-from-bacterial-disease/): In May 2024, the University of Saskatchewan (USask) shared that a research team from Western College of Veterinary Medicine (WCVM) has
- [ILiAD announces positive interim results in SUPER trial](https://vaccinenation.org/technology/iliad-announces-positive-interim-results-in-super-trial/): In May 2024, ILiAD Biotechnologies reported positive topline interim results for BPZE1 in the Stand Up to Pertussis (SUPER) trial. The school-age
- [CMV-vector vaccine a potential “shield” against cancer](https://vaccinenation.org/therapeutic/cmv-vector-vaccine-a-potential-shield-against-cancer/): Researchers at Oregon Health & Science University (OHSU) shared in May 2024 that their platform for cytomegalovirus-based vaccines has “promise”
- [COVID-19 vaccination in children: favourable safety profile](https://vaccinenation.org/global-health/covid-19-vaccination-in-children-favourable-safety-profile/): A paper in Nature Communications in May 2024 presents the results of a self-controlled case-series study of over 5 million children in England
- [Japanese encephalitis virus study highlights vaccine need](https://vaccinenation.org/global-health/japanese-encephalitis-virus-study-highlights-vaccine-need/): A paper by a team from QIMR Berghofer in npj viruses in May 2024 presents insights into the rare sub-type of the mosquito-borne Japanese encephalitis
- [Study investigates mRNA vaccine against HPAI H5N1](https://vaccinenation.org/technology/study-investigates-mrna-vaccine-against-hpai-h5n1/): In May 2024, the University of Pennsylvania announced that its researchers have published research in Nature Communications that suggests
- [Opening doors with MICHADVICES' Dr Micha Roumiantzeff](https://vaccinenation.org/technology/opening-doors-with-michadvices-dr-micha-roumiantzeff/): Our next interview guest from The World Vaccine Congress in Washington is Dr Micha Roumiantzeff, CEO and President at MICHADVICES. Dr Roumiantzeff
- [SpyBiotech and Oxford collaborate on vaccine against EBV](https://vaccinenation.org/technology/spybiotech-and-oxford-collaborate-on-vaccine-against-ebv/): In May 2024 SpyBiotech announced a sponsored research agreement with the University of Oxford for the development of a vaccine against Epstein-Barr
- [PRESTO project to support vaccine clinical trial efforts](https://vaccinenation.org/technology/presto-project-to-support-vaccine-clinical-trial-efforts/): CEPI announced in May 2024 that it is supporting researchers from the University of Oxford on a project called ‘PREpare using Simulated Trial Optimisation
- [Obsessed with changing lives: Acasus' Ahmed Razzak](https://vaccinenation.org/global-health/obsessed-with-changing-lives-acasus-ahmed-razzak/): Our next interview from The World Vaccine Congress in Washington is with Ahmed Razzak from Acasus, the company making "brave change"
- [WHO and RLM share review of climate change and disease](https://vaccinenation.org/global-health/who-and-rlm-share-review-of-climate-change-and-disease/): In May 2024, WHO shared that its Task Team on Climate Change, Neglected Tropical Diseases (NTDs), and Malaria, has issued a scoping review
- [Transformational technology with LumaCyte's Renée Hart](https://vaccinenation.org/technology/transformational-technology-with-lumacytes-renee-hart/): Up next in our series of conversations with experts at The World Vaccine Congress in Washington is an interview with LumaCyte's Renée Hart,
- [Vaccine development: machine learning against malaria](https://vaccinenation.org/technology/vaccine-development-machine-learning-against-malaria/): A study in npj systems biology and applications in April 2024 presents an approach for “identifying and prioritising vaccine antigens” using a machine
- [Next generation ambitions: GeoVax's Dr Mark Newman](https://vaccinenation.org/technology/next-generation-ambitions-geovaxs-dr-mark-newman/): Up next in our series of conversations with experts from The World Vaccine Congress in Washington is an interview with Geovax's Dr Mark Newman.
- [NIAID-funded partnership to develop Chlamydia vaccine](https://vaccinenation.org/technology/niaid-funded-partnership-to-develop-chlamydia-vaccine/): In May 2024, the University of North Carolina at Chapel Hill announced that it is leading a partnership with National Institute of Allergy and Infectious
- [International partnership to fund novel cancer research](https://vaccinenation.org/therapeutic/international-partnership-to-fund-novel-cancer-research/): In May 2024, CureSearch for Children’s Cancer announced a partnership with LifeArc intended to create “far-reaching impact for kids with cancer”.
- [WHO report identifies “major” increase in STIs](https://vaccinenation.org/infection/who-report-identifies-major-increase-in-stis/): A WHO report shared in May 2024 details the continued “significant public health challenges” posed by HIV, viral hepatitis epidemics, and sexually
- [“Promising” replicating RNA vaccine against CCHFV](https://vaccinenation.org/technology/promising-replicating-rna-vaccine-against-cchfv/): A study in npj vaccines in May 2024 presents a “promising" replicating RNA vaccine in a rhesus macaque model of Crimean-Congo haemorrhagic
- [Propelling science into projects: Integrum's Joe Sgherza](https://vaccinenation.org/global-health/propelling-science-into-projects-integrums-joe-sgherza/): Next in our interview series from The World Vaccine Congress in Washington is a conversation with Integrum Scientific's Joe Sgherza; we were glad
- [Serum Institute of India ships malaria vaccine to Africa](https://vaccinenation.org/global-health/serum-institute-of-india-ships-malaria-vaccine-to-africa/): In May 2024 Serum Institute of India (SII) announced that it was shipping the first set of R21/Matrix-M vaccines to the African region in a “significant
- [We need "clear goals, clear aims", says EI's Emily Tiemann](https://vaccinenation.org/global-health/we-need-clear-goals-clear-aims-says-eis-emily-tiemann/): Next in our series of conversations with experts at The World Vaccine Congress in Washington is an interview with Economist Impact's Emily Tiemann,
- [UK cryptosporidium outbreak prompts water concern](https://vaccinenation.org/infection/uk-cryptosporidium-outbreak-prompts-water-concern/): The UKHSA shared guidance and information on cryptosporidium in May 2024 following South West Water’s acknowledgement that “small traces”
- [HPV vaccine “highly effective” against cervical disease](https://vaccinenation.org/global-health/hpv-vaccine-highly-effective-against-cervical-disease/): A study in BMJ in May 2024 reveals that HPV vaccination reduced rates of cervical cancer and pre-cancerous conditions in women in England.
- [UK pledges £85m in fight against AMR, WHO updates BPPL](https://vaccinenation.org/global-health/uk-pledges-85m-in-fight-against-amr-who-updates-bppl/): In May 2024 the UK Government announced that it will commit up to £85 million to the “growing threat" of antimicrobial resistance (AMR). At an event
- [Working towards a common goal with Merck's Dr Jules Millogo](https://vaccinenation.org/global-health/working-towards-a-common-goal-with-mercks-dr-jules-millogo/): Our next interview from the Congress in Washington features Merck's Dr Jules Millogo, who joined us for a panel in the Vaccine Supply and Logistics track:
- [Vernal's versatile technology: Dr Grant Henderson](https://vaccinenation.org/technology/vernals-versatile-technology-dr-grant-henderson/): Our next interview from the Congress in Washington is a conversation with Vernal Biosciences' Dr Grant Henderson, who joined us at the event
- [‘GPS’ vaccine approach guides immune system against HIV](https://vaccinenation.org/technology/gps-vaccine-approach-guides-immune-system-against-hiv/): In May 2024, researchers at Duke University School of Medicine’s Duke Human Vaccine Institute (DHVI) shared that they have developed a vaccine
- [Dengue vaccine prequalification amid disease concern](https://vaccinenation.org/infection/dengue-vaccine-prequalification-amid-disease-concern/): In May 2024 WHO announced the prequalification of Takeda’s dengue vaccine TAK-003, the second dengue vaccine prequalified by WHO. The vaccine
- [Go fast and far together, says Parexel's Dr Anne Kasmar](https://vaccinenation.org/technology/go-fast-and-far-together-says-parexels-dr-anne-kasmar/): Another of experts who made time for us at the Congress in Washington last month is Parexel's Dr Anne Kasmar, who joined us at the event to discuss
- [Valneva reports positive Phase III data in adolescents](https://vaccinenation.org/technology/valneva-reports-positive-phase-iii-data-in-adolescents/): In May 2024, Valneva reported positive pivotal Phase III data in adolescents for the single-shot chikungunya virus (CHIKV) vaccine, VLA1553
- [Nykode and MSD expand therapeutic combination collaboration](https://vaccinenation.org/therapeutic/nykode-and-msd-expand-therapeutic-combination-collaboration/): In May 2024, Nykode Therapeutics announced that it has expanded its collaboration with MSD to include a clinical trial collaboration and supply
- [Takeda and AC Immune sign agreement on Alzheimer's vaccine](https://vaccinenation.org/therapeutic/takeda-and-ac-immune-sign-agreement-on-alzheimers-vaccine/): Takeda announced in May 2024 that it has entered an exclusive, worldwide option and license agreement with AC Immune for the latter’s active
- [Importance of measles double dose for C-section babies](https://vaccinenation.org/global-health/importance-of-measles-double-dose-for-c-section-babies/): In May 2024 the University of Cambridge shared that research published in Nature Microbiology (not open access) in partnership with Fudan University,
- [Novavax and Sanofi enter COVID and flu licensing agreement](https://vaccinenation.org/technology/novavax-and-sanofi-enter-covid-and-flu-licensing-agreement/): In May 2024, Novavax and Sanofi announced that they have entered an agreement to co-commercialise Novavax’s COVID-19 vaccine and develop
- [Science will win, says Valneva's Thomas Lingelbach](https://vaccinenation.org/global-health/science-will-win-says-valnevas-thomas-lingelbach/): Next from our series of conversations with experts at The World Vaccine Congress in Washington this April is our interview with Valneva's Thomas Lingelbach,
- [Experts say “perspective” needed on AstraZeneca withdrawal](https://vaccinenation.org/global-health/experts-say-perspective-needed-on-astrazeneca-withdrawal/): After the announcement that the AstraZeneca COVID vaccine has been withdrawn from the market, public health experts weighed in on media
- [Representative recruitment is key for Dr Michael Caldwell](https://vaccinenation.org/global-health/representative-recruitment-is-key-for-dr-michael-caldwell/): Our next interview from The World Vaccine Congress in Washington this April is with Dr Michael Caldwell of Meharry Medical College, who joined
- [Saudi Arabia reports 3 human cases of MERS-CoV in April](https://vaccinenation.org/infection/saudi-arabia-reports-3-human-cases-of-mers-cov-in-april/): In May 2024 WHO issued a Disease Outbreak News (DON) update stating that it has been notified of three human cases, including one death,
- [UKHSA data show pertussis cases still increasing](https://vaccinenation.org/infection/ukhsa-data-show-pertussis-cases-still-increasing/): In May 2024, the UKHSA shared that recent data reveal cases of whooping cough “continue to increase”, with the highest burden born by infants
- [Partnering for pigs: Pirbright and TVG tackle ASF](https://vaccinenation.org/global-health/partnering-for-pigs-pirbright-and-tvg-tackle-asf/): In May 2024 the Pirbright Institute announced a partnership with researchers at The Vaccine Group on a project that “sets out to control African swine fever
- [Broadening challenge studies: hVIVO's Dr Andrew Catchpole](https://vaccinenation.org/technology/broadening-challenge-studies-hvivos-dr-andrew-catchpole/): During our time in Washington for The World Vaccine Congress in April we were glad to meet some of our experts for exclusive conversations about their work.
- [Vertical transmission milestones for the Americas](https://vaccinenation.org/infection/vertical-transmission-milestones-for-the-americas/): In May 2024 PAHO celebrated the latest countries in the Americas that have received WHO certification of the elimination of mother-to-child transmission
- [Vaccine “fatigue”: drop in NHS worker flu vaccine uptake](https://vaccinenation.org/global-health/vaccine-fatigue-drop-in-nhs-worker-flu-vaccine-uptake/): In May 2024 the Local Democracy Reporting Service (LDRS) told the BBC that a decrease in flu vaccine uptake is being attributed to vaccine “fatigue”.
- [Measuring progress: data for action with EI's Latifat Okara](https://vaccinenation.org/global-health/measuring-progress-data-for-action-with-eis-latifat-okara/): Our next conversation from The World Vaccine Congress in Washington is with Economist Impact's Latifat Okara, who joined us to Chair the Market Access
- [Igniting innovation in vaccine development: Early-stage companies fuel the future](https://vaccinenation.org/technology/igniting-innovation-in-vaccine-development-early-stage-companies-may-fuel-the-future/): Last month, I had the pleasure of attending the World Vaccine Congress—an experience that left me feeling inspired, energized, and excited about the future
- [An emerging global health threat: climate change's impact on infectious diseases](https://vaccinenation.org/infection/an-emerging-global-health-threat-climate-changes-impact-on-infectious-diseases/): This is a guest post, kindly authored by Dr Juan Carlos Jaramillo, Chief Medical Officer, Valneva, and Vice President, Vaccines Europe.
- [Infrastructure for innovation with AAHI's Candice Decaire](https://vaccinenation.org/global-health/infrastructure-for-innovation-with-aahis-candice-decaire/): Our next interview from our time at the Congress in Washington is a conversation with AAHI's Candice Decaire, who joined us at the event for a session
- [Quartet Nanocages against different coronaviruses in study](https://vaccinenation.org/technology/quartet-nanocages-against-different-coronaviruses-in-study/): In May 2024, researchers at the University of Cambridge stated that they have developed a new vaccine technology to provide protection against
- [Conversations across the law continuum: Brian Dean Abramson](https://vaccinenation.org/global-health/conversations-across-the-law-continuum-brian-dean-abramson/): The next in our series of interviews with experts from The World Vaccine Congress in Washington features Brian Dean Abramson of the National Vaccine
- [WHO and IDIA renew agreement for health impact](https://vaccinenation.org/technology/who-and-idia-renew-agreement-for-health-impact-2/): In May 2024, WHO and the International Development Innovation Alliance (IDIA) announced the renewal of their strategic Collaborative Agreement
- [Science, accelerated: Q² Solutions' Dr Luc Gagnon](https://vaccinenation.org/technology/science-accelerated-q²-solutions-dr-luc-gagnon/): At this year's World Vaccine Congress in Washington we were privileged to meet some of our vaccine experts, to hear their insights and learn more
- [“Fierce” response with mRNA vaccine against glioblastoma](https://vaccinenation.org/therapeutic/fierce-response-with-mrna-vaccine-against-glioblastoma/): Researchers at the University of Florida shared in May 2024 that in a first in human trial of four adult patients, an mRNA cancer vaccine “quickly
- [Study identifies need for targeted, sensitive communication](https://vaccinenation.org/global-health/study-identifies-need-for-targeted-sensitive-communication/): In Nature Medicine in April 2024 researchers explore perspectives on COVID-19 and routine immunisation alongside trust in pandemic information
- [The vaccine service A Team: Allucent's Dr Bruce McClenathan](https://vaccinenation.org/technology/the-vaccine-service-a-team-allucents-dr-bruce-mcclenathan/): Next in our series of conversations with experts at the recent Congress in Washington is an interview with Allucent's Dr Bruce McClenathan, who joined
- [Study: in pursuit of a universal live-attenuated RNA vaccine](https://vaccinenation.org/technology/study-in-pursuit-of-a-universal-live-attenuated-rna-vaccine/): A PNAS study shared by researchers at UC Riverside in April 2024 explores the benefits of a “one-and-done" approach to vaccinations for infectious
- [Mabtech: a scientific one-stop shop, says Dr Tyler Sandberg](https://vaccinenation.org/technology/mabtech-a-scientific-one-stop-shop-says-dr-tyler-sandberg/): Our next interview from The World Vaccine Congress in Washington this April is a conversation with Mabtech's Dr Tyler Sandberg, who joined us
- [United in the fight: DRC battles growing mpox outbreak](https://vaccinenation.org/infection/united-in-the-fight-drc-battles-growing-mpox-outbreak/): In April 2024 Ministers of Health and partners in Africa met in Kinshasa, Democratic Republic of Congo, for a high-level emergency regional meeting
- [UK begins trial of personalised mRNA against melanoma](https://vaccinenation.org/therapeutic/uk-begins-trial-of-personalised-mrna-against-melanoma/): In April 2024 we learnt of a trial of a personalised mRNA vaccine against the most dangerous form of skin cancer, melanoma. Recruitment for the University
- [Watch this space: microarray patch vaccine safe, effective](https://vaccinenation.org/technology/watch-this-space-microarray-patch-vaccine-safe-effective/): A study in The Lancet in April 2024 reveals that the use of microarray patches for vaccination is “safe and effective” as the technology has been
- [A sustainable vaccine ecosystem: EI's Miranda Baxa](https://vaccinenation.org/global-health/a-sustainable-vaccine-ecosystem-eis-miranda-baxa/): At The World Vaccine Congress in Washington we were thrilled to meet Economist Impact's Miranda Baxa for a conversation about the work she and her team
- [Avian influenza in milk and a joint risk assessment](https://vaccinenation.org/infection/avian-influenza-in-milk-and-a-joint-risk-assessment/): A joint risk assessment from FAO/WHO/WOAH in April 2024 considers the public health risk and risk of virus spread among animals for the A(H5N1)
- [BTV 3 vaccine authorised for emergency use in Netherlands](https://vaccinenation.org/global-health/btv-3-vaccine-authorised-for-emergency-use-in-netherlands/): In April 2024 Syva Laboratories announced that its vaccine against bluetongue serotype 3 (BTV3) has been authorised for emergency use in the Netherlands.
- [Redefining access with ApiJect's Dr Ed Kelley](https://vaccinenation.org/technology/redefining-access-with-apijects-dr-ed-kelley/): During The World Vaccine Congress in Washington this year we were excited to speak to several of our wonderful vaccine experts to hear about their work.
- [Accelerating the fight: World Malaria Day 2024](https://vaccinenation.org/infection/accelerating-the-fight-world-malaria-day-2024/): For World Malaria Day 2024, WHO shared a message from the Director of the WHO Global Malaria Programme and emphasised the need to return
- [Humanly possible: World Immunisation Week 2024](https://vaccinenation.org/global-health/humanly-possible-world-immunisation-week-2024/): In celebration of World Immunisation Week 2024 (24th-30th April) WHO is urging collective action to ensure that everyone benefits from the life-saving
- [A different kind of knowledge: Dr Christine Stabell Benn](https://vaccinenation.org/global-health/a-different-kind-of-knowledge-dr-christine-stabell-benn/): At The World Vaccine Congress in Washington this year we were lucky to meet some of our experts for exclusive insights into their work and the content
- [ECDC shares “disheartening” data on disease increases](https://vaccinenation.org/infection/ecdc-shares-disheartening-data-on-disease-increases/): During European Immunisation Week 2024 (21st-27th April), the European Centre for Disease Prevention and Control (ECDC) released data that show
- [WHO marks European Immunisation Week and EPI anniversary](https://vaccinenation.org/global-health/who-marks-european-immunisation-week-and-epi-anniversary/): From 21st to 27th April 2024 the European Region celebrates European Immunisation Awareness Week (EIW) with a range of events and initiatives
- [PAHO warns of unprotected children in the Americas](https://vaccinenation.org/global-health/paho-warns-of-unprotected-children-in-the-americas/): In April 2024 the Pan American Health Organisation (PAHO) warned that, despite recent vaccination “gains”, millions of children are unprotected
- [WHO announces prequalification for new cholera vaccine](https://vaccinenation.org/global-health/who-announces-prequalification-for-new-cholera-vaccine/): In April WHO announced that a new oral vaccine for cholera has received prequalification during what has been described as an unprecedented multi-year upsurge
- [Gritstone shares “positive” data in ongoing GRANITE trial](https://vaccinenation.org/therapeutic/gritstone-shares-positive-data-in-ongoing-granite-trial/): In April 2024 Gritstone bio announced “positive” preliminary data from an ongoing Phase II portion of the Phase II/III study to evaluate GRANITE.
- [WHO “sounds alarm” on hepatitis infections and deaths](https://vaccinenation.org/infection/who-sounds-alarm-on-hepatitis-infections-and-deaths/): In April 2024 WHO shared that the 2024 Global Hepatitis Report, released at the World Hepatitis Summit, reveals an increase in the number of lives
- [Measles: preventing a vaccine-preventable disease](https://vaccinenation.org/infection/measles-preventing-a-vaccine-preventable-disease/): This article is a guest post contributed by Giuliana Furiato. Measles is a viral illness caused by infection with the measles virus.
- [Geneos announces positive data in GT-30 clinical trial](https://vaccinenation.org/therapeutic/geneos-announces-positive-data-in-gt-30-clinical-trial/): In April 2024 Geneos Therapeutics announced the publication of “positive” safety, immunogenicity, and efficacy data from a full cohort of patients
- [For World Chagas Disease Day WHO urges early action](https://vaccinenation.org/infection/for-world-chagas-disease-day-who-urges-early-action/): Ahead of World Chagas Disease Day, observed on 14th April for the fifth year, WHO has issued a statement emphasising the importance of “early diagnosis
- [Old news: insights into vaccinating an aging population](https://vaccinenation.org/global-health/old-news-insights-into-vaccinating-an-aging-population/): In response to the “aging of the global population” and growing risks from various diseases, authors for npj vaccines consider the challenges and opportunities
- [Oral vaccine against UTIs shows long-term promise](https://vaccinenation.org/technology/oral-vaccine-against-utis-shows-long-term-promise/): The Royal Berkshire Foundation Trust announced in April 2024 that initial results from a long-term follow-up study of the safety and effectiveness
- [YS Biopharma announces positive Phase III rabies results](https://vaccinenation.org/technology/ys-biopharma-announces-positive-phase-iii-rabies-results/): In April 2024 YS Biopharma announced positive interim results from an ongoing Phase III clinical trial of its next-generation PIKA Rabies Vaccine.
- [WHO shares US avian influenza outbreak update](https://vaccinenation.org/infection/who-shares-us-avian-influenza-outbreak-update/): In April 2024 the United States reported a case of human infection with an influenza A(H5N1) virus; on 9th April 2024 the WHO shared a “disease
- [Tackling the AMR challenge with Reverse Vaccine Development](https://vaccinenation.org/global-health/tackling-the-amr-challenge-with-reverse-vaccine-development/): In an article for npj vaccines, a group of experts present an approach to effectively and efficiently evaluate vaccines against antimicrobial-resistant
- [Laser signal technology to assess mRNA vaccine stability](https://vaccinenation.org/technology/laser-signal-technology-to-assess-mrna-vaccine-stability/): In March 2024 researchers at the University of Albany announced that they have developed a new method to test the integrity of COVID-19 vaccines
- [Intravacc and Primrose Bio announce vaccine partnership](https://vaccinenation.org/technology/intravacc-and-primrose-bio-announce-vaccine-partnership/): In March 2024 Intravacc announced that it has entered a strategic partnership with Primrose Bio to enhance the development and supply of conjugate
- [ICG on Vaccine Provision demands “immediate” cholera action](https://vaccinenation.org/infection/icg-on-vaccine-provision-demands-immediate-cholera-action/): Amid an “unprecedented multi-year upsurge” in global cholera cases, the International Coordinating Group (ICG) on Vaccine Provision is appealing
- [Parents in England trust NHS staff on vaccine matters](https://vaccinenation.org/global-health/parents-in-england-trust-nhs-staff-on-vaccine-matters/): A survey from the UKHSA, shared in March 2024, reveals that “most” parents in England have a “positive view” of the childhood immunisation
- [CastleVax and Jurata: from neighbours to partners at WVC](https://vaccinenation.org/technology/castlevax-and-jurata-from-neighbours-to-partners-at-wvc/): With the Congress in Washington just around the corner VaccineNation is gearing up and getting ready to return to the US to meet our wonderful attendees
- [Altamira and Univercells partner on SemaPhore platform](https://vaccinenation.org/technology/altamira-and-univercells-partner-on-semaphore-platform/): In March 2024 Altamira Therapeutics announced that it has entered a collaboration with Univercells to evaluate the use of its SemaPhore platform
- [Funding for world’s first lung cancer vaccine development](https://vaccinenation.org/global-health/funding-for-worlds-first-lung-cancer-vaccine-development/): In March 2024 the University of Oxford announced that researchers from the university, the Francis Crick Institute, and University College London
- [Article: doctors and the duty against disinformation](https://vaccinenation.org/global-health/article-doctors-and-the-duty-against-disinformation/): In an article for Journal of Evaluation in Clinical Practice, Dr David Robert Grimes and Professor Trisha Greenhalgh consider the argument that regulatory
- [Study to investigate immune adaptations to malaria](https://vaccinenation.org/infection/study-to-investigate-immune-adaptations-to-malaria/): In March 2024 the University of Oxford announced a partnership with the University of Edinburgh to examine the immune system’s response to “repeated
- [WHO African Region shares yellow fever update](https://vaccinenation.org/infection/who-african-region-shares-yellow-fever-update/): In March 2024 the WHO African Region shared a “disease outbreak news” update on yellow fever (YF) in the region from the beginning of 2023. 13
- [Gates MRI begins tuberculosis vaccine trial in South Africa](https://vaccinenation.org/global-health/gates-mri-begins-tuberculosis-vaccine-trial-in-south-africa/): In March 2024 The Bill & Melinda Gates Medical Research Institute (Gates MRI) announced the commencement of a Phase III clinical trial to assess
- [Nykode announces therapeutic vaccine platform advances](https://vaccinenation.org/therapeutic/nykode-announces-therapeutic-vaccine-platform-advances/): In March 2024 Nykode Therapeutics announced “key updates” to the inverse vaccine platform with the potential to treat autoimmune diseases
- [Croda and AAHI announce vaccine innovation agreement](https://vaccinenation.org/technology/croda-and-aahi-announce-vaccine-innovation-agreement/): In March 2024 Croda and The Access to Advanced Health Institute (AAHI) announced the signing of a partnership agreement on innovation and
- [NIH grant supports elephantiasis vaccine development](https://vaccinenation.org/global-health/nih-grant-supports-elephantiasis-vaccine-development/): In March 2024 the University of Illinois Chicago announced that an NIH grant of $2.4 million will support UIC researchers as they bring a vaccine
- [Resilience Centre to use VR for vaccine development](https://vaccinenation.org/technology/resilience-centre-to-use-vr-for-vaccine-development/): In March 2024 the University of Birmingham announced that it is leading UK-wide training to “address critical skills demand in life sciences”. A new
- [Neurological conditions study: 1 in 3 affected](https://vaccinenation.org/global-health/neurological-conditions-study-1-in-3-affected/): In March 2024 WHO shared that a “major new study” in The Lancet Neurology reveals that more than 3 billion people worldwide were living with
- [DNA origami vaccines for precision immunotherapy](https://vaccinenation.org/therapeutic/dna-origami-vaccines-for-precision-immunotherapy/): In March 2024 researchers at Wyss Institute announced the publication of research that indicates the possibility that DNA origami could serve as a
- [Expressing mAbs from filamentous fungus for SARS-CoV-2](https://vaccinenation.org/technology/expressing-mabs-from-filamentous-fungus-for-sars-cov-2/): A study in Nature Communications in March 2024 presents the use of a genetically modified filamentous fungus expression system to produce
- [Parkinson’s: Vaxxinity shares “positive target engagement”](https://vaccinenation.org/therapeutic/parkinsons-vaxxinity-shares-positive-target-engagement/): In March 2024 Vaxxintiy announced “positive clinical data” from the UB-312 programme in Parkinson’s disease, presented by Dr Jean-Cosme Dodart
- [The importance of last mile vaccine delivery in Sierra Leone](https://vaccinenation.org/global-health/the-importance-of-last-mile-vaccine-delivery-in-sierra-leone/): An article in Nature in March 2024 presents the results of an “intervention with last-mile delivery” in Sierra Leone. The authors state that, even 18 month
- [mPower trial for mpox vaccine begins enrolment in UK](https://vaccinenation.org/global-health/mpower-trial-for-mpox-vaccine-begins-enrolment-in-uk/): An investigational mRNA vaccine for mpox is being tested in UK with enrolment for healthy volunteers beginning in March 2024. The mPower trial,
- [WOAH warns of threat from avian influenza in Antarctica](https://vaccinenation.org/infection/woah-warns-of-threat-from-avian-influenza-in-antarctica/): A statement from the World Organisation for Animal Health in March 2024 describes the “unprecedented milestone” reached by highly pathogenic avian
- [UK collaboration to advance henipavirus vaccine development](https://vaccinenation.org/infection/uk-collaboration-to-advance-henipavirus-vaccine-development/): In March 2024 the UK Health Security Agency (UKHSA) announced that a new collaboration with The Pirbright Institute has been launched to support
- [“Welcome progress” as child deaths reach “historic low”](https://vaccinenation.org/global-health/welcome-progress-as-child-deaths-reach-historic-low/): In March 2024 the United Nations Inter-agency Group for Child Mortality Estimation (UN IGME) shared a report that indicates that the number of children
- [Pfizer granted EC marketing authorisation for PREVENAR 20](https://vaccinenation.org/global-health/pfizer-granted-ec-marketing-authorisation-for-prevenar-20/): In March 2024 Pfizer announced that the European Commission (EC) has granted marketing authorisation for the company’s 20-valent pneumococcal
- [Study: communicating COVID-19 information in Australia](https://vaccinenation.org/global-health/study-communicating-covid-19-information-in-australia/): A study in PLOS One in February 2024 considers the factors that shaped COVID-19 communication and engagement efforts during the pandemic
- [Consortium to develop advanced coronavirus vaccines](https://vaccinenation.org/technology/consortium-to-develop-advanced-coronavirus-vaccines/): In March 2024 CEPI announced that an international consortium comprising experts in human challenge studies is beginning a project to develop advanced
- [Sudan responds to poliovirus outbreak with vaccine campaign](https://vaccinenation.org/infection/sudan-responds-to-poliovirus-outbreak-with-vaccine-campaign/): In March 2024 the WHO Eastern Mediterranean Region announced that Sudan’s Federal Ministry of Health (FMOH) is to launch a polio vaccination
- [CEPI funds novel “spin-freezing” vaccine technique](https://vaccinenation.org/technology/cepi-funds-novel-spin-freezing-vaccine-technique/): In March 2024 CEPI announced that it is providing up to $1.9 million to Ghent University to support investigations into a “pioneering vaccine stabilisation
- [Study: metal organic particles for better vaccine delivery](https://vaccinenation.org/technology/study-metal-organic-particles-for-better-vaccine-delivery/): A study in Science Advances in March 2024 reports the Toll-like receptor agonist activity of a nanoscale adjuvant zeolitic imidazolate framework-8 (ZIF-8)
- [Despite “negative” results, Ultimovacs “committed” to UV1](https://vaccinenation.org/therapeutic/despite-negative-results-ultimovacs-committed-to-uv1/): In March 2024 Ultimovacs announced topline results from the Phase II clinical trial INITIUM, which evaluates the therapeutic cancer vaccine
- [UKHSA warns of “continued increase” in pertussis cases](https://vaccinenation.org/infection/ukhsa-warns-of-continued-increase-in-pertussis-cases/): In March 2024 the UKHSA revealed that new data show a “continued increase” in cases of pertussis (whooping cough) at the start of the year.
- [Study: comparing vaccine storage cold boxes in Nepal](https://vaccinenation.org/technology/study-comparing-vaccine-storage-cold-boxes-in-nepal/): A study published in Vaccine X in February 2024 presents an evaluation of freeze prevention of vaccines transported and stored in the WHO-prequalified
- [CEPI invests in Amplitude’s trans-amplifying mRNA approach](https://vaccinenation.org/technology/cepi-invests-in-amplitudes-trans-amplifying-mrna-approach/): CEPI announced in March 2024 that it is providing up to $1 million funding to researchers at Amplitude Therapeutics in the US to support preclinical
- [Gates Foundation announces “historic” step against cancer](https://vaccinenation.org/infection/gates-foundation-announces-historic-step-against-cancer/): In March 2024 the Gates Foundation announced a collection of “major new policy, programmatic, and financial commitments” to contribute to efforts
- [AstraZeneca boosts UK Life Sciences with £650 million](https://vaccinenation.org/technology/astrazeneca-boosts-uk-life-sciences-with-650-million/): In March 2024 the UK Government announced that AstraZeneca plans to invest £650 million in the UK to boost the “world leading Life Sciences sector”
- [“Hypervaccinated” man safe but strategy not endorsed](https://vaccinenation.org/global-health/hypervaccinated-man-safe-but-strategy-not-endorsed/): A man who claims to have received more than 200 vaccinations against COVID-19 has been tested by researchers at Friedrich-Alexander-Universität
- [CARB-X announces funding for GlyProVac’s sepsis efforts](https://vaccinenation.org/technology/carb-x-announces-funding-for-glyprovacs-sepsis-efforts/): In February 2024 Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced that it is awarding GlyProVac $467,000
- [Animal study: Zika virus vaccine shown safe in pregnancy](https://vaccinenation.org/global-health/animal-study-zika-virus-vaccine-shown-safe-in-pregnancy/): In March 2024 the Texas Biomedical Research Institute shared that new research in npj Vaccines reveals that a vaccine against Zika virus is “safe
- [Expanded collaboration against cancer in trial of TG4050](https://vaccinenation.org/therapeutic/expanded-collaboration-against-cancer-in-trial-of-tg4050/): In March 2024 Transgene, NEC Corporation, and BostonGene Corporation announced the expansion of their collaboration for the randomised
- [Empathetic correction of misinformation for vaccine uptake](https://vaccinenation.org/global-health/empathetic-correction-of-misinformation-for-vaccine-uptake/): In March 2024 the University of Bristol shared that a study in Health Psychology identifies the importance of empathetic engagement with healthcare
- [Machine learning predicts vaccine ingestion in wild boars](https://vaccinenation.org/technology/machine-learning-predicts-vaccine-ingestion-in-wild-boars/): A study in Nature scientific reports explores the use of machine learning in predicting vaccine ingestion rate among wild boars in support of efforts
- [One Health leaders call for political will in implementation](https://vaccinenation.org/global-health/one-health-leaders-call-for-political-will-in-implementation/): At the Second Quadripartite Executive Annual Meeting in Nairobi, Kenya, in February 2024, the leaders of the four organisations of the Quadripartite
- [Mpox study shows need for surveillance, behaviour changes](https://vaccinenation.org/infection/mpox-study-shows-need-for-surveillance-behaviour-changes/): A study in Cell in February 2024 explores mpox transmission and population-level changes associated with controlling the spread after the public
- [Pfizer announces top-line ABRYSVO data for RSV](https://vaccinenation.org/technology/pfizer-announces-top-line-abrysvo-data-for-rsv/): In February 2024 Pfizer announced top-line ABRYSVO vaccine efficacy and safety data from the ongoing Phase III RENOIR (RSV vaccine Efficacy
- [Investigating AMR: 18 new enterococci found in study](https://vaccinenation.org/infection/investigating-amr-18-new-enterococci-found-in-study/): In February 2024 Mass Eye and Ear announced the publication of a paper in Proceedings of the National Academy of Sciences (PNAS) that describes
- [Not vaccinated, not protected: UKHSA launches campaign](https://vaccinenation.org/global-health/not-vaccinated-not-protected-ukhsa-launches-campaign/): In February 2024 UKHSA announced that a new marketing campaign is to be launched across England to “remind parents and carers” of the risks
- [Africa CDC learns from COVID-19 for future pandemics](https://vaccinenation.org/global-health/africa-cdc-learns-from-covid-19-for-future-pandemics/): In an article for BMJ Global Health in February 2024 a group of authors from Africa CDC consider the role that their organisation played during
- [WHO: Nipah virus causes two deaths in Bangladesh](https://vaccinenation.org/infection/who-nipah-virus-causes-two-deaths-in-bangladesh/): In February 2024 WHO reported that two laboratory-confirmed cases of Nipah virus (NiV) infection have been identified from the Dhaka division
- [UK needs permanent vaccine ecosystem, says former VTF chair](https://vaccinenation.org/technology/uk-needs-permanent-vaccine-ecosystem-says-former-vtf-chair/): In written evidence submitted to the Committee for Science, Innovation, and Technology for the inquiry into lessons from the pandemic Dr Clive Dix
- [ZosterFluCOV trial opens to volunteers in the UK](https://vaccinenation.org/technology/zosterflucov-trial-opens-to-volunteers-in-the-uk/): In February 2024 the University Hospital Southampton announced that volunteers aged 50 and over are being invited to participate in a trial that
- ["Better vaccines, faster": Deepflare's Piotr and Grzegorz](https://vaccinenation.org/technology/better-vaccines-faster-deepflares-piotr-and-grzegorz/): Another of our Congress Conversations from our European event in October last year was with start-up Deepflare, represented by Piotr and Grzegorz.
- [TherVacB: therapeutic hepatitis B vaccine enters trial](https://vaccinenation.org/therapeutic/thervacb-therapeutic-hepatitis-b-vaccine-enters-trial/): In February 2024 Helmholtz Munich announced that a vaccine designed and developed under its leadership has entered a clinical trial. The vaccine,
- [Donor funding to support pathogen genomic surveillance](https://vaccinenation.org/global-health/donor-funding-to-support-pathogen-genomic-surveillance/): WHO announced in February 2024 that donor funding to a total of $4 million will create a “catalytic grant fund” to support organisations working
- [Study explores benefits of “hexaplex” flu vaccine](https://vaccinenation.org/technology/study-explores-benefits-of-hexaplex-flu-vaccine/): The University of Buffalo shared in February 2024 that a team led by Buffalo researchers is developing a recombinant flu vaccine to “compete with existing
- [Takeda and Biological E partner for access to QDENGA](https://vaccinenation.org/technology/takeda-and-biological-e-partner-for-access-to-qdenga/): In February 2024 Takeda announced that it has entered a strategic partnership to “accelerate access to QDENGA”. In collaboration with India-based
- [EMA’s CHMP: “positive opinions” on avian influenza vaccines](https://vaccinenation.org/global-health/emas-chmp-positive-opinions-on-avian-influenza-vaccines/): In February 2024 the European Medicines Agency (EMA) announced that the human medicines committee (CHMP) had recommended 10 medicines
- ["Worryingly low” MMR uptake triggers global measles clusters](https://vaccinenation.org/infection/worryingly-low-mmr-uptake-triggers-global-measles-clusters/): Cases and clusters of cases of measles are being reported across the world as experts warn of “worryingly low” MMR vaccine uptake, with public
- [Baseimmune secures £9 million funding: vaccines and AI](https://vaccinenation.org/technology/baseimmune-secures-9-million-funding-vaccines-and-ai/): In February 2024 London-based biotech Baseimmune announced the close of £9 million in Series A funding led by MSD Global Health Innovation
- [WHO prequalification for SK bioscience typhoid vaccine](https://vaccinenation.org/global-health/who-prequalification-for-sk-bioscience-typhoid-vaccine/): In February 2024 SK bioscience announced that the company had been granted prequalification (PQ) certification from WHO for SKYTyphoid
- [LimmaTech announces “positive” interim data for Shigella4V](https://vaccinenation.org/technology/limmatech-announces-positive-interim-data-for-shigella4v/): In February 2024 LimmaTech Biologics announced positive interim data from a Phase I/II trial evaluating Shigella4V (S4V). S4V is a tetravalent
- [Gavi and IRC administer 1 million doses in Horn of Africa](https://vaccinenation.org/global-health/gavi-and-irc-administer-1-million-doses-in-horn-of-africa/): In February 2024 Gavi announced that the Zero-Dose Immunisation Programme (ZIP), funded by Gavi and led by the International Rescue Committee
- [Study: could BCG vaccine treat liver cancer tumours?](https://vaccinenation.org/therapeutic/study-could-bcg-vaccine-treat-liver-cancer-tumours/): In February 2024 UC Davis Health announced the results of a study, published in Advanced Science, which show that a single dose of the tuberculosis
- [Do vaccine mandates have “unintended negative consequences”?](https://vaccinenation.org/global-health/do-vaccine-mandates-have-unintended-negative-consequences/): A report in PNAS Social Sciences in February 2024 uses CDC data to explore whether vaccine mandates predicted changes in COVID-19 vaccine
- [Partners push back against polio circulating in Zimbabwe](https://vaccinenation.org/infection/partners-push-back-against-polio-circulating-in-zimbabwe/): In February 2024 UNICEF announced that Zimbabwe’s Ministry of Health and Child Care (MOHCC), in collaboration with UNICEF, WHO, and other partners
- [Ultimovacs announces EMA opinion on UV1 for mesothelioma](https://vaccinenation.org/therapeutic/ultimovacs-announces-ema-opinion-on-uv1-for-mesothelioma/): Ultimovacs announced in February 2024 that the European Medicines Agency (EMA) has issued a “positive opinion” on its application for Orphan
- [Dr Rosalind Hollingsworth, turning "science into action"](https://vaccinenation.org/global-health/dr-rosalind-hollingsworth-turning-science-into-action/): Our next interview from the Barcelona Congress Conversations series is with AstraZeneca's Dr Rosalind Hollingsworth, who joined us at the Congress
- [Africa’s “second independence”: pooled procurement agreed](https://vaccinenation.org/global-health/africas-second-independence-pooled-procurement-agreed/): In February 2024 Africa CDC announced that African leaders had agreed on a pooled procurement mechanism at the African Union summit in A
- [Evaxion and MSD complete initial phases of collaboration](https://vaccinenation.org/technology/evaxion-and-msd-complete-initial-phases-of-collaboration/): In February 2024 Evaxion announced the “successful completion” of initial phases of a vaccine collaboration with MSD to combine “both organisations
- [Desentum raises €12 million for allergy vaccines](https://vaccinenation.org/therapeutic/desentum-raises-e12-million-for-allergy-vaccines/): In February 2024, Finnish biopharmaceutical company Desentum announced that it had raised €12 million in a funding round organised by investment
- [UNICEF and Gavi deliver refrigerated trucks to Nepal](https://vaccinenation.org/technology/unicef-and-gavi-deliver-refrigerated-trucks-to-nepal/): UNCEF and Gavi announced in February 2024 that they have “handed over” four refrigerated trucks for vaccine transportation to the Government
- [Study finds vaccines reduced “triple threat” in US](https://vaccinenation.org/infection/study-finds-vaccines-reduced-triple-threat-in-us/): In February 2024 the Regenstrief Institute announced that two studies from the CDC’s VISION Network demonstrated the effectiveness of flu vaccines
- [Global Vaccine Data Network studies COVID-19 vaccine safety](https://vaccinenation.org/global-health/global-vaccine-data-network-studies-covid-19-vaccine-safety/): A study from the Global COVID Vaccine Safety (GCoVs) Project published in Vaccine in February 2024 explores the risk of 13 medical conditions
- [What does the future of adult immunisations hold?](https://vaccinenation.org/global-health/what-does-the-future-of-adult-immunisations-hold/): An article in npj vaccines in February 2024 considers the future of the adult vaccine landscape, using insights from interviews to “serve as a pivotal
- [Gingko and SaponiQx awarded DTRA funds for adjuvant research](https://vaccinenation.org/technology/gingko-and-saponiqx-awarded-dtra-funds-for-adjuvant-research/): In February 2024 Ginkgo Bioworks announced that it has been awarded a 5-year contract with SaponiQx from the US Defence Threat Reduction Agency
- [Study: Vaxxinity’s cholesterol candidate lowers LDL-C](https://vaccinenation.org/therapeutic/study-vaxxinitys-cholesterol-candidate-lowers-ldl-c/): In February 2024 Vaxxinity announced the publication of pre-clinical data that demonstrate the ability of a vaccine candidate VXX-401 to “reproducibly”
- [Osivax announces first-in-human dose of sarbecovirus vaccine](https://vaccinenation.org/technology/osivax-announces-first-in-human-dose-of-sarbecovirus-vaccine/): In February 2024, Osivax announced that the first participant in a first-in-human study has been dosed in a new Phase I trial to evaluate OVX033.
- [IAVI report: uncovering TB clues for vaccine research](https://vaccinenation.org/infection/iavi-report-uncovering-tb-clues-for-vaccine-research/): In the latest IAVI report from February 2024, Kristen Kresge Abboud spoke to Professor Lalita Ramakrishnan from the University of Cambridge
- [VaccMap to track vaccine doses through Rwanda](https://vaccinenation.org/technology/vaccmap-to-track-vaccine-doses-through-rwanda/): In February 2024 the University of Birmingham announced that a project to use “powerful digital tracking and accountability technology” to determine
- [Replicate’s srRNA platform shows promise for rabies](https://vaccinenation.org/technology/replicates-srrna-platform-shows-promise-for-rabies/): In February 2024 Replicate Bioscience announced “positive” results from a Phase I trial of the comapny’s self-replicating RNA (srRNA)-based rabies vaccine
- [Study: assessing attitudes to adult vaccination in UAE](https://vaccinenation.org/global-health/study-assessing-attitudes-to-adult-vaccination-in-uae/): A paper in Vaccine X presents the result of a study exploring adult vaccination attitudes and practices by physicians in the United Arab Emirates
- [Research shows how antibodies fight herpes simplex virus](https://vaccinenation.org/infection/research-shows-how-antibodies-fight-herpes-simplex-virus/): In February 2024 a team from Dartmouth’s Geisel School of Medicine and Thayer School of Engineering announced that their research in Cell Reports
- [Opportunity and expertise: the “science research gap”](https://vaccinenation.org/global-health/opportunity-and-expertise-the-science-research-gap/): In an article for WEF in February 2024, Africa Research Excellence Fund’s Carla Rivero explores the “science research gap” in Africa and how
- [Cholera vaccine shortage continues to threaten response](https://vaccinenation.org/infection/cholera-vaccine-shortage-continues-to-threaten-response/): In February 2024 WHO commented on the “persistence of cholera” at the start of 2024, a continuation of the global surge in cases revealed in
- [Data sharing dilemmas for zoonotic EID responses](https://vaccinenation.org/global-health/data-sharing-dilemmas-for-zoonotic-eid-responses/): A paper in BMC Infectious Diseases in February 2024 offers an “in-depth understanding” of data sharing practices through an examination of the MERS
- [Ebola study finds vaccination lowers case fatality risk](https://vaccinenation.org/global-health/ebola-study-finds-vaccination-lowers-case-fatality-risk/): A paper in The Lancet Infectious Diseases in February 2024 presents the results of a retrospective cohort analysis of patients with confirmed Ebola
- [MSK’s KRAS-targeting vaccine shows “promise” in trial](https://vaccinenation.org/therapeutic/msks-kras-targeting-vaccine-shows-promise-in-trial/): Researchers at Memorial Sloan Kettering Cancer Centre (MSK) shared in February 2024 that a trial for a vaccine candidate for patients with pancreatic
- [WHO Africa: malaria rollout expansion protecting children](https://vaccinenation.org/global-health/who-africa-malaria-rollout-expansion-protecting-children/): In February the WHO Africa Office reported that “nearly 10,000 children” in Burkina Faso and Cameroon have received the RTS,S malaria vaccine
- [Ireland reports death of adult with confirmed measles](https://vaccinenation.org/infection/ireland-reports-death-of-adult-with-confirmed-measles/): In February 2024 Ireland’s Health Service Executive (HSE) Health Protection Surveillance Centre stated that it had been notified of the death of an
- [MHRA approval update for Pfizer and Novavax vaccines](https://vaccinenation.org/technology/mhra-approval-update-for-pfizer-and-novavax-vaccines/): In February the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) announced the approval of a change to the licence of the
- [An mRNA vaccine for CMV is “most promising” in study](https://vaccinenation.org/global-health/an-mrna-vaccine-for-cmv-is-most-promising-in-study/): Researchers from Weill Cornell Medicine shared in February 2024 that an experimental mRNA vaccine against human cytomegalovirus (CMV)
- [Sanofi and Medidata collaborate for vaccine studies](https://vaccinenation.org/technology/sanofi-and-medidata-collaborate-for-vaccine-studies/): In February 2024 Medidata and Sanofi Vaccines announced a collaboration to “harness” Medidata’s eCOA (Clinical Outcome Assessment) for vaccine studies
- [CEPI and LenioBio go plant-based for vaccine production](https://vaccinenation.org/technology/cepi-and-leniobio-go-plant-based-for-vaccine-production/): CEPI announced in February 2024 that it is providing LenioBio with funding of up to US$2 million to provide preclinical proof-of-concept that a commercially
- [Study: Lassa fever and genetics uncovered with GWAS](https://vaccinenation.org/infection/study-lassa-fever-and-genetics-uncovered-with-gwas/): A paper in Nature microbiology in February 2024 presents the results of investigations into whether human genetic variation “underlies the heterogeneity
- [Butantan’s dengue vaccine and Brazil’s hour of need](https://vaccinenation.org/infection/butantans-dengue-vaccine-and-brazils-hour-of-need/): Research in the New England Journal of Medicine in February 2024 shows that a vaccine candidate against dengue from Brazil’s Instituto Butantan
- [Study: US adults conceal infection to go about daily life](https://vaccinenation.org/infection/study-us-adults-conceal-infection-to-go-about-daily-life/): In January 2024 the Centre for Infectious Disease Research and Policy (CIDRAP) reported on a study in Psychological Science that reveals that
- [HIPRA leads EU project for African Swine Fever](https://vaccinenation.org/global-health/hipra-leads-eu-project-for-african-swine-fever/): In February 2024 HIPRA announced that it is leading the European project VAX4ASF on the aim of developing a next-generation vaccine against African
- [CEPI and PAHO sign MoU for disease preparedness](https://vaccinenation.org/global-health/cepi-and-paho-sign-mou-for-disease-preparedness/): In February 2024 CEPI announced that it has signed a Memorandum of Understanding (MoU) with the Pan American Health Organisation to “strengthen collaboration”
- [Study: COVID-19 vaccine in pregnancy safe for newborns](https://vaccinenation.org/global-health/study-covid-19-vaccine-in-pregnancy-safe-for-newborns/): In February 2024 Karolinska Institutet announced the results of a study in JAMA reveal that COVID-19 vaccination during pregnancy did not increase risk for
- [Researchers encouraged by Phase III R21/Matrix-M data](https://vaccinenation.org/technology/researchers-encouraged-by-phase-iii-r21-matrix-m-data/): The University of Oxford announced in February 2024 that results from a Phase III trial of the R21/Matrix-M vaccine developed in collaboration
- [Invest in immunisation with impact: Gavi's Dr Marta Tufet](https://vaccinenation.org/global-health/invest-in-immunisation-with-impact-gavis-dr-marta-tufet/): Our next interview from the Barcelona Congress Conversations series is with Gavi, the vaccine alliance's Dr Marta Tufet, who joined us at the event
- [Vaxxinity joins UF for work on neurodegenerative diseases](https://vaccinenation.org/therapeutic/vaxxinity-joins-uf-for-work-on-neurodegenerative-diseases/): In January 2024 Vaxxinity announced that it is collaborating with the University of Florida’s (UF) Centre for Translational Research in Neurodegenerative
- [UK patients join mRNA-4359 trial for ‘solid tumour’ cancers](https://vaccinenation.org/therapeutic/uk-patients-join-mrna-4359-trial-for-solid-tumour-cancers/): In February 2024 Imperial College London announced the beginning of a Phase I/II trial in patients at Imperial College Healthcare NHS Trust to
- [World Cancer Day: calls to “close the care gap”](https://vaccinenation.org/therapeutic/world-cancer-day-calls-to-close-the-care-gap/): On 4th February 2024 World Cancer Day took place with a global call to action that marked the end of the “Close the Care Gap” campaign, 2022-2024.
- [Calling for a better safety surveillance model](https://vaccinenation.org/technology/calling-for-a-better-safety-surveillance-model/): In a commentary for Vaccine in January 2024, two familiar members of the vaccine community, Dr Gregory Poland and Dr Steven Black, explored
- [The global cancer burden continues to grow says WHO](https://vaccinenation.org/therapeutic/the-global-cancer-burden-continues-to-grow-says-who/): The 4th of February is World Cancer Day, and in advance of this in 2024 the WHO’s cancer agency, the International Agency for Research on Cancer
- [DNA “origami scaffolds” enhance antibody responses](https://vaccinenation.org/technology/dna-origami-scaffolds-enhance-antibody-responses/): Researchers from MIT announced in January 2024 that they have created a vaccine that induces a “strong antibody response” against SARS-CoV-2
- [Boehringer Ingelheim relaunches poultry coccidiosis vaccine](https://vaccinenation.org/global-health/boehringer-ingelheim-relaunches-poultry-coccidiosis-vaccine/): In January 2024 Boehringer Ingelheim announced the launch of VAXXILIVE COCCI 3, which was previously known as Hatchpak Cocci III
- [EC to support cancer prevention through vaccination](https://vaccinenation.org/global-health/ec-to-support-cancer-prevention-through-vaccination/): In January 2024 the European Commission announced that it is putting forward a “Recommendation to support Member States in their efforts t
- [Learning from COVID-19 to address global vaccine equity](https://vaccinenation.org/global-health/learning-from-covid-19-to-address-global-vaccine-equity/): An article for BMJ Global Health in January 2024 states the importance of moving in the direction of “global vaccine equity with shared goals, intermediate
- [Uvax announces first doses in Phase I HIV vaccines trial](https://vaccinenation.org/technology/uvax-announces-first-doses-in-phase-i-hiv-vaccines-trial/): In January 2024 Uvax announced that the first participant in a Phase I clinical trial to evaluate the company’s HIV-1 vaccine candidates has been dosed
- [MSF launches hepatitis E campaign in South Sudan](https://vaccinenation.org/infection/msf-launches-hepatitis-e-campaign-in-south-sudan/): Amid a “deadly” hepatitis E outbreak in South Sudan, Médecins sans frontières (MSF) announced that it has launched a vaccination campaign
- [BIO report highlights need for greater vaccine investment](https://vaccinenation.org/technology/bio-report-highlights-need-for-greater-vaccine-investment/): In January 2024 the Biotechnology Innovation Organisation (BIO) shared a report, “The State of Innovation in Vaccines and Prophylactic Antibodies
- [“Unite. Act. Eliminate.” Neglected Tropical Disease day 2024](https://vaccinenation.org/global-health/unite-act-eliminate-neglected-tropical-disease-day-2024/): January 30th is World Neglected Tropical Disease Day, an observation that was recognised by WHO in May 2021. WHO describes the purpose
- [Evaxion announces AI-identified target expansion](https://vaccinenation.org/therapeutic/evaxion-announces-ai-identified-target-expansion/): In January 2024 Evaxion announced an “expanded commitment” to developing tailored cancer vaccines using AI-identified tumour antigens, Endogenous Retroviruses
- [Study finds COVID-19 vaccination reduces neonate RD](https://vaccinenation.org/global-health/study-finds-covid-19-vaccination-reduces-neonate-rd/): In January 2024 the University of California Los Angeles (UCLA) shared that results from a study in Nature Communications reveal that infants
- [International collaboration on bowel cancer vaccine](https://vaccinenation.org/therapeutic/international-collaboration-on-bowel-cancer-vaccine/): In January 2024, the UK’s NHS announced that a “ground-breaking” vaccine for the treatment of early bowel cancer will be trialled in patients as p
- [CEPI and HMRI investigate ‘circRNA’ vaccine potential](https://vaccinenation.org/technology/cepi-and-hmri-investigate-circrna-vaccine-potential/): In January 2024 CEPI announced that it is “teaming up with leading scientists” at the Houston Methodist Research Institute to develop a “promising”
- [UKHSA publishes 5-year Pathogen Genomics Strategy](https://vaccinenation.org/technology/ukhsa-publishes-5-year-pathogen-genomics-strategy/): In January 2024 the UKHSA published its Pathogen Genomics Strategy, which sets out a 5-year plan for the organisation’s role in the “wider delivery
- [Toxic shock syndrome vaccine shows promise in trial](https://vaccinenation.org/technology/toxic-shock-syndrome-vaccine-shows-promise-in-trial/): A study in The Lancet eClinical Medicine in January 2024 presents the results of a Phase II study of a vaccine that could protect against toxic shock syndrome
- [CORBEVAX COVID-19 vaccine secures WHO EUL approval](https://vaccinenation.org/technology/corbevax-covid-19-vaccine-secures-who-eul-approval/): In January 2024, Texas Children’s Hospital shared that CORBEVAX, developed and commercialised by Biological E, has been granted WHO approval
- [In pursuit of a highly networked T-cell HIV vaccine](https://vaccinenation.org/technology/in-pursuit-of-a-highly-networked-t-cell-hiv-vaccine/): In January 2024 IAVI announced a collaboration with ReiThera Srl and the Ragon Institute to develop a novel HIV vaccine candidate. This work
- [EnsiliTech wins SBRI contract for thermostable mRNA vaccine](https://vaccinenation.org/technology/ensilitech-wins-sbri-contract-for-thermostable-mrna-vaccine/): In January 2024 EnsiliTech announced that it has been awarded a “highly competitive” research contract from the UK’s Small Business Research
- [PHS finds no cervical cancer in HPV-vaccinated women](https://vaccinenation.org/global-health/phs-finds-no-cervical-cancer-in-hpv-vaccinated-women/): Public Health Scotland (PHS) announced in January 2024 that a study in collaboration with the Universities of Strathclyde and Edinburgh reveals
- [Serum joins CEPI’s network for public health responses](https://vaccinenation.org/global-health/serum-joins-cepis-network-for-public-health-responses/): In January 2024 CEPI announced that the “world’s largest vaccine manufacturer”, Serum Institute of India (SII), is joining its “growing” network
- [Cameroon kickstarts malaria vaccine campaign in Africa](https://vaccinenation.org/global-health/cameroon-kickstarts-malaria-vaccine-campaign-in-africa/): In January 2024 Cameroon initiated the world’s first routine malaria vaccination campaign, with GSK’s WHO-approved RTS,S vaccine; 331,200
- [Vaxart announces BARDA funding for oral COVID-19 vaccine](https://vaccinenation.org/technology/vaxart-announces-barda-funding-for-oral-covid-19-vaccine/): In January 2024, Vaxart announced that the US Biomedical Advanced Research and Development Authority (BARDA) has awarded the organisation
- [Measles concern as UKHSA demands MMR vaccine action](https://vaccinenation.org/infection/measles-concern-as-ukhsa-demands-mmr-vaccine-action/): In January 2024, as a “rapid rise in cases” is observed in the UK and other countries, the UKHSA Chief Executive has called for “immediate action”
- [CARB-X funds Syntiron’s maternal vaccine for neonatal sepsis](https://vaccinenation.org/technology/carb-x-funds-syntirons-maternal-vaccine-for-neonatal-sepsis/): In January 2024, shortly after announcing funding for Intravacc’s gonorrhoea vaccine pursuits, CARB-X (Combatting Antibiotic-Resistant Bacteria
- [Study shows why SA vaccines are failing in trial](https://vaccinenation.org/technology/study-shows-why-sa-vaccines-are-failing-in-trial/): In a study published in Cell Reports Medicine in January 2024, a team at the University of California San Diego School of Medicine offer reasons
- [WEF report: Healthy women key to healthy global economy](https://vaccinenation.org/global-health/wef-report-healthy-women-key-to-healthy-global-economy/): In January 2024 the World Economic Forum and the McKinsey Health Institute shared a report that focuses on the economic implications of an
- [Review: model-based approaches offer vaccine acceleration](https://vaccinenation.org/technology/review-model-based-approaches-offer-vaccine-acceleration/): A review in Current Opinion in Chemical Engineering in 2024 highlights how model-based approaches are critical in “accelerating vaccine manufacturing
- [PDC*line Pharma to develop PDC*neo+ with funding](https://vaccinenation.org/therapeutic/pdcline-pharma-to-develop-pdcneo-with-funding/): In January 2024 PDC*line Pharma announced that the Walloon region and BioWin have selected the PDC*neo+ project for funding after a call
- [COVID-19 vaccine study: > 1.4 million lives saved in Europe](https://vaccinenation.org/global-health/covid-19-vaccine-study-1-4-million-lives-saved-in-europe/): A WHO Europe study issued as a preprint in January 2024 reveals the life-saving extent of COVID-19 vaccines in the region. The paper states
- [Baculovirus butterflies? CEPI funds Algenex CrisBio project](https://vaccinenation.org/technology/baculovirus-butterflies-cepi-funds-algenex-crisbio-project/): CEPI announced in January 2024 that an award of up to $3.12 million will support researchers at Algenex in development of a chrysalis-based
- [CARB-X funds Intravacc’s gonorrhoea vaccine pursuits](https://vaccinenation.org/technology/carb-x-funds-intravaccs-gonorrhoea-vaccine-pursuits/): In January 2024 Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced that it is awarding US$633k to Intravacc
- [Action needed for social media misinformation management](https://vaccinenation.org/global-health/action-needed-for-social-media-misinformation-management/): An article in BMJ in January 2024 explores the role of misinformation in undermining effective population level vaccination campaigns.
- [Jenner Institute trial gives BCG a second chance](https://vaccinenation.org/technology/jenner-institute-trial-gives-bcg-a-second-chance/): In January 2024 the University of Oxford announced that the Jenner Institute is conducting a new study using the current licensed vaccine against tuberculosis
- [Study: undervaccination linked to severe COVID-19 outcomes](https://vaccinenation.org/global-health/study-undervaccination-linked-to-severe-covid-19-outcomes/): A paper in The Lancet, published in January 2024, presents the results of a study investigating rates of “undervaccination” against COVID-19 across
- [Success in the fight: WHO certifies Cabo Verde malaria free](https://vaccinenation.org/infection/success-in-the-fight-who-certifies-cabo-verde-malaria-free/): In January 2024 WHO announced that it has certified Cabo Verde as a malaria-free country, describing it as a “significant achievement in global health”
- [Gavi announces new CEO appointment: Dr Sania Nishtar](https://vaccinenation.org/global-health/gavi-announces-new-ceo-appointment-dr-sania-nishtar/): In January 2024 Gavi, the Vaccine Alliance announced the appointment of Dr Sania Nishtar as the new CEO, taking over from interim CEO David Marlow
- [Health authorities need resources and capacity, says report](https://vaccinenation.org/global-health/health-authorities-need-resources-and-capacity-says-report/): WHO Europe shared in January 2024 that the Behavioural and Cultural Insights (BCI) Unit has published its first status report on the use of BCI
- [Breadth and depth: GRA's Samantha Dowse and Dr Lee Smith](https://vaccinenation.org/technology/breadth-and-depth-gras-samantha-dowse-and-dr-lee-smith/): Our next interview from the Barcelona Congress is with another of our wonderful start-ups: GreyRigge Associates. Dr Lee Smith and Sam Dowse
- [Comparison study explores RSV intervention strategies](https://vaccinenation.org/global-health/comparison-study-explores-rsv-intervention-strategies/): In a study published in The Lancet Regional Health – Europe researchers sought to “facilitate the selection of new RSV intervention programmes”
- [First-in-human ChAdOx1 Nipah vaccine trial begins](https://vaccinenation.org/technology/first-in-human-chadox1-nipah-vaccine-trial-begins/): The Oxford Vaccine Group within the Department for Paediatrics in Oxford announced in January 2024 that a first-in-human trial of the ChAdOx1
- [UK COVID-19 Inquiry postpones vaccine investigation](https://vaccinenation.org/global-health/uk-covid-19-inquiry-postpones-vaccine-investigation/): In January 2024 the Chair of the UK COVID-19 Inquiry, Baroness Hallett, announced an updated timetable for hearings in 2024, postponing the public hearings
- [Potential from pancreatic and colorectal cancer vaccine](https://vaccinenation.org/therapeutic/potential-from-pancreatic-and-colorectal-cancer-vaccine/): A statement from the University of Texas MD Anderson Cancer Centre in January 2024 reported on the “potential” of a vaccine candidate in a Phase I
- [Religion at odds with science? Vaccine tensions explored](https://vaccinenation.org/global-health/religion-at-odds-with-science-vaccine-tensions-explored/): An article in humanities and social sciences communications in January 2023 considers the “slow” progress in ensuring equitable vaccine coverage
- [Transgene and NEC to extend Phase I trial of cancer vaccine](https://vaccinenation.org/therapeutic/transgene-and-nec-to-extend-phase-i-trial-of-cancer-vaccine/): In January 2024 Transgene and NEC announced that they are planning to start an extension of a Phase I trial into a Phase I/II study to
- [Investigating “twin barriers” to vaccine access in LMICs](https://vaccinenation.org/global-health/investigating-twin-barriers-to-vaccine-access-in-lmics/): An article in Health Affairs in December 2023 reflects that “two primary narratives” have been attributed to the “low COVID-19 vaccine uptake”
- [Respiratory season returns with a vengeance, cases rise](https://vaccinenation.org/infection/respiratory-season-returns-with-a-vengeance-cases-rise/): As 2024 begins and, for many, a period of festivity ends, respiratory illnesses are reportedly rising in many regions. For the WHO European Region,
- [Curevo announces shingles results to rival Shingrix](https://vaccinenation.org/technology/curevo-announces-shingles-results-to-rival-shingrix/): In January 2024 Curevo Vaccine announced positive data from a Phase II trial of amezosvatein (also known as CRV-101) in comparison with Shingrix
- [Highlighting genetic influence on COVID-19 vaccine response](https://vaccinenation.org/technology/highlighting-genetic-influence-on-covid-19-vaccine-response/): A paper in the American Journal of Human Genetics in January 2024 presents the results of a genome-wide association study (GWAS) to understand
- [CEPI announces Lemonex DegradaBALL mRNA partnership](https://vaccinenation.org/technology/cepi-announces-lemonex-degradaball-mrna-partnership/): In January 2024 CEPI announced that it has partnered with Lemonex, a biotechnology company in the Republic of Korea. The partnership will
- [POLITICO reveals European vaccine waste worth €4 billion](https://vaccinenation.org/global-health/politico-reveals-european-vaccine-waste-worth-e4-billion/): In an article in December 2023, POLITICO claimed that “at least 215 million doses” of COVID-19 vaccines that had been purchased by EU countries
- [IAVI and Biofabri pursue “promising” TB vaccine MTBVAC](https://vaccinenation.org/technology/iavi-and-biofabri-pursue-promising-tb-vaccine-mtbvac/): In December 2023 IAVI and Biofabri, a subsidiary of Zendal, announced that IAVI has been awarded US$55 million by the Bill & Melinda Gates Foundation
- [Moderna and Merck: continued improvement in combination](https://vaccinenation.org/therapeutic/moderna-and-merck-continued-improvement-in-combination/): In a statement shared by Moderna and Merck (MSD) in December 2023 it was announced that follow-up data from the Phase IIb randomised KEYNOTE
- [CEPI and PATH announce strengthened partnership](https://vaccinenation.org/technology/cepi-and-path-announce-strengthened-partnership/): In December 2023 CEPI and PATH announced a “renewed collaboration” to accelerate vaccine development against emerging infectious diseases.
- [CEPI partners with CBNU to advance mRNA vaccine technology](https://vaccinenation.org/technology/cepi-partners-with-cbnu-to-advance-mrna-vaccine-technology/): In December 2023 CEPI announced that it has partnered with Korea’s Chungbuk National University (CBNU) to “advance development” of the
- [AstraZeneca to acquire Icosavax for further vaccine pursuits](https://vaccinenation.org/technology/astrazeneca-to-acquire-icosavax-for-further-vaccine-pursuits/): In December 2023 AstraZeneca announced that it has entered into a definitive agreement to acquire Icosavax, the US-based clinical-stage bio
- [Catalysing African vaccine manufacturing: AVMA established](https://vaccinenation.org/global-health/catalysing-africa-vaccine-manufacturing-avma-established/): In December 2023 Gavi shared the news that the African Vaccine Manufacturing Accelerator (AVMA) has been approved by the board. The “innovative
- [Games against misinformation: “Cranky Uncle Vaccine” launch](https://vaccinenation.org/technology/games-against-misinformation-cranky-uncle-vaccine-launch/): Tackling vaccine misinformation is high on the list of challenges almost every member of the vaccine community is facing, so an innovative strategy
- [Merck and Moderna announce INTerpath-002 combination study](https://vaccinenation.org/therapeutic/merck-and-moderna-announce-interpath-002-combination-study/): In December 2023 Merck (also known as MSD) and Moderna announced the initiation of INTerpath-002, a pivotal Phase III randomised clinical
- [VitriVax announces two-year Gates Foundation grant](https://vaccinenation.org/technology/vitrivax-announces-two-year-gates-foundation-grant/): In December 2023 VitriVax shared that the Bill and Melinda Gates Foundation has granted the organisation a two-year grant worth $5 million to support
- [Gavi’s vaccine portfolio grows: “leave no child behind”](https://vaccinenation.org/global-health/gavis-vaccine-portfolio-grows-leave-no-child-behind/): In December 2023 Gavi announced that it was expanding its portfolio to include more vaccines to support countries who are eligible. These countries
- [Process fit for purpose: bespark*bio's Dr Matthias Müllner](https://vaccinenation.org/technology/process-fit-for-purpose-besparkbios-dr-matthias-mullner/): Our next interview from our European Congress Conversations series features Dr Matthias Müllner, who joined us to represent bespark*bio as a start-up last month
- [Needle-free partnership for CEPI and Jurata Thin Film](https://vaccinenation.org/technology/needle-free-partnership-for-cepi-and-jurata-thin-film/): In December 2023 CEPI announced that is is partnering with Jurata Thin Film, Inc (Jurata) to adavnce the development of Jurata’s thermostable
- ["Never waste a crisis", says Moderna's Dr Walter Straus](https://vaccinenation.org/technology/never-waste-a-crisis-says-modernas-dr-walter-straus/): Our next interview in the Congress Conversations series from the European Congress is with Dr Walter Straus of Moderna. He joined us to moderate
- [WHO malaria report highlights threat of climate change](https://vaccinenation.org/infection/who-malaria-report-highlights-threat-of-climate-change/): WHO’s 2023 World malaria report, shared in November 2023, suggests that, despite efforts to increase access to interventions, more people are getting sick
- [Valneva reports positive persistence data for CHIKV vaccine](https://vaccinenation.org/technology/valneva-reports-positive-persistence-data-for-chikv-vaccine/): Just a month after the FDA approval of its chikungunya vaccine for use in adults at risk of chikungunya virus exposure, Valneva has reported positive
- ["Efficiency equals speed" for hVIVO's Dr Andrew Catchpole](https://vaccinenation.org/technology/efficiency-equals-speed-for-hvivos-dr-andrew-catchpole/): Up next in our exclusive series of Congress Conversations from the Barcelona event we are delighted to share an interview with Dr Andrew Catchpole, hVIVO.
- [Zika virus protection patch shows promise in recent study](https://vaccinenation.org/technology/zika-virus-protection-patch-shows-promise-in-recent-study/): News shared by the University of Queensland (UQ) in December 2023 details explains how a paper in Molecular Therapy Nucleic Acids presents
- [“Let communities lead!” UNAIDS report, World AIDS Day 2023](https://vaccinenation.org/global-health/let-communities-lead-unaids-report-world-aids-day-2023/): In 1988 the first World AIDs Day was launched under the theme “A world united against AIDS”; in 2023 the global health community continues
- [ADDomer vaccine platform has disease-fighting potential](https://vaccinenation.org/technology/addomer-vaccine-platform-has-disease-fighting-potential/): In research shared by the University of Bristol in November 2023, a team demonstrate the validity of nature-inspired nanoparticle-based reagents
- [Immunotherapy innovation: myNEO Therapeutics' Cedric Bogaert](https://vaccinenation.org/therapeutic/immunotherapy-innovation-myneo-therapeutics-cedric-bogaert/): Last month we were delighted to speak to so many of our fantastic speakers and exhibitors and here we meet Cedric Bogaert
- [Merck (MSD) shares STRIDE-3 pneumococcal vaccine insights](https://vaccinenation.org/technology/merck-msd-shares-stride-3-pneumococcal-vaccine-insights/): In November 2023 Merck, which is known as MSD outside the US and Canada, announced results from a Phase III trial evaluating the company’s
- [CEPI, IVI and Gambia’s MRC launch Preparedness Programme](https://vaccinenation.org/global-health/cepi-ivi-and-gambias-mrc-launch-preparedness-programme/): In November 2023 CEPI, IVI, and Gambia’s Medical Research Council Unit The Gambia (MRCG) announced the launch of the Research Preparedness Programme
- [Canada’s VIDO awarded IDIQ contract by US NIAID](https://vaccinenation.org/technology/canadas-vido-awarded-idiq-contract-by-us-niaid/): In November 2023 the University of Saskatchewan’s Vaccine and Infectious Disease Organisation (VIDO) announced that it has been awarded
- [Back to VacTrack: digital solutions with Gabriella and Emily](https://vaccinenation.org/technology/back-to-vactrack-digital-solutions-with-gabriella-and-emily/): With the World Vaccine Congress West Coast kicking off today we are pleased to share another exclusive interview. This time we are glad that start-up VacTrack
- [UKHSA confirms human case of influenza A(H1N2)v](https://vaccinenation.org/infection/ukhsa-confirms-human-case-of-influenza-ah1n2v/): In November 2023 the UKHSA stated that a single human case of influenza A(H1N2)v has been detected in the UK through routine surveillance.
- [Re-engineered clamp platform produces safe vaccine](https://vaccinenation.org/technology/re-engineered-clamp-platform-produces-safe-vaccine/): The University of Queensland (UQ) announced in November 2023 that its “re-engineered clamp platform” has produced a vaccine that is
- [Security and self-reliance: Africa CDC's Akhona Tshangela](https://vaccinenation.org/global-health/security-and-self-reliance-africa-cdcs-akhona-tshangela/): Our next interview in the European Congress series is with Africa CDC's Akhona Tshangela, who joined us at the event for sessions on vaccine
- [Unpacking America’s “Vaccine Wars” with Professor Mark Navin](https://vaccinenation.org/global-health/unpacking-americas-vaccine-wars-with-professor-mark-navin/): With the Congress only days away we are delighted to share another exclusive Congress Conversation ahead of the event. We hear from Professor Mark Navin,
- [WHO requests information: China’s pneumonia in children](https://vaccinenation.org/infection/who-requests-information-chinas-pneumonia-in-children/): WHO shared a statement in November 2023 that reveals an “official request” to China for “detailed information” on a reported increase in respiratory
- [Malaria vaccines to Africa “herald final steps”](https://vaccinenation.org/global-health/malaria-vaccines-to-africa-herald-final-steps/): A joint news release from WHO, UNICEF, and Gavi in November 2023 states that shipments of the first WHO-recommended malaria vaccine arrived
- [SK bioscience and Hilleman join on Zaire Ebola efforts](https://vaccinenation.org/technology/sk-bioscience-and-hilleman-join-on-zaire-ebola-efforts/): In November 2023 SK bioscience and Hilleman Laboratories shared that they have entered into a development licensing agreement for joint development
- [Targeted immune responses: Belyntic's Andreas Regnery](https://vaccinenation.org/technology/targeted-immune-responses-belyntics-andreas-regnery/): Our next Congress Conversation from the event in Barcelona last month is with Andreas Regnery, who represented Belyntic in our start-up zone.
- [Mpox vaccine prioritisation study: who and how many?](https://vaccinenation.org/global-health/mpox-vaccine-prioritisation-study-who-and-how-many/): In a paper for Vaccine in November 2023 an international group of authors comment on the “unjust” distribution of “scarce” vaccines to mitigate infection harms
- [BMJ investigates RSV informed consent concerns](https://vaccinenation.org/global-health/bmj-investigates-rsv-informed-consent-concerns/): In a feature for The BMJ in November 2023 Hristio Boytchev reports on concern raised by “some experts” that Pfizer should have informed pregnant
- [Micron secures Gates funding for needle-free vaccines](https://vaccinenation.org/technology/micron-secures-gates-funding-for-needle-free-vaccines/): In November 2023 Micron Biomedical announced that the Bill and Melinda Gates Foundation has committed a $23.6 million grant to fund “mass production
- [WHO commissions Vaccine Value Profiles for endemic pathogens](https://vaccinenation.org/global-health/who-commissions-vaccine-value-profiles-for-endemic-pathogens/): In what WHO is describing as a “significant stride towards facilitating and informing priorities in global vaccine development” it has commissioned 16 VVPs
- [Dynamics of nAbs: progress towards HIV-1 vaccine in research](https://vaccinenation.org/global-health/dynamics-of-nabs-progress-towards-hiv-1-in-new-research/): A team of researchers shared in November 2023 that their study, published in Nature Medicine, has provided insight into the longevity of neutralising antibodies
- [Study: how might a Strep A vaccine reduce antibiotic use?](https://vaccinenation.org/global-health/study-how-might-a-strep-a-vaccine-reduce-antibiotic-use/): As the threat presented by antimicrobial resistance (AMR) grows globally, the pressure is mounting on the vaccine community to continue contributing
- [Vaccines Europe explores vaccination strategies for AMR](https://vaccinenation.org/global-health/vaccines-europe-explores-vaccination-strategies-for-amr/): In a white paper shared in November, Vaccines Europe explores how vaccination can be a “valuable tool” to address the considerable and growing threat
- [Technology for "actionable insights": Dr Nicolas Gaudenzio](https://vaccinenation.org/technology/technology-for-actionable-insights-dr-nicolas-gaudenzio/): Next up in our exciting Congress Conversations series is an interview with Genoskin's Dr Nicolas Gaudenzio. He joined us at the Congress for a showcase,
- ["We know what works": the "last mile" with Dr Angus Thomson](https://vaccinenation.org/global-health/we-know-what-works-the-last-mile-with-dr-angus-thomson/): With the Congress behind us we are able to reflect on the key themes and discussions that took place. Such a theme was undoubtedly sparked by Dr Angus Thomso
- [UK JCVI recommends routine childhood chickenpox vaccination](https://vaccinenation.org/global-health/uk-jcvi-recommends-routine-childhood-chickenpox-vaccination/): In November 2023 the UK’s Joint Committee on Vaccination and Immunisation (JCVI) announced that it was recommending a “universal varicella
- [NHS testing finds thousands of bloodborne virus cases](https://vaccinenation.org/infection/nhs-opt-out-testing-finds-thousands-of-bloodborne-viruses/): In November 2023 the UKHSA and University of Bristol shared a report that reveals the results of an NHS England emergency department opt-out testing programme
- [UK JCVI encourages routine vaccination: gonorrhoea and mpox](https://vaccinenation.org/infection/uk-jcvi-encourages-routine-vaccination-gonorrhoea-and-mpox/): In November 2023 the UK’s Joint Committee on Vaccination and Immunisation issued advice to the government on a routine targeted vaccination
- [FDA approves Valneva’s world-first chikungunya vaccine](https://vaccinenation.org/technology/fda-approves-valnevas-world-first-chikungunya-vaccine/): In November 2023 Valneva announced that the US FDA has approved its single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya
- [Childhood vaccine refusal study: what is to be done?](https://vaccinenation.org/global-health/childhood-vaccine-refusal-study-what-is-to-be-done/): In a study published in BMC Medical Ethics the authors present a systematic review of normative arguments made about parental refusal of routine vaccination
- [Vaccines for everyone: study investigates HPV strategies](https://vaccinenation.org/global-health/vaccines-for-everyone-study-investigates-hpv-strategies/): Research published in Cell Host & Microbe in November 2023 reaches a “somewhat provocative conclusion” that HPV vaccination is so effective
- [BioCina and CPN Vaccines expand Gamma-PN partnership](https://vaccinenation.org/technology/biocina-and-cpn-vaccines-expand-gamma-pn-partnership/): In November 2023 BioCina and GPN Vaccines announced that they are expanding their partnership to develop GPN’s proprietary engineered whole-cell vaccine
- [WHO shares Tuberculosis Report 2023: more effort needed](https://vaccinenation.org/global-health/who-shares-tuberculosis-report-2023-more-effort-needed/): In November 2023 the WHO shared the Global Tuberculosis Report 2023, a “comprehensive and up-to-date assessment” on the epidemic and progress
- [EU and Africa CDC share agreement on access and manufacture](https://vaccinenation.org/global-health/eu-and-africa-cdc-share-agreement-on-access-and-manufacture/): In October 2023 at the Global Gateway Forum, held in Brussels, the EU Commission signed €500 million for global health and an additional €134 million
- [4 vaccine hubs get funding: UK Vaccine Network](https://vaccinenation.org/global-health/4-vaccine-hubs-get-funding-uk-vaccine-network/): In November 2023 the UK’s Minister for Health and Secondary Care, Will Quince, announced at the Association of Southeast Asian Nations (ASEAN)
- [MSD Animal Health pursues cattle health success](https://vaccinenation.org/global-health/msd-animal-health-pursues-cattle-health-success/): In October 2023 MSD Animal Health announced that the European Medicines Agency Committee for Veterinary Medicinal Products (CVMP) has issued a “positive opinion
- [Nasal COVID-19 vaccine shows promise in animals](https://vaccinenation.org/technology/nasal-covid-19-vaccine-shows-promise-in-animals/): Researchers from the University of Maryland shared in November 2023 that they have made progress in developing a nasal spray vaccine that delivers SARS-CoV-2
- [CEPI and University of Oxford: vaccines against Junín virus](https://vaccinenation.org/technology/cepi-and-university-of-oxford-vaccines-against-junin-virus/): In November 2023 CEPI and the University of Oxford announced a new project to “initiate the early development of prototype vaccines” against the Junín virus.
- [All for One Health: marking One Health Day 2023](https://vaccinenation.org/global-health/all-for-one-health-marking-one-health-day-2023/): Friday 3rd November 2023 is the 8th annual One Health Day, observed internationally to “raise global awareness” of the importance of One Health
- [Study sheds light on vaccine-related blood clotting](https://vaccinenation.org/global-health/study-sheds-light-on-vaccine-related-blot-clotting/): Researchers from the University of Birmingham shared in October 2023 that a paper in Blood identifies how blood clots associated with VITT
- [Partnership to harness technology against malaria hurdles](https://vaccinenation.org/technology/partnership-to-harness-technology-against-malaria-hurdles/): In October 2023 the European Vaccine Initiative (EVI) announced that it will be coordinating a new partnership to explore how new technologies
- [AI identifies possible vaccine candidates for gonorrhoea](https://vaccinenation.org/technology/ai-identifies-possible-vaccine-candidates-for-gonorrhoea/): Research published in mBio in October 2023 shows that artificial intelligence (AI) could be used to effectively identify vaccine candidates for gonorrhoea.
- [Health preparedness is “fragile” warns GPMB 2023 report](https://vaccinenation.org/global-health/health-preparedness-is-fragile-warns-gpmb-2023-report/): A report shared by the Global Preparedness Monitoring Board (GPMB) in 2023 offers a “warning” that the “fragile progress to strengthen preparedness”
- [A world in polycrisis: disease in AXA’s Future Risks Report](https://vaccinenation.org/global-health/a-world-in-polycrisis-disease-in-axas-future-risks-report/): In October 2023 AXA published the 10th edition of its Future Risks Report, a study that “measures and ranks” global perception of “evolving and rising risks”.
- [CEPI and Moderna announce mRNA strategic partnership](https://vaccinenation.org/technology/cepi-and-moderna-announce-mrna-strategic-partnership/): In October 2023 CEPI and Moderna announced a strategic partnership to “harness Moderna’s mRNA platform” for vaccine development.
- [Tripartite recommendations on oral rabies vaccinations](https://vaccinenation.org/global-health/tripartite-recommendations-on-oral-rabies-vaccinations/): In October 2023 the Tripartite organisations, issued an update on oral vaccination of dogs against rabies: recommendations for field application
- [Human Immune Project shares 5-year ‘Scientific Plan’](https://vaccinenation.org/technology/human-immune-project-shares-5-year-scientific-plan/): Human Immune Project (HIP), a global nonprofit organisation dedicated to “decoding and modelling the immune system”, shared a 5-year “Scientific Plan”
- [Global journals publish climate call: one indivisible crisis](https://vaccinenation.org/global-health/global-journals-publish-climate-call-one-indivisible-crisis/): 200 health journals published an editorial demanding recognition that “climate change and biodiversity loss” are “one indivisible crisis”
- [AI tool EVEscape could predict viral variation emergence](https://vaccinenation.org/technology/ai-tool-evescape-could-predict-viral-variation-emergence/): An artificial intelligence (AI) tool developed by a team from the University of Oxford and Harvard Medical School could help predict new viral variants
- [UKRI funds Oxford study to investigate human immunity](https://vaccinenation.org/technology/ukri-funds-oxford-study-to-investigate-human-immunity/): In October 2023 the University of Oxford’s Oxford Vaccine Group announced funding from the Medical Research Council within UK Research and Innovation (UKRI)
- [Make polio history: World Polio Day, 24th October 2023](https://vaccinenation.org/global-health/make-polio-history-world-polio-day-24th-october-2023/): On 24th October 2023 global health leaders, advocates, and communities highlight efforts to end poliomyelitis (polio). Each year World Polio Day is observed
- [Translating science into survival: BioNTech’s Dr Ruben Rizzi](https://vaccinenation.org/technology/translating-science-into-survival-biontechs-dr-ruben-rizzi/): With our Congress in Barcelona mere days away we are glad to share another of our exclusive speaker interviews, this time with Dr Ruben Rizzi.
- [Polio partnership to support immunisation and health systems](https://vaccinenation.org/global-health/polio-partnership-to-support-immunisation-and-health-systems/): In October 2023 the European Commission, the European Investment Bank, and the Bill & Melinda Gates Foundation announced a new financing partnership
- [Delivering vaccines at "lightspeed": Pfizer's Bill Falstich](https://vaccinenation.org/technology/delivering-vaccines-at-lightspeed-pfizers-bill-falstich/): The World Vaccine Congress in Barcelona is so close (less than a week now!) and we are delighted that our speaker interviews are gearing up in preparation.
- [Vaccine start-ups return to the World Vaccine Congress!](https://vaccinenation.org/technology/vaccine-start-ups-return-to-the-world-vaccine-congress-13/): Our World Vaccine Congress in Barcelona is now next week and our start-up zone has reached capacity! This week we are delighted to introduce another
- [Angany announces start of cat allergy vaccine trial](https://vaccinenation.org/therapeutic/angany-announces-start-of-cat-allergy-vaccine-trial/): In October 2023 Franco-Canadian Angany announced that it has received a Notice of Acceptance from the UK’s Medicines and Healthcare Products Regulatory Agency
- [UKRI announces Tackling Infections funding for projects](https://vaccinenation.org/technology/ukri-announces-tackling-infections-funding-for-projects/): In October 2023 the UK Research and Innovation (UKRI) announced £25 million funding to three projects “designed to build our understanding of viruses”
- [Driving regulatory evolution with EMA's Dr Marco Cavaleri](https://vaccinenation.org/technology/driving-regulatory-evolution-with-emas-dr-marco-cavaleri/): With just a week to go until the Congress in Barcelona we are delighted that another of our wonderful speakers has made time to speak to us. Dr Marco Cavaleri
- [Aberdeen team moves to understand adverse reactions](https://vaccinenation.org/technology/aberdeen-team-moves-to-understand-adverse-reactions/): The University of Aberdeen announced in October 2023 that a team of scientists has “taken an important step” towards understanding the mechanisms
- [Gates announces investments for LMIC mRNA capacity](https://vaccinenation.org/technology/gates-announces-investments-for-lmic-mrna-capacity/): At the 2023 Grand Challenges Annual Meeting in October 2023 Bill Gates announced new Bill and Melinda Gates Foundation investments to encourage mRNA research
- [GSK and Zhifei agree partnership for Shingrix in China](https://vaccinenation.org/technology/gsk-and-zhifei-agree-partnership-for-shingrix-in-china/): In October 2023 GSK announced that it has secured an exclusive agreement with Chongqing Zhifei Biological Products (Zhifei) to “co-promote”
- [Experimental vaccine turns immune system to “Hulk”](https://vaccinenation.org/technology/experimental-vaccine-turns-immune-system-to-hulk/): Research published in Science Translational Medicine and shared by the University of Southern California in October 2023 demonstrates the quick and effective
- [Experts call for “gender-responsive” Pandemic Accord](https://vaccinenation.org/global-health/experts-call-for-gender-responsive-pandemic-accord/): A commentary in The Lancet in October 2023 calls for a “gender-responsive” Pandemic Accord to secure a “healthier, equitable future”. Pandemic Accord
- [“Preparedness far outweighs response” says Dr Amy Shurtleff](https://vaccinenation.org/technology/preparedness-far-outweighs-response-says-dr-amy-shurtleff/): With less than a fortnight to go until the Congress in Barcelona we are thrilled to share another pre-Congress interview. Here we meet Dr Amy Shurtleff
- [Sanofi and Janssen announce E. coli vaccine collaboration](https://vaccinenation.org/technology/sanofi-and-janssen-announce-e-coli-vaccine-collaboration/): In October 2023 Sanofi announced that it has joined forces with Janssen Pharmaceuticals to develop and commercialise the vaccine candidate
- [A crisis management case study: Uganda’s 2022 Ebola outbreak](https://vaccinenation.org/global-health/a-crisis-management-case-study-ugandas-2022-ebola-outbreak/): In a paper published in the Journal of Public Health in Africa in September 2023 a team of authors explore the Ugandan government’s response
- [WHO issues update on Nipah virus outbreak in India](https://vaccinenation.org/infection/who-issues-update-on-nipah-virus-outbreak-in-india/): In October 2023 the WHO issued a statement with updates about the outbreak of Nipah virus that was reported in India last month. The update confirms
- [Vaccine start-ups return to the World Vaccine Congress!](https://vaccinenation.org/technology/vaccine-start-ups-return-to-the-world-vaccine-congress-12/): We are now down to just weeks to the World Vaccine Congress in Barcelona, and our start-up zone is reaching capacity! This week we are delighted to introduce
- [Women, power, and cancer: an investigative Lancet Commission](https://vaccinenation.org/therapeutic/women-power-and-cancer-an-investigative-lancet-commission/): The “nexus of women, power, and cancer” is the subject of investigation by The Lancet Commission in September 2023. Through an intersectional feminist lens
- [VLP based vaccines lower LDL cholesterol in study](https://vaccinenation.org/therapeutic/vlp-based-vaccines-lower-ldl-cholesterol-in-study/): A paper in npj vaccines presents the results of a study assessing the efficacy of VLP-based vaccines displaying linear peptides from PCSK9 reducing cholesterol
- [UKHSA and ONS plan new Winter COVID-19 Infection Study](https://vaccinenation.org/infection/ukhsa-and-ons-plan-new-winter-covid-19-infection-study/): The UKHSA and Office of National Statistics (ONS) announced in October 2023 that they are launching a “vital study” to understand COVID-19 infection data
- [WHO recommends Oxford’s malaria vaccine for use](https://vaccinenation.org/technology/who-recommends-oxfords-malaria-vaccine-for-use/): In October 2023 the University of Oxford announced that the WHO has recommended its malaria vaccine for the prevention of malaria in children.
- [Nobel celebrations for mRNA scientists Karikó and Weissman](https://vaccinenation.org/global-health/nobel-celebrations-for-mrna-scientists-kariko-and-weissman/): On 2nd October 2023 the Nobel Prize in Physiology or Medicine 2023 was announced as jointly awarded to Drs Katalin Karikó and Drew Weissman
- [WHO: southern hemisphere flu vaccine recommendations](https://vaccinenation.org/technology/who-southern-hemisphere-flu-vaccine-recommendations/): In September 2023 the WHO announced recommendations for the viral composition of influenza vaccines for the 2024 influenza season in the southern hemisphere
- [BactiVac announces government funding: vaccines vs AMR](https://vaccinenation.org/technology/bactivac-announces-government-funding-vaccines-vs-amr/): In September 2023 the University of Birmingham shared that the Bacterial Vaccines Network (BactiVac) was awarded £1.4 million by the UK government
- [Gavi’s 2022 progress report: rebounds and challenges](https://vaccinenation.org/global-health/gavis-2022-progress-report-rebounds-and-challenges/): In September 2023 Gavi announced the publication of its 2022 Annual Progress Report, which presents insights into a “year of recovery” for immunisation
- [CEPI and Global Affairs Canada collaborate on biosecurity](https://vaccinenation.org/global-health/cepi-and-global-affairs-canada-collaborate-on-biosecurity/): CEPI announced a “renewed collaboration” with Global Affairs Canada, comprising CAD 1 million in funding to “accelerate the development of vaccines
- [Report: investigating vaccine manufacturing in Africa](https://vaccinenation.org/global-health/report-investigating-vaccine-manufacturing-in-africa/): Before and during the COVID-19 pandemic that Africa’s demand for vaccines exceeds its local supply: 99% of vaccines administered on the continent are imported.
- [COVID-19 vaccines and unexpected vaginal bleeding](https://vaccinenation.org/global-health/covid-19-vaccines-and-unexpected-vaginal-bleeding/): Although insufficient attention has been directed towards the effects of vaccination on menstrual experiences, a study published in Science Advances in 2023
- [Gritstone bio awarded BARDA contract for COVID-19 study](https://vaccinenation.org/technology/gritstone-bio-awarded-barda-contract-for-covid-19-study/): In September 2023 Gritstone bio announced that is has been awarded a contract by BARDA to conduct a Phase IIb comparative study that will evaluate
- [Revital gets Pre-Qualification: early activation AD syringe](https://vaccinenation.org/technology/revital-gets-pre-qualification-early-activation-ad-syringe/): In September 2023 Revital Healthcare announced a “historic milestone in African manufacturing excellence”. The company was awarded Pre-Qualification (PQ)
- [Genomic surveillance strategies: WHO’s step-by-step guide](https://vaccinenation.org/global-health/genomic-surveillance-strategies-whos-step-by-step-guide/): WHO shared Considerations for developing a national genomic surveillance strategy or action plan for pathogens with pandemic and epidemic potential”
- [Vaccine start-ups return to the World Vaccine Congress!](https://vaccinenation.org/technology/vaccine-start-ups-return-to-the-world-vaccine-congress-11/): In the last few weeks before the World Vaccine Congress in Barcelona, our start-up zone is reaching capacity! This week we are pleased to present
- [Cambridge shares further antigen technology success](https://vaccinenation.org/technology/cambridge-shares-further-antigen-technology-success/): The University of Cambridge announced in September 2023 that a vaccine antigen technology developed in collaboration with spin-out DIOSynVax
- [UKHSA and CSL Seqirus partnership: flu pandemic preparation](https://vaccinenation.org/technology/ukhsa-and-csl-seqirus-partnership-flu-pandemic-preparation/): In September the UKHSA announced an agreed deal for “millions of life-saving vaccines” has been signed with CSL Seqirus. The advance purchase agreement (APA)
- [“A New Species of Trouble”: pandemic preparation in Africa](https://vaccinenation.org/global-health/a-new-species-of-trouble-pandemic-preparation-in-africa/): Pandemic Centre at Brown University School of Public Health publication emphasises the importance of “identification, attribution, and consequence management”
- [Tuberculosis goals: leaders reaffirm “collective commitment”](https://vaccinenation.org/global-health/tuberculosis-goals-leaders-reaffirm-collective-commitment/): At the United Nations General Assembly high-level meeting on tuberculosis world leaders approved a political declaration reaffirming their collective commitment
- [WHO’s 2022 statistics reveal global cholera surge](https://vaccinenation.org/infection/whos-2022-statistics-reveal-global-cholera-surge/): Data from the WHO published in September 2023 offer an insight into the extent of cholera surges across the world. The comprehensive statistics for 2022
- [UK government announces health security package at UNGA](https://vaccinenation.org/global-health/uk-government-announces-health-security-package-at-unga/): The UK’s International Development Minister Andrew Mitchell and Health Minister Will Quince announced investments in “ground-breaking research and development
- [Vir Biotechnology begins Phase I HIV vaccine trial](https://vaccinenation.org/technology/vir-biotechnology-begins-phase-i-hiv-vaccine-trial/): In September 2023 Vir Biotechnology announced that the first participant in a Phase I trial has been dosed. The trial of VIR-1388
- [Google’s DeepMind shares catalogue of disease insights](https://vaccinenation.org/technology/googles-deepmind-shares-catalogue-of-disease-insights/): In September 2023 Google’s AI organisation, DeepMind, released a catalogue of genetic mutations intended to accelerate disease diagnosis
- [WHO “welcomes” UNGA landmark pandemic declaration](https://vaccinenation.org/global-health/who-welcomes-unga-landmark-pandemic-declaration/): At the UNGA 78th session in September 2023 a “landmark declaration” was adopted on pandemic prevention, preparedness, and response.
- [Bio Farma and CEPI forge 10-year vaccine partnership](https://vaccinenation.org/technology/bio-farma-and-cepi-forge-10-year-vaccine-partnership/): In September 2023 CEPI and Bio Farmer announced the agreement of a 10-year partnership to “boost rapid manufacturing of outbreak vaccines”
- [Vaccine start-ups return to the World Vaccine Congress!](https://vaccinenation.org/technology/vaccine-start-ups-return-to-the-world-vaccine-congress-10/): With less than a month until the World Vaccine Congress in Barcelona, our start-up zone is continuing to grow! This week we are pleased to present
- [Report: how can the EU improve its vaccine industry appeal?](https://vaccinenation.org/global-health/report-how-can-the-eu-improve-its-vaccine-industry-appeal/): A study carried out by Charles River Associates (CRA) for Vaccines Europe (VE) in June 2023 investigates the state of the vaccines industry in the EU
- [Oxford: PSI begins ChAdOx1 MERS vaccine trial](https://vaccinenation.org/technology/oxford-psi-begins-chadox1-mers-vaccine-trial/): In September 2023 the University of Oxford’s Pandemic Sciences Institute (PSI) announced that a Phase I clinical trial for a vaccine against MERS
- [BioNTech and CEPI announce mRNA mpox partnership](https://vaccinenation.org/technology/biontech-and-cepi-announce-mrna-mpox-partnership/): In September 2023 BioNTech and CEPI announced a strategic partnership to advance mRNA-based vaccine candidates for the prevention of mpox.
- [Bluetongue virus: serotype 3 confirmed on Dutch sheep farms](https://vaccinenation.org/infection/bluetongue-virus-serotype-3-confirmed-on-dutch-sheep-farms/): An update from Wageningen Bioveterinary Research in September 2023 shared that the European reference laboratory in Madrid has confirmed the characterisation
- [High alert: confirmed outbreak of Nipah in India](https://vaccinenation.org/infection/high-alert-confirmed-outbreak-of-nipah-in-india/): India announces containment measures to control the spread of Nipah, detected in the southern state of Kerala, attention is returning to the need for a vaccine
- [CEPI and UC Davis partner on Rift Valley fever virus vaccine](https://vaccinenation.org/technology/cepi-and-uc-davis-partner-on-rift-valley-fever-virus-vaccine/): In September 2023 CEPI and the University of California, Davis (UC Davis) announced a partnership to advance human trials of a novel vaccine
- [UKHSA expands SIREN study on respiratory pathogens](https://vaccinenation.org/infection/ukhsa-expands-siren-study-on-respiratory-pathogens/): In September 2023 the UKHSA announced that the flagship SIREN study is “entering a new phase” of surveillance of respiratory infections in healthcare workers.
- [WHO urges health commitment at 78th UN General Assembly](https://vaccinenation.org/global-health/who-urges-health-commitment-at-78th-un-general-assembly/): Next week, from 18th to 26th September 2023, the United Nations General Assembly (UNGA) will take place in New York and virtually.
- [Oxford begins first-in-human trials for CCHF vaccine](https://vaccinenation.org/technology/oxford-begins-first-in-human-trials-for-cchf-vaccine/): In September 2023 the Oxford Vaccine Group (OVG) and Pandemic Sciences Institute (PSI) of the University of Oxford announced the commencement of a study
- [Vaccine start-ups return to the World Vaccine Congress!](https://vaccinenation.org/technology/vaccine-start-ups-return-to-the-world-vaccine-congress-9/): With just over a month until the World Vaccine Congress in Barcelona, our start-up zone is continuing to grow! This week we continue introducing organisations
- [Off-the-shelf lung cancer vaccine makes “major” progress](https://vaccinenation.org/therapeutic/off-the-shelf-lung-cancer-vaccine-makes-major-progress/): In September 2023 Ose Immunotherapeutics announced the publication of new data supporting its cancer vaccine, Tedopi, in HLA-A2 positive patients
- [An mRNA vaccine offers “promise” against Lassa virus](https://vaccinenation.org/technology/an-mrna-vaccine-offers-promise-against-lassa-virus/): A paper published in Nature Communications in September 2023 presents the results of an investigation into the effects of mRNA vaccines against Lassa virus
- [Inverse vaccine could stop autoimmune reactions](https://vaccinenation.org/technology/inverse-vaccine-could-stop-autoimmune-reactions/): A vaccine developed by researchers at the University of Chicago’s PME has demonstrated in the lab that it can reverse autoimmune diseases
- [Elevating the potential of cancer vaccines: Dr Kyle Holen](https://vaccinenation.org/therapeutic/elevating-the-potential-of-cancer-vaccines-dr-kyle-holen/): As we find ourselves in September and ever closer to the Congress in Barcelona next month, our interview series is kicking off with vigour.
- [Research into intranasal RNA COVID-19 vaccines at MIT](https://vaccinenation.org/technology/research-into-intranasal-rna-covid-19-vaccines-at-mit/): A team at the Massachusetts Institute of Technology (MIT) is working on COVID-19 RNA vaccine optimisation to try and improve immune responses at lower doses.
- [IVI and CEPI announce renewed vaccine collaboration](https://vaccinenation.org/global-health/ivi-and-cepi-announce-renewed-vaccine-collaboration/): In September 2023 the Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI) announced a “renewed collaboration”
- [Changes at molecular level: vaccines against leishmaniasis](https://vaccinenation.org/technology/changes-at-molecular-level-vaccines-against-leishmaniasis/): Researchers at Ohio State University offered an insight into their work against leishmaniasis in August 2023. Phase I human trial planning is underway
- [Vaccine start-ups return to the World Vaccine Congress](https://vaccinenation.org/technology/vaccine-start-ups-return-to-the-world-vaccine-congress-8/): Getting closer to the World Vaccine Congress in Barcelona this October, our start-up zone is continuing to grow! We are pleased to present more organisations
- [England to bring forward autumn vaccination programmes](https://vaccinenation.org/infection/england-to-bring-forward-autumn-vaccination-programmes/): The UK government announced in August 2023 that the autumn flu and COVID-19 vaccine programmes will start “earlier than planned
- [Microwave freeze-drying technology: is it rocket science?](https://vaccinenation.org/technology/microwave-freeze-drying-technology-is-it-rocket-science/): A lot of attention has been directed towards vaccine stability as the COVID-19 pandemic highlighted the weaknesses of traditional supply chain approaches.
- [Partners approach human trials for drug overdose vaccines](https://vaccinenation.org/global-health/partners-approach-human-trials-for-drug-overdose-vaccines/): A partnership involving a team at the University of Montana, funded by NIH, suggests that it is “nearing human trials” for vaccines
- [CEPI partners with Oxford, funding vaccines for Disease X](https://vaccinenation.org/technology/cepi-partners-with-oxford-funding-vaccines-for-disease-x/): In August 2023 CEPI announced a commitment of up to $80 million to support the design, manufacture, and strategies of globally accessible vaccines
- [Chikungunya “invisibility” insights may accelerate vaccines](https://vaccinenation.org/infection/chikungunya-invisibility-insights-may-accelerate-vaccines/): Albert Einstein College of Medicine announced in August that their publication in Nature Microbiology could help vaccine development for chikungunya fever.
- [C-TAP and MPP announce new licensing agreements](https://vaccinenation.org/technology/c-tap-and-mpp-announce-new-licensing-agreements/): In August 2023 WHO announced that the COVID-19 Technology Access Pool (C-TAP) has announced three new licensing agreements
- [GC Biopharma and EuBiologics join forces on cholera](https://vaccinenation.org/technology/gc-biopharma-and-eubiologics-join-forces-on-cholera/): A business agreement signed between GC Biopharma and EuBiologics in August 2023 allows the companies to jointly produce EuBiologic’s oral cholera vaccine,
- [Wellcome supports Vaxxas with HD-MAP technology](https://vaccinenation.org/technology/wellcome-supports-vaxxas-with-hd-map-technology/): In August 2023 Vaxxas announced that Wellcome has awarded the company £2.84 million to conduct IND-enabling studies and a first-in-human clinical study
- [“Tremendously exciting” results in malaria combination trial](https://vaccinenation.org/infection/tremendously-exciting-results-in-malaria-combination-trial/): In August 2023 researchers in an international partnership shared the results of a Phase III study in The Lancet Infectious Diseases.
- [UKHSA meningitis warning: 1 in 8 students unprotected](https://vaccinenation.org/infection/ukhsa-meningitis-warning-1-in-8-students-unprotected/): In August 2023 as the new academic year looms, the UKHSA and leading meningitis charities are “urging” students to check their vaccination status
- [Project NextGen awarded HHS funding against COVID-19](https://vaccinenation.org/technology/project-nextgen-awarded-hhs-funding-against-covid-19/): The US Department of Health and Human Services (HHS) announced in August 2023 that it awarded more than $1.4 billion for Project NextGen
- [Misled America: KFF study tracks vaccine misinformation](https://vaccinenation.org/global-health/misled-america-kff-study-tracks-vaccine-misinformation/): In August 2023 KFF shared the results of its Health Misinformation Tracking Poll Pilot as part of a wider effort provide accurate information to guide policy
- [CARsgen and Moderna unite to tackle Claudin18.2](https://vaccinenation.org/therapeutic/carsgen-and-moderna-unite-to-tackle-claudin18-2/): A collaboration between Chinese company CARsgen and Texas-based Moderna was announced by the former in August 2023. The agreement was initiated
- [Vaccine start-ups return to the World Vaccine Congress!](https://vaccinenation.org/technology/vaccine-start-ups-return-to-the-world-vaccine-congress-7/): With under two months until our World Vaccine Congress in Barcelona this October, our start-up zone is continuing to grow!
- [Pfizer’s maternal RSV vaccine gets FDA approval](https://vaccinenation.org/technology/pfizers-maternal-rsv-vaccine-gets-fda-approval/): In August 2023 Pfizer announced that the US FDA has approved its vaccine against RSV in infants through immunisation of pregnant individuals
- [UK announces £210 million AMR investment from aid budget](https://vaccinenation.org/global-health/uk-announces-210-million-amr-investment-from-aid-budget/): The UK Department of Health and Social Care announced that it was supporting “laboratories”, disease surveillance, and a “bigger global workforce”
- [Bovine TB: cattle pathway planning already underway](https://vaccinenation.org/global-health/bovine-tb-cattle-pathway-already-planning-underway/): Farmers Weekly reported on discussions to develop a pathway for approval of the export of cattle vaccinated with the “much-anticipated” bovine TB vaccine
- [Patient advocate by choice: Solve M.E.'s Oved Amitay](https://vaccinenation.org/therapeutic/patient-advocate-by-choice-solve-m-e-s-oved-amitay/): In this post we are thrilled to share a pre-event conversation with Solve M.E.'s President and CEO Oved Amitay, in which we discuss his team's work
- [Moderna’s updated COVID-19 jab fit for variants](https://vaccinenation.org/infection/modernas-updated-covid-19-jab-fit-for-variants/): In a statement released in August 2023 Moderna announced that preliminary clinical trial data “confirm” that the updated COVID-19 vaccine for the autumn 2023
- [The threat of the unknown: what is “Disease X”?](https://vaccinenation.org/global-health/the-threat-of-the-unknown-what-is-disease-x/): In August 2023 the announcement of the newly unveiled Vaccine Development and Evaluation Centre in the UK provoked consternation on social media.
- [Vaccine start-ups return to the World Vaccine Congress!](https://vaccinenation.org/technology/vaccine-start-ups-return-to-the-world-vaccine-congress-6/): We are inching ever closer to World Vaccine Congress in Barcelona this October, and our start-up zone is still growing! This week we are pleased to continue introducing more organisations that have already booked their place at the event. To see previous introductions head over to our technology section. Why be a start-up at the World Vaccine Congress?
- [International partnership targets parasitic worms in sheep](https://vaccinenation.org/global-health/international-partnership-targets-parasitic-worms-in-sheep/): Moredun Research Institute announced that it is leading an international partnership with the University of Glasgow and the University of New England
- [Gritstone and Genevant announce vaccine agreement](https://vaccinenation.org/technology/gritstone-and-genevant-announce-vaccine-agreement/): In August 2023 Gritstone bio and Genevant Sciences announced an agreement through which Gritstone will be able to develop and commercialise self-amplifying RNA
- ["Eris" variant more infectious: are there vaccines?](https://vaccinenation.org/infection/eris-variant-more-infectious-are-there-vaccines/): The EG.5 variant of SARS-CoV-2, identified in February 2023, has been classed as a “variant of interest (VOI) by the WHO.
- [Gavi leadership: Berkley passes the baton to Marlow](https://vaccinenation.org/global-health/gavi-leadership-berkley-passes-the-baton-to-marlow/): 2nd August 2023, Dr Seth Berkley’s tenure as CEO of Gavi came to an end after 12 years. The position of Interim CEO was assumed by David Marlow
- [Study: how effective are seasonal flu vaccines?](https://vaccinenation.org/global-health/study-how-effective-are-seasonal-flu-vaccines/): A study in Vaccines against Influenza virus presents a systematic review and meta-analysis of RCTs and TNDs to assess the VE
- [EBV vaccine candidate makes progress in study](https://vaccinenation.org/therapeutic/ebv-vaccine-candidate-makes-progress-in-study/): In a study published in Nature Communications in August 2023 presents early findings for a “cutting-edge” vaccine candidate developed at QIMR Berghofer.
- [UK's COVID-19 autumn booster groups announced](https://vaccinenation.org/global-health/uks-covid-19-autumn-booster-groups-announced/): In August 2023 the UKHSA shared an announcement from the Joint Committee on Vaccination and Immunisation (JCVI) regarding who will be eligible
- [Vaccine start-ups return to the World Vaccine Congress!](https://vaccinenation.org/technology/vaccine-start-ups-return-to-the-world-vaccine-congress-5/): Another week closer to World Vaccine Congress in Barcelona this October, and our start-up zone is expanding all the time! This week
- [CEPI and Gennova collaborate on saRNA against Disease X](https://vaccinenation.org/technology/cepi-and-gennova-collaborate-on-sarna-against-disease-x/): In August 2023 CEPI and Gennova Biopharmaceuticals Ltd announced a funding agreement of up to $3.6 million to advance Gennova’s saRNA platform.
- [UK’s Vaccine Development and Evaluation Centre opens](https://vaccinenation.org/global-health/uks-vaccine-development-and-evaluation-centre-opens/): In August 2023 the UKHSA announced the opening of its “world-leading” Vaccine Development and Evaluation Centre in the science and defence technology campus
- [Nationwide survey finds Nipah virus in Indian bats](https://vaccinenation.org/infection/nationwide-survey-finds-nipah-virus-in-indian-bats/): In July 2023 The Indian Express reported that the Pune-based ICMR-NIV nationwide survey had found evidence of Nipah virus in circulation in the bat population
- [Economist Impact launches Immunisation Readiness Index](https://vaccinenation.org/global-health/economist-impact-launches-immunisation-readiness-index/): Economist Impact’s The Vaccine Ecosystem launched the Immunisation Readiness Index, which measures the enabling environment for immunisation
- [AAHI awarded millions for chikungunya vaccine pursuit](https://vaccinenation.org/technology/aahi-awarded-millions-for-chikungunya-vaccine-pursuit/): In August 2023 the Access to Advanced Health Institute (AAHI) announced that it had received an $18 million award from the NIH in support of its efforts
- [Vaccine start-ups return to the World Vaccine Congress!](https://vaccinenation.org/technology/vaccine-start-ups-return-to-the-world-vaccine-congress-4/): With just over two months left until the World Vaccine Congress in Barcelona this October our start-up zone continues to grow!
- [CDC’s Dr Cohen on gaining back America’s trust](https://vaccinenation.org/global-health/cdcs-dr-cohen-on-gaining-back-americas-trust/): Just weeks into her new role as Director of the US CDC, Dr Mandy Cohen has been busy, emphasising the importance of encouraging trust
- [EMA works towards better emergency clinical trials](https://vaccinenation.org/technology/ema-works-towards-better-emergency-clinical-trials/): In a report published by the European Medicines Agency in July 2023 the lessons from the COVID-19 and mpox PHEICs are explored, considering the need to improve
- [Vaccine combinations against bladder cancer: IO Biotech](https://vaccinenation.org/therapeutic/cancer-combinations-against-bladder-cancer-io-biotech/): IO Biotech announced that the University of California Davis Comprehensive Cancer Centre has dosed the first patient in an investigator-initiated trial
- [Religion and vaccines: a study in religious scepticism](https://vaccinenation.org/global-health/religion-and-vaccines-a-study-in-religious-scepticism/): An article in Vaccine: X in August 2023 acknowledges that previous research has identified religion as one of “numerous factors” contributing to delay
- [Targeting inflamed brain cells to reduce Alzheimer’s](https://vaccinenation.org/therapeutic/targeting-inflamed-brain-cells-to-reduce-alzheimers/): A team from Japan’s Juntendo University suggest that their latest vaccine, “SAGP”, may revolutionise treatment of Alzheimer’s disease.
- [National Sheep Association raises vaccine concerns](https://vaccinenation.org/global-health/national-sheep-association-raises-vaccine-concerns/): In July 2023, just days after we reported on a concerning lack of EAE vaccines in the UK, the National Sheep Association stated that there is a “critical need”
- [World Hepatitis Day 2023: “We’re not waiting”](https://vaccinenation.org/infection/world-hepatitis-day-2023-were-not-waiting/): Under the call to action “We’re not waiting”, World Hepatitis Day takes place on 28th July 2023. This slogan highlights the need for accelerated elimination
- [Stressed? It might affect your vaccine response, says study](https://vaccinenation.org/global-health/stressed-it-might-affect-your-vaccine-response-says-study/): In research published in Brain, Behaviour, and Immunity in July 2023, a group from Tel Aviv University found that there is a link between behavioural stress
- [UK risks losing top vaccination status, warn MPs](https://vaccinenation.org/global-health/uk-risks-losing-top-vaccination-status-warn-mps/): MPs in the UK have warned that the country risks losing its place as a global leader in vaccination after the Health and Social Care Committee report
- [EAE vaccine supply delays concern sheep farmers](https://vaccinenation.org/technology/eae-vaccine-supply-delays-concern-sheep-farmers/): In July 2023 Farmers Guide reported that delays in the supply of a vaccine for EAE (enzootic abortion of ewes) are expected to last
- [Merck and Moderna begin Phase III melanoma trial](https://vaccinenation.org/therapeutic/merck-and-moderna-begin-phase-iii-melanoma-trial/): Merck and Moderna announced the initiation of a Phase III clinical trial evaluating V940 (mRNA-4157) in combination with KEYTRUDA
- [Vaccine start-ups return to the World Vaccine Congress!](https://vaccinenation.org/technology/vaccine-start-ups-return-to-the-world-vaccine-congress-3/): As we get closer to the World Vaccine Congress in Barcelona this October our start-up zone is growing every week. This week we continue
- [“Unusual increase” in GBS cases in Peru causes alert](https://vaccinenation.org/infection/unusual-increase-in-gbs-cases-in-peru-causes-alert/): WHO reported in July 2023 that the National Centre for Epidemiology, Prevention, and Disease Control (CDC) of Peru has issued an epidemiological alert
- [UKHSA establishes 3-year health threat strategy](https://vaccinenation.org/global-health/ukhsa-establishes-3-year-health-threat-strategy/): In July 2023 the UK Health Security Agency (UKHSA) announced a new strategy, outlining its “vision and goals” over 3 years.
- [New study models effect of vaccines against AMR](https://vaccinenation.org/global-health/new-study-models-effect-of-vaccines-against-amr/): A study in BMJ Global Health in July 2023 uses a static proportional impact model to explore the effect of vaccination on 15 bacterial pathogens.
- [IQVIA report: COVID-19 affected adult immunisations](https://vaccinenation.org/global-health/iqvia-report-covid-19-affected-adult-immunisations/): A report by IQVIA Institute for Human Data Science, in collaboration with GSK and the Global Coalition on Aging (GCOA), explores global adult vaccination
- [Vaccine adjuvants: problems and prospects in review](https://vaccinenation.org/technology/vaccine-adjuvants-problems-and-prospects-in-review/): A review in July 2023 describes adjuvants as “indispensable components of vaccines” that are widely used but not completely understood
- [Canada prepares for animal FMD with vaccine bank](https://vaccinenation.org/global-health/canada-prepares-for-animal-fmd-with-vaccine-bank/): After a meeting of the Federal, Provincial, and Territorial (FPT) Ministers of Agriculture in Canada, Ministers confirmed their “commitment”
- [US DoD awards VitriVax 5-year vaccine contract](https://vaccinenation.org/technology/us-dod-awards-vitrivax-5-year-vaccine-contract/): In July 2023 VitriVax announced that it had been awarded a $29 million contract over 5 years from the Defence Threat Reduction Agency (DTRA)
- [Continued progress for Vaxxinity against Parkinson’s](https://vaccinenation.org/therapeutic/continued-progress-for-vaxxinity-against-parkinsons/): Less than a month since we reported Vaxxinity’s “promising” results in a trial of UB-312, the company has released further encouraging news; new data
- [Pfizer’s maternal GBS6 may offer “meaningful” protection](https://vaccinenation.org/technology/pfizers-maternal-gbs6-may-offer-meaningful-protection/): Pfizer announced data from a Phase II study investigating its hexavalent capsular polysaccharide (CPS) conjugate Group B Streptococcus (GBS)
- [Vaccines are the "future" in cancer, says Dr Pravin Kaumaya](https://vaccinenation.org/therapeutic/vaccines-are-the-future-in-cancer-says-dr-pravin-kaumaya/): During the Congress last month we were pleased to meet Dr Pravin Kaumaya for a conversation about the state of play in the cancer vaccine field.
- [New partnership to strengthen Africa’s health security](https://vaccinenation.org/global-health/new-partnership-to-strengthen-africas-health-security/): Africa CDC, WHO, and the Robert Koch Institute (RKI) launched a Health Security Partnership intended to strengthen disease surveillance
- [Blue Water preclinical progress on mpox vaccine](https://vaccinenation.org/technology/blue-water-preclinical-progress-on-mpox-vaccine/): Blue Water Biotech announced preliminary preclinical data in support of the use of a norovirus shell and protrusion (S&P) virus-like particle (VLP)
- [AI to accelerate Disease X preparation and prevention](https://vaccinenation.org/technology/ai-to-accelerate-disease-x-preparation-and-prevention/): In a partnership announced in July 2023, CEPI and the Houston Methodist Research Institute (HMRI) will combine cutting-edge artificial intelligence (AI)
- [UNAIDS: ‘The Path that Ends Aids’ report released](https://vaccinenation.org/infection/unaids-the-path-that-ends-aids-report-released/): In July 2023 UNAIDS released a report outlining a “clear path” to end AIDS and prepare for and tackle future pandemics in line with SDGs
- [Building back childhood immunisations after COVID-19](https://vaccinenation.org/global-health/building-back-childhood-immunisations-after-covid-19/): Data from WHO and UNICEF, shared in July 2023, suggest that fewer children missed routine vaccinations in 2022 than in the previous year.
- [Dengue during pregnancy poses health risks to newborns](https://vaccinenation.org/infection/dengue-during-pregnancy-poses-health-risks-to-newborns/): Although dengue, a viral infection transmitted through mosquito bites, threatens the health of “about half of the world’s population”, little investigation
- [UKHSA measles modelling shows London is at risk](https://vaccinenation.org/infection/ukhsa-measles-modelling-shows-london-is-at-risk/): Data from the UKHSA in July 2023 suggests a “steady rise” in measles cases in the UK throughout the year, with the organisation suggesting
- [HHS to COVID-19 vaccine manufacturers: be "reasonable"](https://vaccinenation.org/technology/hhs-to-covid-19-vaccine-manufacturers-be-reasonable/): A letter from the US Secretary of Health and Human Services (HHS) in July 2023 to COVID-19 vaccine manufacturers expressed appreciation
- [What do Africa CDC’s appointments mean for immunisation?](https://vaccinenation.org/global-health/what-do-africa-cdcs-appointments-mean-for-immunisation/): Africa CDC, the “autonomous public health institution of the African Union” (AU) announced in July 2023 that a strategic shakeup of its ATC
- [PATH and SIIPL’s MenFive vaccine prequalified by WHO](https://vaccinenation.org/technology/path-and-siipls-menfive-vaccine-prequalified-by-who/): Serum Institute of India (SIIPL) and PATH announced that the first conjugate vaccine against the five predominant causes of meningococcal meningitis in Africa,
- [Vaccine start-ups return to the World Vaccine Congress!](https://vaccinenation.org/technology/vaccine-start-ups-return-to-the-world-vaccine-congress-2/): As we gear up for October’s World Vaccine Congress in Europe, we are delighted to see our start-up zone growing with new and familiar names.
- [WHO warns of “ongoing risks” to humans from bird flu](https://vaccinenation.org/infection/who-warns-of-ongoing-risks-to-humans-from-bird-flu/): WHO, Food and Agriculture Organisation (FAO), and the World Organisation for Animal Health (WOAH) united in a statement urging countries to collaborate
- [HIV vaccine trial shows “encouraging” early results](https://vaccinenation.org/technology/hiv-vaccine-trial-shows-encouraging-early-results/): In July 2023 it was announced that preliminary analysis of vaccine trial results demonstrates the induction of “high frequencies” of broadly specific T cells.
- [Long COVID paper recognises several “unknowns”](https://vaccinenation.org/infection/long-covid-paper-recognises-several-unknowns/): In a paper in Nature reviews immunology in July 2023 a group of scientists investigate the “immunology” long COVID. The authors describe the condition
- [WEF calls for “ambitious investment” in childhood vaccines](https://vaccinenation.org/global-health/wef-calls-for-ambitious-investment-in-childhood-vaccines/): In an article for the World Economic Forum in July 2023 the importance of investment in childhood vaccines and vaccination programmes is emphasised.
- [Conspiracies complicate childhood COVID-19 vaccinations](https://vaccinenation.org/global-health/conspiracies-complicate-childhood-covid-19-vaccinations/): In a study published in Frontiers in Psychology researchers examine the link between conspiracy mindsets and uptake of COVID-19 vaccines for children in the US.
- [Reaching 2030 rabies goals requires vaccination](https://vaccinenation.org/infection/reaching-2030-rabies-goals-requires-vaccination/): The World Organisation for Animal Health reminds us that rabies continues to kill around 59,000 people a year, with a case fatality rate of almost 100%
- [Enterovirus cases in newborns causing concern in Europe](https://vaccinenation.org/infection/enterovirus-cases-in-newborns-causing-concern-in-europe/): WHO reported in July 2023 that Member States within the European Region had notified the organisation of cases of enterovirus Echovirus 11 (E-11)
- [FIGO advocates for sustainable vaccination programmes](https://vaccinenation.org/global-health/figo-advocates-for-sustainable-vaccination-programmes/): In July 2023 the International Federation of Gynaecology and Obstetrics (FIGO) published a supplement in the International Journal of Gynaecology and Obstetrics
- [Sanofi sets sights on Saudi drugmakers Lifera and Arabio](https://vaccinenation.org/global-health/sanofi-sets-sights-on-saudi-drugmakers-lifera-and-arabio/): In July 2023 it was announced that Sanofi had signed a Memorandum of Understanding (MoU) with Lifer and Arabio, two Saudi Arabian drugmakers.
- [Moderna deal to bring China into the mRNA era](https://vaccinenation.org/global-health/moderna-deal-to-bring-china-into-the-mrna-era/): In July 2023 it was announced that Moderna had established an agreement with China to develop mRNA products for use in the country. This news comes amid tension
- [UK government and BioNTech join forces on cancer trials](https://vaccinenation.org/therapeutic/uk-government-and-biontech-join-forces-on-cancer-trials/): Following the signing of a memorandum between the UK government and BioNTech in January 2023, an agreement has been established to provide “improved access”
- [Gavi announces malaria vaccine for 12 African countries](https://vaccinenation.org/global-health/gavi-announces-malaria-vaccine-for-12-african-countries/): In a collaboration 12 countries across different regions in Africa are expected to receive a total of 18 million doses of the first-ever malaria vaccine
- [Farmers want government-led TB vaccination strategies](https://vaccinenation.org/global-health/farmers-want-government-led-tb-vaccination-strategies/): In a Defra-commissioned study published in VetRecord researchers investigated the attitudes of farmers to different vaccination approaches to tackling bTB
- [UK secondary school pupils eligible for flu spray this year](https://vaccinenation.org/global-health/uk-secondary-school-pupils-eligible-for-flu-spray-this-year/): In an update from the UK government in July 2023 over 3 million secondary school pupils will be offered a free flu vaccine for the 2023/2024 season
- [FVVA framework guides vaccine value assessments](https://vaccinenation.org/global-health/fvva-framework-guides-vaccine-value-assessments/): A paper in BMC Medicine presents an apparent solution to the economic obstacles to the development and use of vaccines. The solution is the FVVA framework
- [Pandemic preparedness: EU Commission strikes vaccine deals](https://vaccinenation.org/global-health/pandemic-preparedness-eu-commission-strikes-vaccine-deals/): At the end of June 2023 reports circulated that the EU Commission was preparing deals in anticipation of future global health emergencies
- [Data sharing key to tackling animal influenza, says OFFLU](https://vaccinenation.org/global-health/data-sharing-key-to-tackling-animal-influenza-says-offlu/): As animal influenza continues to cause concern across the world, OFFLU has shared a 2022 report to showcase its “commitment to collaboration”
- [Is a new tuberculosis vaccine on the horizon?](https://vaccinenation.org/global-health/is-a-new-tuberculosis-vaccine-on-the-horizon/): In June 2023 Wellcome and the Bill and Melinda Gates Foundation announced funding to advance a tuberculosis (TB) vaccine candidate through a Phase III trial
- [Vaccine start-ups return to the World Vaccine Congress!](https://vaccinenation.org/technology/vaccine-start-ups-return-to-the-world-vaccine-congress/): As we gear up for October’s World Vaccine Congress in Europe, we are delighted to see our start-up zone growing with new and familiar names
- [Zoonotic risk: UK bat screening finds coronaviruses](https://vaccinenation.org/infection/zoonotic-risk-uk-bat-screening-finds-coronaviruses/): In a Nature Communications article in June 2023 a group of European-based researchers present results of screening for coronaviruses in UK bat species
- [How did a vaccine mandate affect English care homes?](https://vaccinenation.org/global-health/how-did-a-vaccine-mandate-affect-english-care-homes/): The contentious introduction of a vaccine mandate for staff in elderly care homes in England in 2021 was an attempt to protect some of the country’s vulnerable
- [Study: immune cell age affects vaccination response](https://vaccinenation.org/global-health/study-immune-cell-age-affects-vaccination-response/): An article in Nature Communications in June 2023 presents research into age-associated B cells (ABCs) and how they can affect responses to COVID-19 vaccination.
- [Review of vaccine hesitancy in pregnancy finds continuum](https://vaccinenation.org/global-health/review-of-vaccine-hesitancy-in-pregnancy-finds-continuum/): A narrative review of vaccine hesitancy in pregnant women concludes that “hesitancy is dynamic”, and people “do not always hold a static level”.
- [CEPI to provide funding for RVAC’s mRNA platform technology](https://vaccinenation.org/technology/cepi-to-provide-funding-for-rvacs-mrna-platform-technology/): CEPI announced a new partnership agreement to “advance and accelerate” RVAC’s manufacturing process for next-generation mRNA vaccine platform technology.
- [Vaxxinity announces positive Parkinson’s trial results](https://vaccinenation.org/therapeutic/vaxxinity-announces-positive-parkinsons-trial-results/): In June 2023 Vaxxinity announced positive results from Part B of the Phase I clinical trial of UB-312, an investigational vaccine for Parkinson’s disease.
- [WHO project strengthened African health and vaccine systems](https://vaccinenation.org/global-health/who-project-strengthened-african-health-and-vaccine-systems/): The WHO reported that a project from 2022 helped health systems become more resilient, arming them against epidemics of vaccine-preventable diseases.
- [GSK granted Fast Track designation for gonorrhoea vaccine](https://vaccinenation.org/technology/gsk-granted-fast-track-designation-for-gonorrhoea-vaccine/): In June 2023 GSK announced that the US FDA has granted fast track designation for its Neisseria gonorrhoeae investigational vaccine (NgG).
- [CEPI issues call for betacoronavirus challenge studies](https://vaccinenation.org/technology/cepi-issues-call-for-betacoronavirus-challenge-studies/): CEPI issued a Call for Proposals for research teams interested in collaborating on a consortium to create a human-challenge-model platform
- [Epigraph algorithm enables swine flu vaccine research](https://vaccinenation.org/technology/epigraph-algorithm-enables-swine-flu-vaccine-research/): Researchers in Nebraska believe they are getting closer to an effective and potentially universal vaccine for swine flu. With results of a study published
- [Political economy study finds COVID-19 "imbalance"](https://vaccinenation.org/global-health/political-economy-study-finds-covid-19-imbalance/): During the COVID-19 pandemic the rate of technology acceleration was remarkable, and many communities across the globe were able to benefit from this.
- [AI algorithms to support vaccine development for Disease X](https://vaccinenation.org/technology/ai-algorithms-to-support-vaccine-development-for-disease-x/): In June 2023 CEPI and the Institute for Drug Discovery at Leipzig University announced a partnership to speed up the development of future vaccines
- [EU grant advances universal DeltaFLU vaccine development](https://vaccinenation.org/technology/eu-grant-advances-universal-deltaflu-vaccine-development/): A grant of €7.6 million from the EU will contribute to the efforts of a consortium of academic and industry partners that is advancing a universal flu vaccine.
- [DRIVing vaccine innovation with Dr Sandeep Patel](https://vaccinenation.org/technology/driving-vaccine-innovation-with-dr-sandeep-patel/): Our next interview from the Congress last month was a recorded conversation with BARDA's Dr Sandeep Patel. Dr Patel joined us for the Biodefence workshop
- [CEPI and aVaxziPen partner on vaccine delivery for access](https://vaccinenation.org/technology/cepi-and-avaxzipen-partner-on-vaccine-delivery-for-access/): CEPI and aVaxziPen Ltd announced in June 2023 that they are partnering to advance the development of two vaccine candidates that use aVaxziPen’s
- [Moderna and Merck announce positive DMFS results from trial](https://vaccinenation.org/therapeutic/moderna-and-merck-announce-positive-dmfs-results-from-trial/): In June 2023 Moderna and Merck, who have been collaborating on a Phase IIb study to evaluate mRNA-4157 (V940), announced distant metastasis-free survival (DMFS)
- [Novavax and Gates partner for adjuvant in vaccine research](https://vaccinenation.org/technology/novavax-and-gates-partner-for-adjuvant-in-vaccine-research/): Novavax announced in June 2023 that it has signed a three-year agreement with the Bill and Melinda Gates Medical Research Institute to provide its adjuvant
- [VaxEquity and CPI announce Innovate UK manufacturing grant](https://vaccinenation.org/technology/vaxequity-and-cpi-announce-innovate-uk-manufacturing-grant/): In June 2023 VaxEquity and CPI announced a grant of around £700k from Innovate UK, which will fund a collaborative project to advance RNA vaccines
- [Transgene presents positive cancer vaccine data for HPV](https://vaccinenation.org/therapeutic/transgene-presents-positive-cancer-vaccine-data-for-hpv/): French-based biotechnology company Transgene announced in June 2023 that new data confirm that its novel investigational therapeutic cancer vaccine
- [Meeting unmet medical needs with Valneva's Thomas Lingelbach](https://vaccinenation.org/infection/meeting-unmet-medical-needs-with-valnevas-thomas-lingelbach/): Next in our series of conversations with experts at the Congress last month is founding CEO of Valneva, Thomas Lingelbach.
- [Strategies from a cross-sector workshop at WVC - Together we can achieve & maintain vaccination coverage](https://vaccinenation.org/global-health/strategies-from-a-cross-sector-workshop-at-wvc-together-we-can-achieve-maintain-vaccination-coverage/): Global disruptions to routine vaccination occurred during the COVID-19 pandemic setting vaccination programs back decades, risking future disease outbreaks
- [Planetary health meets public health: Dr Alex Dehgan](https://vaccinenation.org/infection/planetary-health-meets-public-health-dr-alex-dehgan/): At the Congress in Washington last month we were lucky to meet Conservation X Labs CEO and co-founder, Dr Alex Dehgan. He joined us at the event
- [Access through innovation: Dr Carmen Ledesma-Feliciano](https://vaccinenation.org/technology/access-through-innovation-dr-carmen-ledesma-feliciano/): Our next conversation from the Congress last month is an interview with PharmaJet's Dr Carmen Ledesma-Feliciano. Dr Ledesma-Feliciano joined us for a
- [Geo-diversification of vaccines: CEPI's Dr Matthew Downham](https://vaccinenation.org/global-health/geo-diversification-of-vaccines-cepis-dr-matthew-downham/): Next in our interview series is CEPI's Dr Matthew Downham, who joined us at the Congress for a plenary session and a panel.
- [Diseases are "not done with us", says Dr Ofer Levy](https://vaccinenation.org/technology/diseases-are-not-done-with-us-says-dr-ofer-levy/): Our next interviewee is Dr Ofer Levy of Boston Children's Hospital; he joined us in Washington for several sessions to explore adjuvants and immune profiling
- [Animal diseases are "red flags" says Professor James Roth](https://vaccinenation.org/global-health/animal-diseases-are-red-flags-says-professor-james-roth/): As part of our series of conversations with experts at the Congress in Washington last month we were lucky to meet Professor James Roth for an interview
- [Agricultural equilibrium: old meets new with Joel Harris](https://vaccinenation.org/global-health/agricultural-equilibrium-old-meets-new-with-joel-harris/): Our next interview guest from the Congress last month is Genvax Technologies' CEO and Co-Founder, Joel Harris. Joel joined us for a presentation and a panel
- [Dr Jules Millogo: "human beings want to do the right thing"](https://vaccinenation.org/global-health/dr-jules-millogo-human-beings-want-to-do-the-right-thing/): During the Congress last month we were lucky that Dr Jules Millogo made time to meet for a conversation about his work. He joined us
- [Galvanising the vaccine ecosystem: David Humphreys](https://vaccinenation.org/global-health/galvanising-the-vaccine-ecosystem-david-humphreys/): Next up in our exclusive series of Congress interviews is this conversation with David Humphreys, Global Head of Health Policy at Economist Impact.
- [Conducting challenge trials: hVIVO's Dr Andrew Catchpole](https://vaccinenation.org/technology/conducting-challenge-trials-hvivos-dr-andrew-catchpole/): Our next guest is Dr Andrew Catchpole, hVIVO's Chief Scientific Officer, who joined us in Washington for the Clinical Development and Trials track.
- [Universal influenza vaccine trial begins in the US](https://vaccinenation.org/technology/universal-influenza-vaccine-trial-begins-in-the-us/): The clinical trial of an experimental universal influenza vaccine developed by researchers from the Vaccine Research Centre has started to enrol volunteers.
- [Africa innovating with the world: Professor Petro Terblanche](https://vaccinenation.org/technology/africa-innovating-with-the-world-professor-petro-terblanche/): Next up in our series of Congress interviews is our conversation with Professor Petro Terblanche, CEO of Afrigen. She joined us at the Congress for a plenary
- [T cells and cancer immunosuppression: Dr Jay Berzofsky](https://vaccinenation.org/therapeutic/t-cells-and-cancer-immunosuppression-dr-jay-berzofsky/): Our next interview is with Dr Jay Berzofsky, Chief of the Vaccine Branch at NCI's Centre for Cancer Research. He joined us at the Congress
- ["Vaccines are the great levelling field", says Dr Nora Disis](https://vaccinenation.org/therapeutic/vaccines-are-the-great-levelling-field-says-dr-nora-disis/): At the World Vaccine Congress last month we were lucky to meet Dr Nora Disis of the University of Washington (UW), an expert in oncology.
- [Mpox, like COVID-19, no longer a PHEIC says WHO](https://vaccinenation.org/infection/mpox-like-covid-19-no-longer-a-pheic-says-who/): Just days after the COVID-19 pandemic was declared no longer a public health emergency of international concern (PHEIC), mpox has followed suit.
- [PDAC progress with personalised RNA neoantigen vaccines](https://vaccinenation.org/therapeutic/pdac-progress-with-personalised-rna-neoantigen-vaccines/): An article in Nature in May 2023 presents work from a collaboration between Genentech, Memorial Sloan Kettering Cancer Centre (MSKCC), and BioNTech.
- [Challenging conventional thinking with Mei Mei Hu](https://vaccinenation.org/technology/challenging-conventional-thinking-with-mei-mei-hu/): In this interview we meet Mei Mei Hu, CEO and Co-Founder of Vaxxinity. She joined us at the Congress to explore the ideas of using vaccines for chronic diseases
- [Tilting the cancer battlefield with Dr Andrew Allen](https://vaccinenation.org/therapeutic/tilting-the-cancer-battlefield-with-dr-andrew-allen/): At last month's Congress we were lucky to meet Dr Andrew Allen, CEO and Co-Founder of Gritstone Bio, for a conversation about cancer vaccines
- [Driving public health conversations: Dr Jennifer McQuiston](https://vaccinenation.org/global-health/driving-public-health-conversations-dr-jennifer-mcquiston/): Captain Dr Jennifer McQuiston joined us at the Congress last month to discuss the importance of animal vaccines and diseases that start at animal level.
- [NIH funds research into coronaviruses after 3-year pause](https://vaccinenation.org/infection/nih-funds-research-into-coronaviruses-after-3-year-pause/): After the "termination and suspension” of a grant awarded in 2019, NIH and EcoHealth Alliance have announced a grant to research zoonotic coronaviruses.
- ["Sentinels around the globe": meeting the Integrum team](https://vaccinenation.org/infection/sentinels-around-the-globe-meeting-the-integrum-team/): In 2018 Integrum Scientific was formed by a "group of global innovators" in response to "the need to address the deficiencies" and "broaden the benefits"
- [“Trusted parents” encourage parents to vaccinate children](https://vaccinenation.org/global-health/trusted-parents-encourage-parents-to-vaccinate-children/): A study in Pediatrics in May 2023 explores the effects of different messaging angles on parents’ intentions to vaccinate their children against COVID-19
- [COVID-19 “established and ongoing” but no longer PHEIC](https://vaccinenation.org/infection/covid-19-established-and-ongoing-but-no-longer-pheic/): Committee members advised the WHO Director General that the pandemic is no longer a public health emergency of international concern (PHEIC).
- [West Nile virus needs vaccines say health experts](https://vaccinenation.org/infection/west-nile-virus-needs-vaccines-say-health-experts/): In an article published in NEJM in May 2023 experts from the Division of Vector-Borne Diseases “revisit the need for human West Nile virus (WNV) vaccines”
- [UKHSA warns parents after increase in measles case](https://vaccinenation.org/infection/ukhsa-warns-parents-after-increase-in-measles-case/): The UK Health Security Agency (UKHSA) published data in May 2023 that reveal a rise in measles cases, mostly in London. Some have been identified in other areas
- [A world first for GSK: US FDA approves RSV vaccine](https://vaccinenation.org/technology/a-world-first-for-gsk-us-fda-approves-rsv-vaccine/): In May 2023 the US FDA announced approval of Arexvy, the first respiratory syncytial virus vaccine to be approved for use in the US and the rest of the world.
- [VacTrack: "a digital solution", says CEO Gabriella Hakim](https://vaccinenation.org/technology/vactrack-a-digital-solution-says-ceo-gabriella-hakim/): Our next interview in the exclusive Congress series is our conversation with Gabriella Hakim of VacTrack. Gabriella is the CEO
- [AI to design stable mRNA COVID-19 vaccine sequences](https://vaccinenation.org/technology/ai-to-design-stable-mrna-covid-19-vaccine-sequences/): Research shared in Nature in May 2023 details work by a team from Baidu to develop an AI algorithm that can design stable mRNA vaccine sequences.
- [Hitting HIV where it hurts: interview with Dr Gaurav Gaiha](https://vaccinenation.org/therapeutic/exclusive-congress-interviews-dr-gaurav-gaiha/): Continuing our series of exclusive Congress interviews we are delighted to share a conversation with Dr Gaurav Gaiha at the Congress this month
- [Breaking One Health barriers with Dr Jomana Musmar](https://vaccinenation.org/infection/exclusive-congress-interviews-dr-jomana-musmar/): As part of our exclusive interviews conducted at the World Vaccine Congress this month we are delighted to share our conversation with Dr Jomana Musmar.
- [Transforming global access: UNICEF’s pooled procurement](https://vaccinenation.org/global-health/transforming-global-access-unicefs-pooled-procurement/): Shortly after the publication of UNICEF’s State of the World’s Children report in April 2023, UNICEF explored the reasons for its procurement approach
- [African vaccines in Ghana: a study in decolonisation](https://vaccinenation.org/global-health/african-vaccines-in-ghana-a-study-in-decolonisation/): As became apparent during the COVID-19 pandemic, long-existing health inequalities mean that a location’s experience of public health threats varies widely
- [Liverpool begins Phase I trial of Zika virus vaccine](https://vaccinenation.org/technology/liverpool-begins-phase-i-trial-of-zika-virus-vaccine/): The University of Liverpool announced in April 2023 that the first participant has received a dose of a new Zika virus vaccine, being trialled
- [Gavi’s ‘ZIP’: bringing vaccines to hard-to-reach children](https://vaccinenation.org/global-health/gavis-zip-bringing-vaccines-to-hard-to-reach-children/): Gavi announced in April 2023 that it is beginning a “push” to reach zero-dose children through a Zero-Dose Immunisation Programme (ZIP).
- [World Malaria Day 2023: invest, innovate, implement](https://vaccinenation.org/infection/world-malaria-day-2023-invest-innovate-implement/): On 25th April 2023 the WHO observed World Malaria Day with a call for “increased implementation” of “new and existing interventions” to save lives from malaria.
- [Ultimovacs trial delayed by slow disease progression](https://vaccinenation.org/therapeutic/ultimovacs-trial-delayed-by-slow-disease-progression/): In April 2023 Ultimovacs ASA announced that it has adjusted guidance for communication of top-line data from early 2023 to later in the year.
- [Vaccine printer produces thermostable mRNA MNPs](https://vaccinenation.org/technology/vaccine-printer-produces-thermostable-mrna-mnps/): An article in Nature Biotechnology explores the possibility presented through an automated process for printing microneedle patch (MNP) mRNA vaccines
- [Cambridge begins needle-free vaccine trials for SARS-CoV-2](https://vaccinenation.org/technology/cambridge-begins-needle-free-vaccine-trials-for-sars-cov-2/): A team at the University of Cambridge and spin-out DIOSynVax has developed a vaccine to protect against SARS-CoV-2. DIOS-CoVax is needle-free vaccine
- [World Immunisation Week: “The Big Catch-Up" begins](https://vaccinenation.org/global-health/world-immunisation-week-the-big-catch-up-begins/): As World Immunisation week (24-30 April) begins, we are exploring some of the WHO’s goals for the coming year. Under the “banner” of “The Big Catch-Up"
- [UKHSA concern over drop in adolescent vaccine uptake](https://vaccinenation.org/global-health/ukhsa-concern-over-drop-in-adolescent-vaccine-uptake/): UKHSA issued a press release and blog, coinciding with the start of World Immunisation Week, which suggested that teenage vaccine uptake “has fallen”
- [Community engagement comes first for WHO expert](https://vaccinenation.org/infection/community-engagement-comes-first-for-who-expert/): After an update from WHO in March 2023 on the Marburg virus situation in Equatorial Guinea and Tanzania, Gavi shares an interview with WHO’s Anaïs Legand
- [Gut instinct: microbial parameters and immune variations](https://vaccinenation.org/global-health/gut-instinct-microbial-parameters-and-immune-variations/): A study published in Nature communications biology identifies “several factors associated with COVID-19 vaccine-induced adaptive immune responses”.
- [UNICEF’s ‘state of the world’ immunisation warning](https://vaccinenation.org/global-health/unicefs-state-of-the-world-immunisation-warning/): In April 2023 UNICEF published its The State of the World’s Children report with a focus on the global vaccination situation for children.
- [mRNA Technology Transfer Programme progresses](https://vaccinenation.org/technology/mrna-technology-transfer-programme-progresses/): In April 2023 the participants of the mRNA Technology Transfer Programme met for their first face-to-face meeting in Cape Town.
- [Allergy Therapeutics continues with peanut allergy study](https://vaccinenation.org/therapeutic/allergy-therapeutics-continues-with-peanut-allergy-study/): Allergy Therapeutics announced that patients with peanut allergies had “successfully” taken the “innovative short-course peanut allergy vaccine candidate”
- [PharmaJet announces expansion and extension with DTRA](https://vaccinenation.org/technology/pharmajet-announces-expansion-and-extension-with-dtra/): In April 2023 PharmaJet announced that it had received a “scope expansion” and “3-year extension” of a multi-year agreement with the DTRA.
- [Better pandemic preparedness: WHO launches PRET](https://vaccinenation.org/global-health/better-pandemic-preparedness-who-launches-pret/): WHO announced in 2023 that it was launching a new initiative to equip countries with the “systems and capacities” to accelerate emerging threat management
- [MinervaX starts Phase I GBS trial in older adults](https://vaccinenation.org/technology/minervax-starts-phase-i-gbs-trial-in-older-adults/): MinervaX announced in April 2023 that it is beginning a Phase I clinical study of its novel Group B Streptococcus (GBS) vaccine in older adults
- [The Vaccination Trust Indicator (VTI) in validation study](https://vaccinenation.org/global-health/the-vaccination-trust-indicator-vti-in-validation-study/): A study in PLOS Global Public Health in April 2023 presents a validation of the Vaccination Trust Indicator (VTI) with data from two surveys across 15 countries
- [ChAdOx1 vaccine for Rift Valley fever shows promise in trial](https://vaccinenation.org/infection/chadox1-vaccine-for-rift-valley-fever-shows-promise-in-trial/): In a paper published in The Lancet Infectious Diseases, researchers detailed the results of a trial for a ChAdOx1 vaccine against Rift Valley fever
- [EPSRC invests £12m in Future Vaccines Manufacturing Hub](https://vaccinenation.org/technology/epsrc-invests-12m-in-future-vaccines-manufacturing-hub/): The Engineering and Physical Sciences Research Council (EPSRC) announced a £12 million investment to fund the Future Vaccines Manufacturing Hub until 2030
- [Ghana approves “world-changer” malaria vaccine for children](https://vaccinenation.org/infection/ghana-approves-world-changer-malaria-vaccine-for-children/): In April 2023 it was reported that Ghana is the first country to approve a new malaria vaccine, described by its developers as a “world-changer”
- [UK researchers assesses TBEV risk to population as low](https://vaccinenation.org/infection/uk-researchers-assesses-tbev-risk-to-population-as-low/): UKHSA issued a press release explaining the risk assessment produced by HAIRS on the risk presented to the UK population by tick-borne encephalitis virus
- [“Time is of essence” in outbreaks says Dr Jane Ruth Aceng](https://vaccinenation.org/global-health/time-is-of-essence-in-outbreaks-says-dr-jane-ruth-aceng/): In an interview between Africa CDC and the Minister for Health in the Republic of Uganda, Dr Aceng described the country’s approach to the recent outbreak
- [Moderna granted PRIME designation by EMA for therapy](https://vaccinenation.org/therapeutic/moderna-granted-prime-designation-by-ema-for-therapy/): Moderna announced in April 2023 that the mRNA-4157/V940 has been awarded Priority Medicines (PRIME) scheme designation by the EMA
- [GlobalData warning follows WHO COVID-19 vaccine update](https://vaccinenation.org/technology/globaldata-warning-follows-who-covid-19-vaccine-update/): After WHO revised vaccine guidance following a SAGE meeting, GlobalData issued a statement warning about the effects on the “future of COVID-19 vaccine rollouts
- [A better vaccine ecosystem: what does the future hold?](https://vaccinenation.org/global-health/a-better-vaccine-ecosystem-what-does-the-future-hold/): After experts called for “transformational change” to the “epidemic countermeasures ecosystem”, our interest has been drawn to The Vaccine Ecosystem Initiative.
- [Exclusive interview with Dr Fadil Bidmos](https://vaccinenation.org/technology/exclusive-interview-with-dr-fadil-bidmos/): As the countdown to the World Vaccine Congress in Washington continues with only days to go, we are excited to share another pre-event interview.
- [SAGE revises roadmap for COVID-19 vaccination use](https://vaccinenation.org/global-health/sage-revises-roadmap-for-covid-19-vaccination-use/): After a meeting in March 2023, WHO’s Strategic Advisory Group of Experts on Immunisation (SAGE) revised the roadmap for prioritising vaccines
- [Study explores COVID-19 vaccine fatigue determinants](https://vaccinenation.org/global-health/study-explores-covid-19-vaccine-fatigue-determinants/): A study published in Nature Medicine in March explores the factors associated with so-called “vaccine fatigue”, with a specific focus on the recent campaigns
- [Quadripartite calls for One Health action for “safer world”](https://vaccinenation.org/global-health/quadripartite-calls-for-one-health-action-for-safer-world/): In March 2023 the heads of the Quadripartite organisations working on One Health issued a call for greater global action for a safer world.
- [CDC warns of "alarming” threat from Candida auris](https://vaccinenation.org/infection/cdc-warns-of-alarming-threat-from-candida-auris/): In March 2023 the CDC commented on data that revealed an “alarming” spread of the emerging fungus Candida auris in healthcare facilities
- [COVID-19 vaccine not linked to menstruation changes in study](https://vaccinenation.org/global-health/covid-19-vaccine-not-linked-to-menstruation-changes-in-study/): A study released in iScience suggests that COVID-19 infection was a greater factor than COVID-19 vaccination in observed changes to a patient’s menstrual cycle.
- [WHO offers update on Marburg cases in Equatorial Guinea](https://vaccinenation.org/infection/who-offers-update-on-marburg-cases-in-equatorial-guinea/): Just under a month after the confirmation of an outbreak of Marburg virus disease (MVD) in Equatorial Guinea, WHO has issued an update confirming further cases
- [The politics of pandemics: WHO questions data secrecy](https://vaccinenation.org/global-health/the-politics-of-pandemics-who-questions-data-secrecy/): After we reported in March 2023 that possibly critical data concerning the Huanan Seafood Wholesale Market had been quietly released on GISAID,
- [Universal oral COVID-19 vaccine protects hamsters in study](https://vaccinenation.org/technology/universal-oral-covid-19-vaccine-protects-hamsters-in-study/): A study in Microbiology Spectrum in March 2023 demonstrated the benefits of an oral vaccine for COVID-19 that could “dramatically improve immunisation rates”.
- [Marking World TB Day 2023: “Yes! We can end TB!”](https://vaccinenation.org/infection/marking-world-tb-day-2023-yes-we-can-end-tb/): On Friday 24th March 2023 the WHO and other organisations and individuals observe ‘World Tuberculosis Day’ with the theme “Yes! We can end TB!”.
- [Vaccine equity as good as it sounds, study suggests](https://vaccinenation.org/global-health/vaccine-equity-as-good-as-it-sounds-study-suggests/): In a study published in Nature Communications, researchers investigate the socioeconomic benefits of a set of “idealised” vaccine distribution scenarios
- [China accepts first mRNA vaccine for COVID-19 from CSPC](https://vaccinenation.org/technology/china-accepts-first-mrna-vaccine-for-covid-19-from-cspc/): In March 2023 the board of directors at CSPC Pharmaceutical Group Limited announced that the company’s COVID-19 mRNA vaccine has been included
- [Africa CDC confirms outbreak of Marburg virus in Tanzania](https://vaccinenation.org/infection/africa-cdc-confirms-outbreak-of-marburg-virus-in-tanzania/): Africa CDC has confirmed that the Ministry of Health of the Republic of Tanzania declared an outbreak of Marburg virus disease (MVD) on 21st March 2023
- [Vaxxinity starts trial of LDL cholesterol vaccine candidate](https://vaccinenation.org/technology/vaxxinity-starts-trial-of-ldl-cholesterol-vaccine-candidate/): Vaxxinity announced that the first subjects of a Phase I trial had been dosed. The trial of VXX-401 will evaluate the safety, tolerability, and immunogenicity
- [Vaccitech announces “promising” data for HPV vaccine](https://vaccinenation.org/therapeutic/vaccitech-announces-promising-data-for-hpv-vaccine/): In March 2023, Vaccitech announced top-line interim data from a Phase Ib/II clinical trial of its VTP-200 vaccine in women with low-grade cervical HPV lesions
- [SpyBiotech granted funding for SpyVector platform project](https://vaccinenation.org/technology/spybiotech-granted-funding-for-spyvector-platform-project/): SpyBiotech, a biotechnology company spin out from the University of Oxford, announced in March 2023 that it had received a grant of $4,094,561
- [Exclusive interview with Dr Niranjan Sardesai](https://vaccinenation.org/therapeutic/exclusive-interview-with-dr-niranjan-sardesai/): With just weeks to go until the World Vaccine Congress in Washington, we are delighted to share our series of exclusive interviews with some fantastic speakers
- [RVAC and Penn collaborate on possible mRNA therapies](https://vaccinenation.org/therapeutic/rvac-and-penn-collaborate-on-possible-mrna-therapies/): In March 2023, RVAC Medicines and the University of Pennsylvania (Penn) announced a collaboration to pursue the development of mRNA vaccines
- [WHO weighs in on new SARS-CoV-2 data from China](https://vaccinenation.org/infection/who-weighs-in-on-new-sars-cov-2-data-from-china/): In March 2023 new metagenomics data and SARS-CoV-2 sequences appeared on GISAID and were available to researchers across the world for a short period of time.
- [Vaccine-derived polio: Burundi and DRC start investigations](https://vaccinenation.org/infection/vaccine-derived-polio-burundi-and-drc-start-investigations/): The Global Polio Eradication Initiative (GPEI) and WHO Africa confirmed that cases of circulating vaccine-derived poliovirus type 2
- [A GBS vaccine could save lives and money, say researchers](https://vaccinenation.org/global-health/a-gbs-vaccine-could-save-lives-and-money-say-researchers/): A study published in PLOS Medicine in March 2023 suggests that the human and financial benefits of a Group B Streptococcus (GBS) vaccine would be significant
- [Uganda’s plan to vaccinate children against yellow fever](https://vaccinenation.org/infection/ugandas-plan-to-vaccinate-children-against-yellow-fever/): In March 2023 WHO Africa reported that the Ugandan Ministry of Health is planning to vaccinate over 1.9 million children against yellow fever
- [LG Chem wins bid to supply essential vaccines for children](https://vaccinenation.org/global-health/lg-chem-wins-bid-to-supply-essential-vaccines-for-children/): South Korean chemical company LG Chem announced in March 2023 that it will supply essential vaccines for infants and young children
- [GSK’s 5-in-1 Meningococcal vaccine shows promise in trial](https://vaccinenation.org/technology/gsks-5-in-1-meningococcal-vaccine-shows-promise-in-trial/): In March 2023 GSK announced positive headline results from a Phase III trial evaluating its MenABCWY combination vaccine candidate.
- [Experts call for change in the epidemic ecosystem](https://vaccinenation.org/global-health/experts-call-for-change-in-the-epidemic-ecosystem/): Writing in The Lancet in March 2023, public health experts called for “ambitious, transformational change” to the “epidemic countermeasures ecosystem”.
- [Exclusive interview with Dr Ike James](https://vaccinenation.org/technology/exclusive-interview-with-dr-ike-james/): With just weeks to go until the World Vaccine Congress in Washington this April, we are delighted to continue sharing interviews from our exclusive series.
- [Thermostable tuberculosis vaccine meets Phase I goals](https://vaccinenation.org/technology/thermostable-tuberculosis-vaccine-meets-phase-i-goals/): Tuberculosis is one of the leading infectious causes of morbidity and mortality across the world. In 2020 it killed 1.5 million people
- [Study suggests sleep key to successful vaccine responses](https://vaccinenation.org/global-health/study-suggests-sleep-key-to-successful-vaccine-responses/): A study published in Current Biology suggests that getting sufficient sleep in the days surrounding vaccination is key to optimising antibody responses.
- [VIE awards 2023: the final shortlist announced!](https://vaccinenation.org/technology/vie-awards-2023-the-final-shortlist-announced/): We are pleased to share the organisations and individuals who have progressed to the final shortlist for the VIE Awards at the World Vaccine Congress
- [Researchers in Israel develop mRNA vaccine against bacteria](https://vaccinenation.org/infection/researchers-in-israel-develop-mrna-vaccine-against-bacteria/): Researchers at Tel Aviv University and the Israel Institute for Biological Research announced that they have developed an mRNA-based vaccine
- [Will cell-free processes accelerate vaccine development?](https://vaccinenation.org/technology/will-cell-free-processes-accelerate-vaccine-development/): Carrie Arnold explores cell-free processes and a “growing number of biomanufacturing firms” that are “embracing” a cell-free biosynthesis strategy.
- [Lassa vaccine in monkeys: protection not therapy](https://vaccinenation.org/therapeutic/lassa-vaccine-in-monkeys-protection-not-therapy/): Researchers in France published a paper in Nature Communications in March detailing the results of an investigation into their Lassa fever vaccine candidate.
- [Exclusive interview with Dr Yongjun Sui](https://vaccinenation.org/technology/exclusive-interview-with-dr-yongjun-sui/): As we continue our countdown to the World Vaccine Congress in Washington we are delighted to share conversations with our fascinating speakers
- [GSK “delighted” by VRBPAC vote on RSV candidate](https://vaccinenation.org/technology/gsk-delighted-by-vrbpac-vote-on-rsv-candidate/): Just after Pfizer announced that the Vaccines and Related Biological Products Advisory Committee had voted on its RSV vaccine, GSK announced the results
- [Pfizer “encouraged” by VRBPAC vote on RSV candidate](https://vaccinenation.org/technology/pfizer-encouraged-by-fda-vote-on-rsv-candidate/): In 2023, a few days after the FDA requested further studies into the link between GBS and its RSV vaccine candidate, Pfizer announced that the FDA had voted
- [Exclusive interview with Dr Mark Feinberg](https://vaccinenation.org/global-health/exclusive-interview-with-dr-mark-feinberg/): With just two months until the World Vaccine Congress we are delighted that some of our wonderful speakers are keen to take part in exclusive interviews
- [WHO issues update on avian flu in Cambodia](https://vaccinenation.org/infection/who-issues-update-on-avian-flu-in-cambodia/): After the news of the death of a child from avian influenza A (H5N1) in Cambodia in February 2023, the WHO has published an update on the situation
- [Ghana confirms two cases of Lassa fever in Accra](https://vaccinenation.org/infection/ghana-confirms-two-cases-of-lassa-fever-in-accra/): Just months after the conclusion of an outbreak of Marburg, the Ghana Health Service has issued a statement to confirm two cases of Lassa fever
- [WHO issues update on Marburg in Equatorial Guinea](https://vaccinenation.org/infection/who-issues-update-on-marburg-in-equatorial-guinea/): Following the announcement of an outbreak of Marburg virus in Equatorial Guinea in February 2023, WHO has issued a situation update
- [FDA requests research into Pfizer’s RSV GBS risk](https://vaccinenation.org/technology/fda-requests-research-into-pfizers-rsv-gbs-risk/): Following the FDA’s acceptance for review for Pfizer’s respiratory syncytial virus (RSV) vaccine candidate, the agency has asked for further studies
- [Queensland’s quest for an Australian cattle vaccine](https://vaccinenation.org/global-health/queenslands-quest-for-an-australian-cattle-vaccine/): Researchers at the University of Queensland are pursuing an experimental vaccine to tackle a venereal disease that “causes cattle infertility and costs
- [Maternal vaccination information in New Zealand](https://vaccinenation.org/global-health/maternal-vaccination-information-in-new-zealand/): A study in Midwifery in February 2023 examines the quality of maternal vaccination information available in pregnancy to patients in Aotearoa/New Zealand.
- [Concern after avian influenza kills child in Cambodia](https://vaccinenation.org/infection/concern-after-avian-influenza-kills-child-in-cambodia/): With growing concern at the increasing cases of avian influenza in mammals across the world, the spread has caused the death of an 11-year-old girl in Prey Veng
- [The Measles and Rubella Initiative enters “new era”](https://vaccinenation.org/infection/the-measles-and-rubella-initiative-enters-new-era/): After an update from WHO in November 2022 that almost 40 million children are “dangerously susceptible” to measles, the Measles and Rubella Initiative (M&RI)
- [LinKinVax welcomes HIV candidate Phase I results](https://vaccinenation.org/technology/linkinvax-welcomes-hiv-candidate-phase-i-results/): In February 2023 LinKinVax announced positive interim results from the ANRS VRI06 Phase I trial, evaluating a preventative HIV vaccine.
- [Moderna and Merck granted BTD for cancer therapy](https://vaccinenation.org/therapeutic/moderna-and-merck-granted-btd-for-cancer-therapy/): Following positive results from a Phase IIb trial in December 2022, Moderna and Merck have announced that their personalised mRNA cancer vaccine, in combination
- [When pigs fly – or vaccinate themselves against Salmonella](https://vaccinenation.org/technology/when-pigs-fly-or-vaccinate-themselves-against-salmonella/): The complex process of vaccinating pigs is time consuming and requires direct interaction between humans and animals, or so we thought.
- [Funding Australian efforts for mRNA Strep A vaccine](https://vaccinenation.org/technology/funding-australian-efforts-for-mrna-strep-a-vaccine/): The University of Queensland, Australia, announced in February 2023 that a university-led research effort had secured almost $8 million in philanthropic funding
- [Synthetic squalene: a sustainable alternative to shark?](https://vaccinenation.org/technology/synthetic-squalene-a-sustainable-alternative-to-shark/): An article in npj vaccine in February 2023 explores the role of squalene in vaccine development and how a synthetic alternative, squalane, opens new doors
- [African leaders unite on routine immunisation goals](https://vaccinenation.org/global-health/african-leaders-unite-on-routine-immunisation-goals/): In February 2023, at a meeting of the African Union in Addis Ababa, African Heads of State agreed on the need to “revamp routine immunisation”
- [World Vaccine Congress Washington: meet our start-ups!](https://vaccinenation.org/technology/world-vaccine-congress-washington-meet-our-start-ups-7/): As we get closer to the World Vaccine Congress in Washington our introductions to the start-up zone continue! We are pleased to present
- [Montenegro’s “Health Caravan” promotes immunisation](https://vaccinenation.org/global-health/montenegros-health-caravan-promotes-immunisation/): In February 2023 WHO announced a collaboration with Montenegro’s Ministry of Health and Institute of Public Health (IPH) to launch the “Health Caravan”.
- [BactiVac secures £1 million in Wellcome funding](https://vaccinenation.org/infection/bactivac-secures-1-million-in-wellcome-funding/): BactiVac, the Bacterial Vaccines Network, announced it had secured £1 million in funding from Wellcome to “accelerate the development of bacterial vaccines”
- [Scancell announces “encouraging” early Modi-1 data](https://vaccinenation.org/therapeutic/scancell-announces-encouraging-early-modi-1-data/): In February 2023 Scancell announced completion of a monotherapy dose finding arm of the Phase I/II ModiFY clinical trial.
- [Dr Jean Kaseya appointed Director General of Africa CDC](https://vaccinenation.org/global-health/dr-jean-kaseya-appointed-director-general-of-africa-cdc/): Dr Jean Kaseya was announced the new Director General of Africa CDC at the African Union summit in February 2023. He was approved by African heads of state
- [French study explores vaccination and housing situation](https://vaccinenation.org/global-health/french-study-explores-vaccination-and-housing-situation/): A paper published in February 2023 examines the results of a study investigating how a person’s housing situation might factor into their vaccination status.
- [Pfizer and Valneva issue update on Lyme vaccine trial](https://vaccinenation.org/technology/pfizer-and-valneva-issue-update-on-lyme-vaccine-trial/): Pfizer, study sponsor of the VALOR Phase III clinical study, has decided to “discontinue a significant percentage of participants in the US”
- [US researchers develop platform for viral pathogens](https://vaccinenation.org/technology/us-researchers-develop-platform-for-viral-pathogens/): Harvard T.H. Chan School of Public Health announced a new and “highly adaptable” vaccine platform with potential applications against viral pathogens.
- [Exclusive interview with the US BIOLOGIC team](https://vaccinenation.org/global-health/exclusive-interview-with-the-us-biologic-team/): Next up in our series of interviews in preparation for the Congress are our speakers from US BIOLOGIC: Dr Jolieke van Oosterwijk and Chris Przybyszewski.
- [Moderna announces “mixed” interim flu results](https://vaccinenation.org/technology/moderna-announces-mixed-interim-flu-results/): In February 2023 Moderna announced interim results from its Phase III safety and immunogenicity trial of mRNA-1010 (P301).
- [CEPI supports Sudan ebolavirus antibody standard](https://vaccinenation.org/technology/cepi-supports-sudan-ebolavirus-antibody-standard/): CEPI announced that it was supporting development of an international antibody standard against Sudan ebolavirus (SUDV) following the recent outbreak in Uganda
- [Mpox: still a PHEIC, says IHR Emergency Committee](https://vaccinenation.org/infection/mpox-still-a-pheic-says-ihr-emergency-committee/): During a meeting of the IHR Emergency Committee in February 2023 on the mpox outbreak, the current infection rates and containment measures
- [Gritstone bio and NCI collaborate on clinical trial](https://vaccinenation.org/therapeutic/gritstone-bio-and-nci-collaborate-on-clinical-trial/): Gritstone bio and NCI announce a collaboration to evaluate an “autologous T cell therapy expressing a T cell receptor targeting mutated KRAS in combination
- [VBI Vaccines announces Phase II data for HBV therapy](https://vaccinenation.org/therapeutic/vbi-vaccines-announces-phase-ii-data-for-hbv-therapy/): In February 2023 VBI Vaccines announced interim data evaluating a combination treatment of VBI-2601 and BRII-835 in chronically infected HBV patients
- [WHO responds to Nature “error in reporting” article](https://vaccinenation.org/infection/who-responds-to-nature-error-in-reporting-article/): After it was suggested that WHO had abandoned plans to continue the investigation into the origins of COVID-19, senior members of the organisation responded
- [One Health approaches: the agricultural perspective](https://vaccinenation.org/global-health/one-health-approaches-the-agricultural-perspective/): In our discussions at the World Vaccine Congress and in published posts we continue to explore the meaning and applications of the concept of One Health.
- [Nature: WHO investigation into pandemic origin dropped](https://vaccinenation.org/infection/who-investigation-into-pandemic-origin-dropped/): WHO has “quietly shelved the second phase” of the “much-anticipated scientific investigation” into the origins of the COVID-19 pandemic.
- [Bavarian Nordic announces Emergent travel vaccine agreement](https://vaccinenation.org/technology/bavarian-nordic-announces-emergent-travel-vaccine-agreement/): In February 2023 Bavarian Nordic announced that it has entered into an agreement with Emergent BioSolutions to acquire to marketed travel vaccines.
- [World Vaccine Congress Washington: meet our start-ups!](https://vaccinenation.org/technology/world-vaccine-congress-washington-meet-our-start-ups-6/): With just 7 weeks until the World Vaccine Congress in Washington in April we are still announcing the amazing start-ups registered so far.
- [Vaxart announces start of Phase II norovirus trial](https://vaccinenation.org/technology/vaxart-announces-start-of-phase-ii-norovirus-trial/): In February 2023 Vaxart announced that it had dosed its first subject in the Phase II clinical trial of an oral tablet bivalent norovirus candidate.
- [US and Novavax announce modified COVID-19 agreement](https://vaccinenation.org/technology/us-and-novavax-announce-modified-covid-19-agreement/): In February 2023 Novavax and the US Department of Health and Human Services (HHS) announced a modification to their existing agreement,
- [Equatorial Guinea confirms outbreak of Marburg virus](https://vaccinenation.org/infection/equatorial-guinea-confirms-outbreak-of-marburg-virus/): In February 2023, WHO Africa confirmed that Equatorial Guinea had announced an outbreak of Marburg virus disease following the deaths of at least nine people.
- [Gavi appoints Dr Muhammad Ali Pate as CEO](https://vaccinenation.org/global-health/gavi-appoints-dr-muhammad-ali-pate-as-ceo/): In February 2023 Gavi announced the conclusion of a process that had begun in 2021: appointing a CEO to succeed Dr Seth Berkley. Dr Muhammad Ali Pate
- [Health inequity or vaccine hesitancy: understanding barriers](https://vaccinenation.org/global-health/health-inequity-or-vaccine-hesitancy-understanding-barriers/): A report in Nature Human Behaviour in February 2023 examines reporting oversights in examining the factors behind vaccine intentions and uptake.
- [New diagnostic test identifies virus types and strains](https://vaccinenation.org/technology/new-diagnostic-test-identifies-virus-types-and-strains/): Researchers from the University of Oxford announced in February 2023 that they had developed a new diagnostic test to replace current methods for detection.
- [SK bioscience launches R&PD Centre for global health](https://vaccinenation.org/technology/sk-bioscience-launches-rpd-centre-for-global-health/): In February 2023 SK bioscience announced its intention to establish the ‘Songdo Global Research & Process Development Centre (The R&PD Centre)’
- [Challenges and opportunities of VLP-based vaccines](https://vaccinenation.org/technology/challenges-and-opportunities-of-vlp-based-vaccines/): In a paper published in Frontiers in Immunology in February 2023, researchers review the challenges associated with the development of VLP-based vaccines.
- [Concern grows as avian flu affects more mammals](https://vaccinenation.org/infection/concern-grows-as-avian-flu-affects-more-mammals/): With reports of avian flu sweeping through other mammals across the world, concern is growing about the threat both to human and animal health from H5N1
- [Maternal Tdap vaccine reduces pertussis in infants](https://vaccinenation.org/infection/maternal-tdap-vaccine-reduces-pertussis-in-infants/): In findings published in Jama Pediatrics in February 2023 a CDC study revealed that the maternal Tdap vaccine decreases incidence of pertussis
- [Exclusive interview with Dr Francesca Micoli](https://vaccinenation.org/global-health/exclusive-interview-with-dr-francesca-micoli/): With just under 10 weeks to go until the World Vaccine Congress in Washington we are already getting prepared and meeting some of our amazing speakers.
- [UNEP report “Bracing for Superbugs”: AMR and One Health](https://vaccinenation.org/global-health/unep-report-bracing-for-superbugs-amr-and-one-health/): The United Nations Environment Programme released a report in 2023 that addresses the role of the environment in the development and distribution of AMR.
- [Gerresheimer and Corning partner on Velocity Vials](https://vaccinenation.org/technology/gerresheimer-and-corning-partner-on-velocity-vials/): Gerresheimer AG and Corning Incorporated announced in February 2023 that they were collaborating to “increase global access to the Velocity Vial technology”
- [Africa CDC hosts Biomanufacturing Workforce workshop](https://vaccinenation.org/global-health/africa-cdc-hosts-biomanufacturing-workforce-workshop/): Between 7th and 9th February 2023 30 partner organisations came together to participate in the first Biomanufacturing Workforce Development workshop.
- [UK MHRA grants Takeda authorisation for Dengue vaccine](https://vaccinenation.org/infection/uk-mhra-grants-takeda-authorisation-for-dengue-vaccine/): In February 2023 Takeda UK Ltd. announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) had granted marketing authorisation for Qdenga
- [World Vaccine Congress Washington: meet our start-ups!](https://vaccinenation.org/technology/world-vaccine-congress-washington-meet-our-start-ups-5/): As excitement builds for the World Vaccine Congress in Washington this April we are pleased to share a further update to our start-up zone:
- [mRNA sights shift to universal flu potential](https://vaccinenation.org/technology/mrna-sights-shift-to-universal-flu-potential/): Professor Deborah Fuller, writing for The Conversation in February 2023, states that “for everything there is a season, and for the flu, it’s wintertime”.
- [Pharma companies ride the economic wave of 2022](https://vaccinenation.org/technology/pharma-companies-ride-the-economic-wave-of-2022/): In research from GlobalData in December 2022, 13 of the top 20 pharmaceutical companies saw increases in market capitalisation.
- [The Pandemic Fund invites submissions for projects](https://vaccinenation.org/global-health/the-pandemic-fund-invites-submissions-for-projects/): In February 2023 the World Bank Pandemic Fund announced $300 million for a first round of funding to help “developing countries better prepare for pandemics”
- [UK announces progress on bovine TB vaccine and test](https://vaccinenation.org/global-health/uk-announces-progress-on-bovine-tb-vaccine-and-test/): In February 2023 the UK Animal and Plant Health Agency (APHA) announced that field trials for a cattle vaccine against bovine tuberculosis (bTB)
- [NIH researchers develop promising SUDV vaccine](https://vaccinenation.org/infection/nih-researchers-develop-promising-sudv-vaccine/): Research in The Lancet Microbe in February 2023 presents a positive update from an NIH group with their vaccine candidate against Sudan virus (SUDV)
- [IVAC runs vaccine hesitancy training course in India](https://vaccinenation.org/global-health/ivac-runs-vaccine-hesitancy-training-course-in-india/): In December 2022 the International Vaccine Access Centre was able to conduct a test run of its newly developed training course on vaccine hesitancy
- [Exclusive interview with Dr Ofer Levy last year](https://vaccinenation.org/technology/exclusive-interview-with-dr-ofer-levy-last-year/): As we continue preparations for the World Vaccine Congress in Washington this April we are delighted to share our final interview from the Congress in Europe
- [Bird flu affecting otters and foxes in the UK](https://vaccinenation.org/infection/bird-flu-affecting-otters-and-foxes-in-the-uk/): After reports of an outbreak of HPAI in minks from a farm in Spain, updates from the UK reveal that the virus has been detected in other mammals
- [CEPI to support 20Med mRNA vaccine technology](https://vaccinenation.org/technology/cepi-to-support-20med-mrna-vaccine-technology/): In February 2023 CEPI announced a partnership with 20Med to advance the development of 20Med’s bioresponsive polymeric nanoparticle technology.
- [African leaders vow to end AIDS in children by 2030](https://vaccinenation.org/infection/african-leaders-vow-to-end-aids-in-children-by-2030/): At the first ministerial meeting of the Global Alliance to end AIDS in children, leaders from African countries discussed commitments to ending AIDS in children
- [The 100 days mission: UKHSA assumes responsibility](https://vaccinenation.org/global-health/the-100-days-mission-ukhsa-assumes-responsibility/): Of the many lessons that we are endeavouring to learn from the COVID-19 pandemic, the importance of uniting speed with safety is one of the most obvious.
- [Cancer vaccines strengthened against aggressive tumours](https://vaccinenation.org/therapeutic/cancer-vaccines-strengthened-against-aggressive-tumours/): In research published in Nature biomedical engineering a team of scientists at Northwestern University’s IIN explored the effects of structural changes
- [World Vaccine Congress Washington: meet our start-ups!](https://vaccinenation.org/technology/world-vaccine-congress-washington-meet-our-start-ups-4/): Following our previous posts, moving through the start-up zone at the World Vaccine Congress in Washington at speed, we are excited to share a further update
- [Moderna secures FDA Breakthrough Therapy Designation for RSV](https://vaccinenation.org/infection/moderna-secures-fda-breakthrough-therapy-designation-for-rsv/): Moderna announced in January 2023 that its investigational mRNA vaccine candidate for RSV, mRNA-1345, has been granted Breakthrough Therapy Designation
- [White paper from IAVI: vaccine partnerships for EIDs](https://vaccinenation.org/global-health/white-paper-from-iavi-vaccine-partnerships-for-eids/): In January 2023 IAVI released a white paper after a meeting between global health experts. As a result of a convergence of several diseases in 2022
- [Marburg vaccine candidate shows in-human promise](https://vaccinenation.org/infection/marburg-vaccine-candidate-shows-in-human-promise/): A study in The Lancet with NIH funding reported that a vaccine candidate against Marburg virus (MARV) was safe and induced and immune response
- [WHO in January 2023: COVID-19 still a PHEIC](https://vaccinenation.org/infection/who-in-january-2023-covid-19-still-a-pheic/): The 14th meeting of the International Health Regulations (IHR) Emergency Committee regarding COVID-19 took place on Friday 27th January 2023.
- [World Neglected Tropical Diseases Day 2023: WHO’s report](https://vaccinenation.org/global-health/world-neglected-tropical-disease-day-2023-whos-report/): On 30th January 2023, WHO released a progress report on neglected tropical diseases (NTD) to coincide with World Neglected Tropical Disease Day
- [AC Immune Alzheimer’s vaccine shows promise in early trials](https://vaccinenation.org/therapeutic/ac-immune-alzheimers-vaccine-shows-promise-in-early-trials/): Swiss based AC Immune reported in January 2023 that ACI-24.060, its anti-amyloid-beta (Abeta) vaccine, had “elicited an anti-Abeta antibody response”
- [Vaccines: the missing piece in the dementia puzzle?](https://vaccinenation.org/global-health/vaccines-the-missing-piece-in-the-dementia-puzzle/): Dementia is described by the NHS as a syndrome associated with an “ongoing decline of brain functioning”. This may manifest in an impaired ability to remember,
- [COVID-19 vaccine strategies: the UK and US plan ahead](https://vaccinenation.org/infection/covid-19-vaccine-strategies-the-uk-and-us-plan-ahead/): Moving into another year of emergence from the COVID-19 pandemic, with vaccines continuing to be a core tool in this process, the UK and US are making moves
- [Sierra Leone receives CoVDP support worth $2.8 million](https://vaccinenation.org/technology/sierra-leone-receives-covdp-support-worth-2-8-million/): In January 2023 Gavi announced a delivery of vehicles and technological goods to the Government of Sierra Leone to support its COVID-19 vaccine deployment.
- [Conversations with AI: we spoke to ChatGPT about vaccines](https://vaccinenation.org/technology/conversations-with-ai-we-spoke-to-chatgpt-about-vaccines/): As exciting as the rush around ChatGPT is, many of us may be (understandably) concerned about the implications that artificial intelligence has for our futures
- [White paper from MMIP: UK Life Sciences Vision](https://vaccinenation.org/technology/white-paper-from-mmip-uk-life-sciences-vision/): The UK government established the Life Sciences Vision in July 2021 with the ambition of creating a competitive environment for Life Sciences
- [World Vaccine Congress Washington: meet our start-ups!](https://vaccinenation.org/technology/world-vaccine-congress-washington-meet-our-start-ups-3/): Following our previous post, in which we introduced the C-E of our start-up zone for the Congress in Washington, we are excited to share a further update
- [Vaccine Industry Excellence awards now open for voting!](https://vaccinenation.org/technology/vaccine-industry-excellence-awards-now-open-for-voting/): With just 10 weeks to go before the World Vaccine Congress in Washington, we are delighted to share the nominations for each category of the VIE awards
- [WHO launches 2023 funding appeal for $2.54 billion](https://vaccinenation.org/global-health/who-launches-2023-funding-appeal-for-2-54-billion/): In January 2023 the WHO launched its 2023 health emergency appeal to support millions of people around the world. The aim is to secure $2.54 billion
- [Cervical cancer awareness: UKHSA promotes HPV vaccine](https://vaccinenation.org/global-health/cervical-cancer-awareness-ukhsa-promotes-hpv-vaccine/): As Cervical Cancer Prevention Week starts on 23rd January 2023, the UKHSA report on routine adolescent HPV immunisation reveals a concerning decrease
- [Vaccines Europe pipeline review highlights key candidates](https://vaccinenation.org/global-health/vaccines-europe-pipeline-review-highlights-key-candidates/): In its first pipeline review of its 15 member companies, Vaccines Europe explores the 100 vaccine candidates in development as of July 2022.
- [Avian flu detected in farmed minks in Spain](https://vaccinenation.org/infection/avian-flu-detected-in-farmed-minks-in-spain/): A report by European researchers details an outbreak of highly pathogenic avian influenza detected in “intensively farmed minks in Europe”
- [LinKinVax and Gustave Roussy collaborate for human trial](https://vaccinenation.org/therapeutic/linkinvax-and-gustave-roussy-collaborate-for-human-trial/): In January 2023 LinKinVax and Gustave Roussy announced a collaboration towards a first-in-human Phase I/IIa clinical trial on a therapeutic vaccine candidate
- [Report shows increase in US pharmacy vaccine administration](https://vaccinenation.org/global-health/report-shows-increase-in-us-pharmacy-vaccine-administration/): A report from the Global Healthy Living Foundation (GHLF) and the IQVIA Institute revealed an increase in people receiving vaccines at pharmacies in the US
- [CEPI and IPD announce partnership for Global South](https://vaccinenation.org/global-health/cepi-and-ipd-announce-partnership-for-global-south/): In January 2023 CEPI and the Institut Pasteur de Dakar (IPD) announced a 10-year partnership to “advance equitable access to vaccines in Africa
- [INTERCOVID-2022 study: vaccination a pregnancy priority](https://vaccinenation.org/global-health/intercovid-2022-study-vaccination-a-pregnancy-priority/): In January 2023 results in The Lancet from a network led by the Oxford Maternal and Perinatal Health Institute (OMPHI) emphasised the importance of vaccination
- [Janssen’s HIV vaccine hopes dashed in Phase III study](https://vaccinenation.org/infection/janssens-hiv-vaccine-hopes-dashed-in-phase-iii-study/): In January 2023 Janssen and global partners announced the results of an “independent, scheduled data review” of a Phase III Mosaico study
- [Moderna meets RSV endpoints for older adults](https://vaccinenation.org/infection/moderna-meets-rsv-endpoints-for-older-adults/): Just months after the announcement that Pfizer, and later GSK, had strong results in trials for RSV vaccines, Moderna released a statement in January 2023
- [GSK announces positive results for RSV candidate](https://vaccinenation.org/technology/gsk-announces-positive-results-for-rsv-candidate/): In a press release on 13th October 2022 GSK plc announced “positive pivotal phase III trial results” for a vaccine candidate against RSV.
- [WHO to establish TB Vaccine Accelerator Council](https://vaccinenation.org/infection/who-to-establish-tb-vaccine-accelerator-council/): At a WEF panel on TB in January 2023, WHO Director-General Dr Tedros Adhanom Ghebreyesus announced intentions to establish a TB Vaccine Accelerator Council.
- [CEPI to provide $4.3m for Vaxxas’ HD-MAP technology](https://vaccinenation.org/technology/cepi-to-provide-4-3m-for-vaxxas-hd-map-technology/): In January 2023 CEPI announced that it would provide up to $4.3 million (AUD6.4 million) to Vaxxas, to advance development of its high-density microarray patch
- [EnsiliTech raises £1.2m for fridge-free vaccines](https://vaccinenation.org/technology/ensilitech-raises-1-2m-for-fridge-free-vaccines/): EnsiliTech, a British-based biopharmaceutical company, announced in January 2023 that it had raised £1.2 million in pre-seed funding
- [Intravacc: positive pre-clinical data for gonorrhoea vaccine](https://vaccinenation.org/infection/intravacc-positive-pre-clinical-data-for-gonorrhoea-vaccine/): In January 2023 Intravacc announced that the intranasal gonorrhoea candidate vaccine it is developing in partnership with Therapyx inc.
- [CDC identifies stroke signal but satisfied vaccine is safe](https://vaccinenation.org/technology/cdc-identifies-stroke-signal-but-satisfied-vaccine-is-safe/): In a statement published in January 2023 the US CDC and FDA indicated that CDC’s VSD “met the statistical criteria” to investigate a safety concern
- [Dr Kim’s pandemic warning identifies 4 gaps](https://vaccinenation.org/global-health/dr-kims-pandemic-warning-identifies-4-gaps/): Writing for STAT in January 2023 Dr Jerome Kim warned that the world was not learning from pandemic experience. He identified 4 key areas of concern
- [Study shows vaccine effective against COVID-19 brain damage](https://vaccinenation.org/infection/study-shows-vaccine-effective-against-covid-19-brain-damage/): A study in Nature Neuroscience explores the role of COVID-19 infection on the brain and demonstrates that the MVA-CoV2-S vaccine candidate has potential
- [Uganda declares end of Ebola outbreak after four months](https://vaccinenation.org/infection/uganda-declares-end-of-ebola-outbreak-after-four-months/): Just four months after the declaration of an outbreak of the Sudan strain of Ebola in Uganda the Ministry of Health and WHO have confirmed that it is over.
- [Wellcome Sanger Institute launches virus initiative](https://vaccinenation.org/infection/wellcome-sanger-institute-launches-virus-initiative/): The Wellcome Sanger Institute in Cambridge, UK, announced a new initiative in January 2023 to improve our understanding of respiratory viruses.
- [White paper from ICON: fortifying for the future](https://vaccinenation.org/infection/white-paper-from-icon-fortifying-for-the-future/): In a white paper from ICON in January 2023 the importance of preparing strong vaccines for future infectious diseases is explored
- [World Vaccine Congress Washington: meet our start-ups!](https://vaccinenation.org/technology/world-vaccine-congress-washington-meet-our-start-ups-2/): With the success of our previous post introducing the A-B of our Washington start-up zone we are delighted to bring you the C-E with a few more companies
- [CanSinoBIO announces positive progress with mRNA vaccine](https://vaccinenation.org/global-health/cansinobio-announces-positive-progress-with-mrna-vaccine/): As China continues to extract itself from its former COVID-19 policies CanSino Biologics announced in January that it had seen “encouraging clinical progress
- [Nature study: accurate information influences intentions](https://vaccinenation.org/global-health/nature-study-accurate-information-influences-intentions/): In an article published in Nature Communications in January 2023, researchers from the US explored the importance of accurate information sharing
- [UN report: childhood loss of early life in 2021](https://vaccinenation.org/global-health/un-report-childhood-loss-of-early-life-in-2021/): The UN IGME released estimates in January 2023 that revealed that approximately 5 million children died before their fifth birthday in 2021
- [IVI and Batavia sign MoU on vaccine research and development](https://vaccinenation.org/technology/ivi-and-batavia-sign-mou-on-vaccine-research-and-development/): In January 2023 the International Vaccine Institute (IVI) and Batavia Biosciences signed a Memorandum of Understanding to “promote cooperation
- [World Vaccine Congress Washington: meet our start-ups!](https://vaccinenation.org/technology/world-vaccine-congress-washington-meet-our-start-ups/): With just a few months to go before the Congress in Washington our start-up zone is already filling up quickly! We are delighted to share a quick preview
- [UK and BioNTech sign MoU for mRNA cancer therapies](https://vaccinenation.org/therapeutic/uk-and-biontech-sign-mou-for-mrna-cancer-therapies/): In January 2023 BioNTech announced that it had signed a Memorandum of Understanding (MoU) with the UK government to “benefit patients”.
- [Vaccine Industry Excellence awards now open for nominations!](https://vaccinenation.org/technology/vaccine-industry-excellence-awards-now-open-for-nominations/): As we count down until the World Vaccine Congress in Washington in April, we are looking forward to hosting the VIE awards on the evening of the 4th April
- [Dual-action vaccine turns cancer on itself](https://vaccinenation.org/therapeutic/dual-action-vaccine-turns-cancer-on-itself/): In findings from Brigham and Women’s Hospital published in Science Translational Medicine, researchers reveal newly discovered potential to exploit cancer cells
- [Bee vaccine granted conditional license by USDA](https://vaccinenation.org/global-health/bee-vaccine-granted-conditional-license-by-usda/): In January 2023 Dalan Animal Health announced that the USDA had granted a conditional license for vaccination of honeybees against American Foulbrood disease
- [Exclusive interview with Professor Miles Carroll](https://vaccinenation.org/infection/exclusive-interview-with-professor-miles-carroll/): Here at VaccineNation we are delighted to kickstart the new year with another one of our recorded interviews from the World Vaccine Congress in Europe.
- [Cancer vaccine potential in 2023: mRNA moves forward](https://vaccinenation.org/therapeutic/cancer-vaccine-potential-in-2023-mrna-moves-forward/): Towards the end of 2022 we noted the positive results of a Moderna/Merck trial for a personalised cancer vaccine in combination with KEYTRUDA therapy.
- [EU collaboration for China’s COVID-19 concerns](https://vaccinenation.org/global-health/eu-collaboration-for-chinas-covid-19-concerns/): As COVID-19 continues to circulate across much of the world, China is feeling the effects of an insecure vaccination strategy into 2023.
- [Vaccines arrive in Haiti as cholera cases continue](https://vaccinenation.org/infection/vaccines-arrive-in-haiti-as-cholera-cases-continue/): Amid a surge of cholera cases in Haiti the Pan-American Health Organization (PAHO) reported in December 2022 that 1.17 million doses of vaccines had arrived
- [The future of COVAX: what did we learn from COVID-19?](https://vaccinenation.org/global-health/the-future-of-covax-what-did-we-learn-from-covid-19/): In an article in Science in December 2022 the fate of COVAX, the “vaccines pillar” of the Access to COVID-19 Tools (ACT) Accelerator, was discussed
- [Bergstrom’s rules for combating medical misinformation](https://vaccinenation.org/global-health/bergstroms-rules-for-combating-medical-misinformation/): In an article published in Nature Medicine in December, Professor Bergstrom highlights the responsibility of authors to “provide clear and accurate information
- [Global vaccine strategies still failing says Berkley](https://vaccinenation.org/global-health/global-vaccine-strategies-still-failing-says-berkley/): In an article in Nature in December 2022 Dr Seth Berkley, CEO of Gavi, explored the failings of global vaccine strategies as we continue to emerge from COVID-19
- [World Cup worries: whispers of MERS mar the fun](https://vaccinenation.org/infection/world-cup-worries-whispers-of-mers-mar-the-fun/): The FIFA World Cup in 2022 has had its fair share of controversy, but as the competition continues anyway, fresh fears are coming to light.
- [Moderna and Merck meet mRNA melanoma efficacy endpoints](https://vaccinenation.org/therapeutic/moderna-and-merck-meet-mrna-cancer-efficacy-endpoints/): In December 2022 Moderna and Merck announced positive results from a Phase IIb trial of mRNA-4157/v940, an investigational personalised cancer vaccine,
- [Aspen, CEPI, and Gates commit to African vaccines](https://vaccinenation.org/global-health/aspen-cepi-and-gates-commit-to-african-vaccines/): In an announcement on 12 December 2022, Aspen revealed that it would receive $30 million from the Gates Foundation and CEPI
- [Group A strep continues to cause concern in England](https://vaccinenation.org/infection/group-a-strep-continues-to-cause-concern-in-england/): With the tragic news of the deaths of 15 children in England from strep A infection, researchers are under pressure to explain the increase in cases.
- [Ebola vaccine candidates arrive in Uganda for trials](https://vaccinenation.org/infection/ebola-vaccine-candidates-arrive-in-uganda-for-trials/): Just days after reports that the final case of Ebola had been declared in Uganda, casting doubt on the future of vaccine trials against the virus
- [Study shows circadian rhythms influence immune responses](https://vaccinenation.org/technology/study-shows-circadian-rhythms-influence-immune-responses/): Research published in Nature Communications in December 2022 suggests that vaccination at different stages of a mouse’s circadian rhythm has different effects
- [Ebola: cases decrease before vaccine trials begin](https://vaccinenation.org/infection/ebola-cases-decrease-before-vaccine-trials-begin/): As positive news from Uganda emerges that no new cases of Ebola have been identified concerns about the future of anticipated vaccine trials in the region.
- [Merck finds frozen Ebola vaccines to test in Uganda spread](https://vaccinenation.org/infection/merck-finds-frozen-ebola-vaccines-to-test-in-uganda-spread/): As Uganda’s Ebola outbreak continues to claim lives the need for a vaccine grows greater. The outbreak was announced in September 2022,
- [Maternal Zika vaccines urgently needed says Gavi](https://vaccinenation.org/infection/maternal-zika-vaccines-urgently-needed-says-gavi/): In recent research approximately one third of children who were exposed to Zika virus before birth “developed neurological impairments or microcephaly
- [China's vaccination challenges: targeting the elderly](https://vaccinenation.org/global-health/chinas-vaccination-challenges-targeting-the-elderly/): Amidst widely reported protests and unrest at the continuation of a stringent zero-COVID strategy, China has admitted that it has struggled to vaccinate
- [Valneva reports positive persistence data for chikungunya](https://vaccinenation.org/infection/valneva-reports-positive-persistence-data-for-chikungunya/): Valneva published a report in December 2022 that detailed positive antibody persistence data a year after vaccination with a single dose of its vaccine
- [Lassa success from The Vaccine Group and DARPA](https://vaccinenation.org/technology/lassa-success-from-the-vaccine-group-and-darpa/): In December 2022 The Vaccine Group (TVG) reported that a DARPA funded project against Lassa fever had been successfully completed.
- [COVID-19 vaccine for infants: antibodies persist a year on](https://vaccinenation.org/infection/covid-19-vaccine-for-infants-antibodies-persist-in-toddlers/): During the COVID-19 pandemic immunisation of infants has been a highly contentious and confusing issue. From initial advice
- [Pfizer/Valneva Lyme disease vaccine persists 6 months on](https://vaccinenation.org/infection/pfizer-valneva-lyme-disease-vaccine-persists-6-months-on/): On 1st December 2022 Pfizer and Valneva reported antibody persistence data 6 months after vaccination with their Lyme disease vaccine candidate, VLA15.
- [Africa CDC gets mpox vaccine donation from Republic of Korea](https://vaccinenation.org/infection/africa-cdc-gets-mpox-vaccine-donation-from-republic-of-korea/): During a meeting between Acting Director General of Africa CDC, and KDCA Commissioner it was announced that the KDCA will donate a batch of the mpox vaccine
- [HDT Bio and UTMB partner against CCHFV and NiV](https://vaccinenation.org/technology/hdt-bio-and-utmb-partner-against-cchfv-and-niv/): In November 2022 HDT Bio Corp. and the University of Texas Medical Branch (UTMB) revealed that they had been awarded a project agreement worth up to $87.4 m
- [Marking World AIDS Day 2022: "equalise" theme](https://vaccinenation.org/infection/marking-world-aids-day-2022-equalise-theme/): 1st December 2022 is World AIDS Day, with global communities observing it under the theme “equalise”. This year, the WHO is calling on “leaders and citizens
- [AELIX Therapeutics study in Nature meets endpoints](https://vaccinenation.org/therapeutic/aelix-therapeutics-study-in-nature-meets-endpoints/): In November 2022 the results of the AELIX-002 trial were published in Nature by collaborators from Aelix Therapeutics and Gilead Sciences.
- [US announces further Global Health Security Partnerships](https://vaccinenation.org/global-health/us-announces-further-global-health-security-partnerships/): White House issued a statement indicating the intention of the Biden-Harris Administration to continue to “prioritise global health security”
- [PharmaJet announces grant from NIH for HPV](https://vaccinenation.org/technology/pharmajet-announces-grant-from-nih-for-hpv/): PharmaJet announced that it had received an NIH grant towards their Phase II investigation of the immunogenicity of intradermal administration of HPV vaccine.
- [WHO approval for Republic of Korea regulator](https://vaccinenation.org/global-health/who-approval-for-republic-of-korea-regulator/): The WHO announced in November that the Ministry of Food and Drug Safety (MFDS), Republic of Korea, achieved maturity level 4 (ML4) in its ranking
- [CEPI collaboration with UQ on Disease X platform](https://vaccinenation.org/technology/cepi-collaboration-with-uq-on-disease-x-platform/): In November 2022 CEPI announced an investment of U$5.7 million towards the development of a second-generation molecular clamp vaccine platform at the UQ
- [WHO: Monkeypox virus gets rebranded as Mpox](https://vaccinenation.org/infection/who-monkeypox-virus-gets-rebranded-as-mpox/): The WHO announced in November 2022 that, after “consultations with global experts”, it will begin using a preferred term “mpox” for monkeypox.

## Pages

- [Home](https://vaccinenation.org/): Latest news and insights into the world of vaccines from the World Vaccine Congress, as well as details on our events.
- [Subscribe](https://vaccinenation.org/subscribe/): [et_pb_section fb_built=”1″ _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”][et_pb_row column_structure=”3_4,1_4″ _builder_version=”4.17.4″ _module_preset=”default” width=”100%” max_width=”1200px” custom_padding=”30px|||||” global_colors_info=”{}”][et_pb_column type=”3_4″ _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”][et_pb_code _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFFFF” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″] [/et_pb_code][/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”POPULAR Header” _builder_version=”4.17.6″ text_font=”||||||||” text_line_height=”1.8em” header_font=”||||||||” header_2_font=”Work Sans|700|||||||” header_2_font_size=”35px” header_2_line_height=”1.5em” header_5_font=”|700|||||||” header_5_text_color=”#EC008C” header_6_font=”|700|||||||” header_6_text_align=”left” header_6_text_color=”#00ADEF” custom_margin=”||10px||false|false” custom_padding=”||||false|false” header_2_font_size_tablet=”30px” header_2_font_size_phone=”20px” header_2_font_size_last_edited=”on|phone” global_colors_info=”{}”]MOST POPULAR THIS MONTH[/et_pb_text][et_pb_blog posts_number=”8″ include_categories=”1363,1362,1361,1364″ use_manual_excerpt=”off” show_author=”off”
- [Post a Press Release](https://vaccinenation.org/post-a-press-release/): [et_pb_section fb_built=”1″ _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”][et_pb_row column_structure=”3_4,1_4″ _builder_version=”4.17.4″ _module_preset=”default” width=”100%” max_width=”1200px” custom_padding=”30px|||||” global_colors_info=”{}”][et_pb_column type=”3_4″ _builder_version=”4.17.3″ _module_preset=”default” global_colors_info=”{}”][et_pb_text module_id=”subscribe” _builder_version=”4.25.2″ text_font=”||||||||” text_text_color=”#000000″ text_line_height=”2em” header_font=”||||||||” header_text_color=”#000000″ header_2_text_color=”#000000″ header_3_font=”Work Sans|700|||||||” header_3_text_color=”#000000″ header_3_font_size=”25px” header_3_line_height=”1.5em” header_4_text_color=”#000000″ header_5_text_color=”#000000″ header_6_text_color=”#000000″ background_color=”#FFFFFF” text_orientation=”center” max_width=”1000px” max_width_tablet=”” max_width_phone=”” max_width_last_edited=”on|tablet” module_alignment=”center” custom_margin=”||40px||false|false” custom_padding=”20px||||false|false” header_3_font_size_tablet=”30px” header_3_font_size_phone=”15px” header_3_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}” header_2_font_size__hover=”26px” header_2_font_size__hover_enabled=”26px” header_2_line_height__hover=”1em” header_2_line_height__hover_enabled=”1em” header_2_letter_spacing__hover=”0px” header_2_letter_spacing__hover_enabled=”0px” header_2_text_shadow_style__hover=”none” header_2_text_shadow_style__hover_enabled=”none” header_2_text_shadow_color__hover=”rgba(0,0,0,0.4)”
- [Contact](https://vaccinenation.org/contact/): [et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.16″ custom_margin=”||||false|false” custom_width_px__hover=”1080px” custom_width_px__hover_enabled=”1080px” custom_width_percent__hover=”80%” custom_width_percent__hover_enabled=”80%” locked=”off” global_colors_info=”{}” gutter_width__hover=”3″ gutter_width__hover_enabled=”3″ parallax_1__hover=”off” parallax_1__hover_enabled=”off” parallax_2__hover=”off” parallax_2__hover_enabled=”off” parallax_3__hover=”off” parallax_3__hover_enabled=”off” parallax_method_1__hover=”on” parallax_method_1__hover_enabled=”on” parallax_method_2__hover=”on” parallax_method_2__hover_enabled=”on” parallax_method_3__hover=”on” parallax_method_3__hover_enabled=”on” use_background_color_gradient__hover=”off” use_background_color_gradient__hover_enabled=”off” background_color_gradient_start__hover=”#2b87da” background_color_gradient_start__hover_enabled=”#2b87da” background_color_gradient_end__hover=”#29c4a9″ background_color_gradient_end__hover_enabled=”#29c4a9″ background_color_gradient_type__hover=”linear” background_color_gradient_type__hover_enabled=”linear” background_color_gradient_direction__hover=”180deg” background_color_gradient_direction__hover_enabled=”180deg” background_color_gradient_direction_radial__hover=”center” background_color_gradient_direction_radial__hover_enabled=”center” background_color_gradient_start_position__hover=”0%” background_color_gradient_start_position__hover_enabled=”0%” background_color_gradient_end_position__hover=”100%” background_color_gradient_end_position__hover_enabled=”100%” background_color_gradient_overlays_image__hover=”off” background_color_gradient_overlays_image__hover_enabled=”off” parallax__hover=”off” parallax__hover_enabled=”off” parallax_method__hover=”on” parallax_method__hover_enabled=”on” background_size__hover=”cover” background_size__hover_enabled=”cover” background_position__hover=”center” background_position__hover_enabled=”center” background_repeat__hover=”no-repeat” background_repeat__hover_enabled=”no-repeat” background_blend__hover=”normal” background_blend__hover_enabled=”normal”
- [About](https://vaccinenation.org/about/): [et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.16″ background_color=”#FFFFFF” custom_margin=”||||false|false” custom_width_px__hover=”1080px” custom_width_px__hover_enabled=”1080px” custom_width_percent__hover=”80%” custom_width_percent__hover_enabled=”80%” locked=”off” global_colors_info=”{}” gutter_width__hover=”3″ gutter_width__hover_enabled=”3″ parallax_1__hover=”off” parallax_1__hover_enabled=”off” parallax_2__hover=”off” parallax_2__hover_enabled=”off” parallax_3__hover=”off” parallax_3__hover_enabled=”off” parallax_method_1__hover=”on” parallax_method_1__hover_enabled=”on” parallax_method_2__hover=”on” parallax_method_2__hover_enabled=”on” parallax_method_3__hover=”on” parallax_method_3__hover_enabled=”on” use_background_color_gradient__hover=”off” use_background_color_gradient__hover_enabled=”off” background_color_gradient_start__hover=”#2b87da” background_color_gradient_start__hover_enabled=”#2b87da” background_color_gradient_end__hover=”#29c4a9″ background_color_gradient_end__hover_enabled=”#29c4a9″ background_color_gradient_type__hover=”linear” background_color_gradient_type__hover_enabled=”linear” background_color_gradient_direction__hover=”180deg” background_color_gradient_direction__hover_enabled=”180deg” background_color_gradient_direction_radial__hover=”center” background_color_gradient_direction_radial__hover_enabled=”center” background_color_gradient_start_position__hover=”0%” background_color_gradient_start_position__hover_enabled=”0%” background_color_gradient_end_position__hover=”100%” background_color_gradient_end_position__hover_enabled=”100%” background_color_gradient_overlays_image__hover=”off” background_color_gradient_overlays_image__hover_enabled=”off” parallax__hover=”off” parallax__hover_enabled=”off” parallax_method__hover=”on” parallax_method__hover_enabled=”on” background_size__hover=”cover” background_size__hover_enabled=”cover” background_position__hover=”center” background_position__hover_enabled=”center” background_repeat__hover=”no-repeat” background_repeat__hover_enabled=”no-repeat” background_blend__hover=”normal”
- [Therapeutic](https://vaccinenation.org/therapeutic/): [et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.17.3″ min_height=”181.5px” custom_margin=”||-50px||false|false” custom_width_px__hover=”1080px” custom_width_px__hover_enabled=”1080px” custom_width_percent__hover=”80%” custom_width_percent__hover_enabled=”80%” locked=”off” global_colors_info=”{}” gutter_width__hover=”3″ gutter_width__hover_enabled=”3″ parallax_1__hover=”off” parallax_1__hover_enabled=”off” parallax_2__hover=”off” parallax_2__hover_enabled=”off” parallax_3__hover=”off” parallax_3__hover_enabled=”off” parallax_method_1__hover=”on” parallax_method_1__hover_enabled=”on” parallax_method_2__hover=”on” parallax_method_2__hover_enabled=”on” parallax_method_3__hover=”on” parallax_method_3__hover_enabled=”on” use_background_color_gradient__hover=”off” use_background_color_gradient__hover_enabled=”off” background_color_gradient_start__hover=”#2b87da” background_color_gradient_start__hover_enabled=”#2b87da” background_color_gradient_end__hover=”#29c4a9″ background_color_gradient_end__hover_enabled=”#29c4a9″ background_color_gradient_type__hover=”linear” background_color_gradient_type__hover_enabled=”linear” background_color_gradient_direction__hover=”180deg” background_color_gradient_direction__hover_enabled=”180deg” background_color_gradient_direction_radial__hover=”center” background_color_gradient_direction_radial__hover_enabled=”center” background_color_gradient_start_position__hover=”0%” background_color_gradient_start_position__hover_enabled=”0%” background_color_gradient_end_position__hover=”100%” background_color_gradient_end_position__hover_enabled=”100%” background_color_gradient_overlays_image__hover=”off” background_color_gradient_overlays_image__hover_enabled=”off” parallax__hover=”off” parallax__hover_enabled=”off” parallax_method__hover=”on” parallax_method__hover_enabled=”on” background_size__hover=”cover” background_size__hover_enabled=”cover” background_position__hover=”center” background_position__hover_enabled=”center” background_repeat__hover=”no-repeat” background_repeat__hover_enabled=”no-repeat” background_blend__hover=”normal”
- [Technology](https://vaccinenation.org/technology/): [et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.17.3″ min_height=”181.5px” custom_margin=”||-50px||false|false” custom_width_px__hover=”1080px” custom_width_px__hover_enabled=”1080px” custom_width_percent__hover=”80%” custom_width_percent__hover_enabled=”80%” locked=”off” global_colors_info=”{}” gutter_width__hover=”3″ gutter_width__hover_enabled=”3″ parallax_1__hover=”off” parallax_1__hover_enabled=”off” parallax_2__hover=”off” parallax_2__hover_enabled=”off” parallax_3__hover=”off” parallax_3__hover_enabled=”off” parallax_method_1__hover=”on” parallax_method_1__hover_enabled=”on” parallax_method_2__hover=”on” parallax_method_2__hover_enabled=”on” parallax_method_3__hover=”on” parallax_method_3__hover_enabled=”on” use_background_color_gradient__hover=”off” use_background_color_gradient__hover_enabled=”off” background_color_gradient_start__hover=”#2b87da” background_color_gradient_start__hover_enabled=”#2b87da” background_color_gradient_end__hover=”#29c4a9″ background_color_gradient_end__hover_enabled=”#29c4a9″ background_color_gradient_type__hover=”linear” background_color_gradient_type__hover_enabled=”linear” background_color_gradient_direction__hover=”180deg” background_color_gradient_direction__hover_enabled=”180deg” background_color_gradient_direction_radial__hover=”center” background_color_gradient_direction_radial__hover_enabled=”center” background_color_gradient_start_position__hover=”0%” background_color_gradient_start_position__hover_enabled=”0%” background_color_gradient_end_position__hover=”100%” background_color_gradient_end_position__hover_enabled=”100%” background_color_gradient_overlays_image__hover=”off” background_color_gradient_overlays_image__hover_enabled=”off” parallax__hover=”off” parallax__hover_enabled=”off” parallax_method__hover=”on” parallax_method__hover_enabled=”on” background_size__hover=”cover” background_size__hover_enabled=”cover” background_position__hover=”center” background_position__hover_enabled=”center” background_repeat__hover=”no-repeat” background_repeat__hover_enabled=”no-repeat” background_blend__hover=”normal”
- [Infection](https://vaccinenation.org/infection/): [et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.17.3″ min_height=”181.5px” custom_margin=”||-50px||false|false” custom_width_px__hover=”1080px” custom_width_px__hover_enabled=”1080px” custom_width_percent__hover=”80%” custom_width_percent__hover_enabled=”80%” locked=”off” global_colors_info=”{}” gutter_width__hover=”3″ gutter_width__hover_enabled=”3″ parallax_1__hover=”off” parallax_1__hover_enabled=”off” parallax_2__hover=”off” parallax_2__hover_enabled=”off” parallax_3__hover=”off” parallax_3__hover_enabled=”off” parallax_method_1__hover=”on” parallax_method_1__hover_enabled=”on” parallax_method_2__hover=”on” parallax_method_2__hover_enabled=”on” parallax_method_3__hover=”on” parallax_method_3__hover_enabled=”on” use_background_color_gradient__hover=”off” use_background_color_gradient__hover_enabled=”off” background_color_gradient_start__hover=”#2b87da” background_color_gradient_start__hover_enabled=”#2b87da” background_color_gradient_end__hover=”#29c4a9″ background_color_gradient_end__hover_enabled=”#29c4a9″ background_color_gradient_type__hover=”linear” background_color_gradient_type__hover_enabled=”linear” background_color_gradient_direction__hover=”180deg” background_color_gradient_direction__hover_enabled=”180deg” background_color_gradient_direction_radial__hover=”center” background_color_gradient_direction_radial__hover_enabled=”center” background_color_gradient_start_position__hover=”0%” background_color_gradient_start_position__hover_enabled=”0%” background_color_gradient_end_position__hover=”100%” background_color_gradient_end_position__hover_enabled=”100%” background_color_gradient_overlays_image__hover=”off” background_color_gradient_overlays_image__hover_enabled=”off” parallax__hover=”off” parallax__hover_enabled=”off” parallax_method__hover=”on” parallax_method__hover_enabled=”on” background_size__hover=”cover” background_size__hover_enabled=”cover” background_position__hover=”center” background_position__hover_enabled=”center” background_repeat__hover=”no-repeat” background_repeat__hover_enabled=”no-repeat” background_blend__hover=”normal”
- [Global Health](https://vaccinenation.org/global-health/): [et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.17.3″ min_height=”181.5px” custom_margin=”||-50px||false|false” custom_width_px__hover=”1080px” custom_width_px__hover_enabled=”1080px” custom_width_percent__hover=”80%” custom_width_percent__hover_enabled=”80%” locked=”off” global_colors_info=”{}” gutter_width__hover=”3″ gutter_width__hover_enabled=”3″ parallax_1__hover=”off” parallax_1__hover_enabled=”off” parallax_2__hover=”off” parallax_2__hover_enabled=”off” parallax_3__hover=”off” parallax_3__hover_enabled=”off” parallax_method_1__hover=”on” parallax_method_1__hover_enabled=”on” parallax_method_2__hover=”on” parallax_method_2__hover_enabled=”on” parallax_method_3__hover=”on” parallax_method_3__hover_enabled=”on” use_background_color_gradient__hover=”off” use_background_color_gradient__hover_enabled=”off” background_color_gradient_start__hover=”#2b87da” background_color_gradient_start__hover_enabled=”#2b87da” background_color_gradient_end__hover=”#29c4a9″ background_color_gradient_end__hover_enabled=”#29c4a9″ background_color_gradient_type__hover=”linear” background_color_gradient_type__hover_enabled=”linear” background_color_gradient_direction__hover=”180deg” background_color_gradient_direction__hover_enabled=”180deg” background_color_gradient_direction_radial__hover=”center” background_color_gradient_direction_radial__hover_enabled=”center” background_color_gradient_start_position__hover=”0%” background_color_gradient_start_position__hover_enabled=”0%” background_color_gradient_end_position__hover=”100%” background_color_gradient_end_position__hover_enabled=”100%” background_color_gradient_overlays_image__hover=”off” background_color_gradient_overlays_image__hover_enabled=”off” parallax__hover=”off” parallax__hover_enabled=”off” parallax_method__hover=”on” parallax_method__hover_enabled=”on” background_size__hover=”cover” background_size__hover_enabled=”cover” background_position__hover=”center” background_position__hover_enabled=”center” background_repeat__hover=”no-repeat” background_repeat__hover_enabled=”no-repeat” background_blend__hover=”normal”
- [Video](https://vaccinenation.org/video/): [et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.25.1″ _module_preset=”default”][et_pb_row _builder_version=”4.25.1″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″][et_pb_column _builder_version=”4.25.1″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” theme_builder_area=”post_content” admin_label=”Text” hover_enabled=”0″ sticky_enabled=”0″]Check out the latest videos from our YouTube channel![/et_pb_text][et_pb_video _builder_version=”4.25.1″ _module_preset=”default” theme_builder_area=”post_content” src=”https://www.youtube.com/playlist?list=PLbjQfI3QrlFqC42W6ViIXsRQkC9xPDfoJ” hover_enabled=”0″ sticky_enabled=”0″][/et_pb_video][et_pb_cta _builder_version=”4.25.1″ _module_preset=”default” theme_builder_area=”post_content” button_text=”More expert interviews!” button_url=”https://www.youtube.com/playlist?list=PLbjQfI3QrlFqC42W6ViIXsRQkC9xPDfoJ” button_alignment=”center” hover_enabled=”0″ sticky_enabled=”0″ background_color=”#FFFFFF”][/et_pb_cta][/et_pb_column][/et_pb_row][/et_pb_section]
- [Events](https://vaccinenation.org/events/): [et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.16″ custom_margin=”||||false|false” custom_width_px__hover=”1080px” custom_width_px__hover_enabled=”1080px” custom_width_percent__hover=”80%” custom_width_percent__hover_enabled=”80%” locked=”off” global_colors_info=”{}” gutter_width__hover=”3″ gutter_width__hover_enabled=”3″ parallax_1__hover=”off” parallax_1__hover_enabled=”off” parallax_2__hover=”off” parallax_2__hover_enabled=”off” parallax_3__hover=”off” parallax_3__hover_enabled=”off” parallax_method_1__hover=”on” parallax_method_1__hover_enabled=”on” parallax_method_2__hover=”on” parallax_method_2__hover_enabled=”on” parallax_method_3__hover=”on” parallax_method_3__hover_enabled=”on” use_background_color_gradient__hover=”off” use_background_color_gradient__hover_enabled=”off” background_color_gradient_start__hover=”#2b87da” background_color_gradient_start__hover_enabled=”#2b87da” background_color_gradient_end__hover=”#29c4a9″ background_color_gradient_end__hover_enabled=”#29c4a9″ background_color_gradient_type__hover=”linear” background_color_gradient_type__hover_enabled=”linear” background_color_gradient_direction__hover=”180deg” background_color_gradient_direction__hover_enabled=”180deg” background_color_gradient_direction_radial__hover=”center” background_color_gradient_direction_radial__hover_enabled=”center” background_color_gradient_start_position__hover=”0%” background_color_gradient_start_position__hover_enabled=”0%” background_color_gradient_end_position__hover=”100%” background_color_gradient_end_position__hover_enabled=”100%” background_color_gradient_overlays_image__hover=”off” background_color_gradient_overlays_image__hover_enabled=”off” parallax__hover=”off” parallax__hover_enabled=”off” parallax_method__hover=”on” parallax_method__hover_enabled=”on” background_size__hover=”cover” background_size__hover_enabled=”cover” background_position__hover=”center” background_position__hover_enabled=”center” background_repeat__hover=”no-repeat” background_repeat__hover_enabled=”no-repeat” background_blend__hover=”normal” background_blend__hover_enabled=”normal”
- [Advertise / Exhibit](https://vaccinenation.org/advertise-exhibit/): [et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.16″ custom_margin=”||||false|false” custom_width_px__hover=”1080px” custom_width_px__hover_enabled=”1080px” custom_width_percent__hover=”80%” custom_width_percent__hover_enabled=”80%” locked=”off” global_colors_info=”{}” gutter_width__hover=”3″ gutter_width__hover_enabled=”3″ parallax_1__hover=”off” parallax_1__hover_enabled=”off” parallax_2__hover=”off” parallax_2__hover_enabled=”off” parallax_3__hover=”off” parallax_3__hover_enabled=”off” parallax_method_1__hover=”on” parallax_method_1__hover_enabled=”on” parallax_method_2__hover=”on” parallax_method_2__hover_enabled=”on” parallax_method_3__hover=”on” parallax_method_3__hover_enabled=”on” use_background_color_gradient__hover=”off” use_background_color_gradient__hover_enabled=”off” background_color_gradient_start__hover=”#2b87da” background_color_gradient_start__hover_enabled=”#2b87da” background_color_gradient_end__hover=”#29c4a9″ background_color_gradient_end__hover_enabled=”#29c4a9″ background_color_gradient_type__hover=”linear” background_color_gradient_type__hover_enabled=”linear” background_color_gradient_direction__hover=”180deg” background_color_gradient_direction__hover_enabled=”180deg” background_color_gradient_direction_radial__hover=”center” background_color_gradient_direction_radial__hover_enabled=”center” background_color_gradient_start_position__hover=”0%” background_color_gradient_start_position__hover_enabled=”0%” background_color_gradient_end_position__hover=”100%” background_color_gradient_end_position__hover_enabled=”100%” background_color_gradient_overlays_image__hover=”off” background_color_gradient_overlays_image__hover_enabled=”off” parallax__hover=”off” parallax__hover_enabled=”off” parallax_method__hover=”on” parallax_method__hover_enabled=”on” background_size__hover=”cover” background_size__hover_enabled=”cover” background_position__hover=”center” background_position__hover_enabled=”center” background_repeat__hover=”no-repeat” background_repeat__hover_enabled=”no-repeat” background_blend__hover=”normal” background_blend__hover_enabled=”normal”
- [News](https://vaccinenation.org/news/): [et_pb_section fb_built=”1″ _builder_version=”4.16″ background_color=”#FFFFFF” custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_row column_structure=”3_4,1_4″ _builder_version=”4.17.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” width=”100%” max_width=”1200px” global_colors_info=”{}”][et_pb_column type=”3_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.17.6″ _module_preset=”default” header_font=”|700|||||||” header_text_align=”left” header_text_color=”#000000″ global_colors_info=”{}”]Latest News[/et_pb_text][et_pb_code _builder_version=”4.17.6″ _module_preset=”default” global_colors_info=”{}”]NewsMicroneedle technology wins Gates grants of $6.6 millionCharlotte KilpatrickOctober 24, 2024Technologyaccess,development,funding,gates,grant,innovation,microarray,microneedle,needle-free,patch,research,technology,uptake,vaccine(2) The University of Connecticut (UConn) announced in October 2024 that associate Professor Thanh Nguyen’s research has

## MailPoet Page

- [MailPoet Page](https://vaccinenation.org/?mailpoet_page=captcha): [mailpoet_page]
- [MailPoet Page](https://vaccinenation.org/?mailpoet_page=subscriptions): [mailpoet_page]

## Categories

- [Therapeutic](https://vaccinenation.org/category/therapeutic/)
- [Technology](https://vaccinenation.org/category/technology/)
- [Infection](https://vaccinenation.org/category/infection/)
- [Global Health](https://vaccinenation.org/category/global-health/)
- [Video](https://vaccinenation.org/category/video/)

## Tags

- [vaccine](https://vaccinenation.org/tag/vaccine/)
- [covid-19](https://vaccinenation.org/tag/covid-19/)
- [genetic](https://vaccinenation.org/tag/genetic/)
- [study](https://vaccinenation.org/tag/study/)
- [research](https://vaccinenation.org/tag/research/)
- [shingles](https://vaccinenation.org/tag/shingles/)
- [data](https://vaccinenation.org/tag/data/)
- [disease](https://vaccinenation.org/tag/disease/)
- [respiratory](https://vaccinenation.org/tag/respiratory/)
- [flu](https://vaccinenation.org/tag/flu/)
- [influenza](https://vaccinenation.org/tag/influenza/)
- [rsv](https://vaccinenation.org/tag/rsv/)
- [WHO](https://vaccinenation.org/tag/who/)
- [cancer](https://vaccinenation.org/tag/cancer/)
- [therapy](https://vaccinenation.org/tag/therapy/)
- [therapeutic](https://vaccinenation.org/tag/therapeutic/)
- [partnership](https://vaccinenation.org/tag/partnership/)
- [science](https://vaccinenation.org/tag/science/)
- [religion](https://vaccinenation.org/tag/religion/)
- [pancreatic](https://vaccinenation.org/tag/pancreatic/)
- [colorectal](https://vaccinenation.org/tag/colorectal/)
- [inquiry](https://vaccinenation.org/tag/inquiry/)
- [pandemic](https://vaccinenation.org/tag/pandemic/)
- [uk](https://vaccinenation.org/tag/uk/)
- [nipah](https://vaccinenation.org/tag/nipah/)
- [virus](https://vaccinenation.org/tag/virus/)
- [trial](https://vaccinenation.org/tag/trial/)
- [oxford](https://vaccinenation.org/tag/oxford/)
- [ethics](https://vaccinenation.org/tag/ethics/)
- [pathogen](https://vaccinenation.org/tag/pathogen/)
- [health](https://vaccinenation.org/tag/health/)
- [BCI](https://vaccinenation.org/tag/bci/)
- [behaviour](https://vaccinenation.org/tag/behaviour/)
- [resources](https://vaccinenation.org/tag/resources/)
- [gavi](https://vaccinenation.org/tag/gavi/)
- [ceo](https://vaccinenation.org/tag/ceo/)
- [malaria](https://vaccinenation.org/tag/malaria/)
- [infection](https://vaccinenation.org/tag/infection/)
- [risk](https://vaccinenation.org/tag/risk/)
- [lancet](https://vaccinenation.org/tag/lancet/)
- [vaccination](https://vaccinenation.org/tag/vaccination/)
- [tb](https://vaccinenation.org/tag/tb/)
- [tuberculosis](https://vaccinenation.org/tag/tuberculosis/)
- [inhaled](https://vaccinenation.org/tag/inhaled/)
- [technology](https://vaccinenation.org/tag/technology/)
- [hesitancy](https://vaccinenation.org/tag/hesitancy/)
- [social media](https://vaccinenation.org/tag/social-media/)
- [misinformation](https://vaccinenation.org/tag/misinformation/)
- [funding](https://vaccinenation.org/tag/funding/)
- [amr](https://vaccinenation.org/tag/amr/)
- [gonorrhoea](https://vaccinenation.org/tag/gonorrhoea/)
- [sti](https://vaccinenation.org/tag/sti/)
- [bacteria](https://vaccinenation.org/tag/bacteria/)
- [omv](https://vaccinenation.org/tag/omv/)
- [cepi](https://vaccinenation.org/tag/cepi/)
- [access](https://vaccinenation.org/tag/access/)
- [staphylococcus aureus](https://vaccinenation.org/tag/staphylococcus-aureus/)
- [europe](https://vaccinenation.org/tag/europe/)
- [neoantigen](https://vaccinenation.org/tag/neoantigen/)
- [vaccine development](https://vaccinenation.org/tag/vaccine-development/)
- [model](https://vaccinenation.org/tag/model/)
- [manufacture](https://vaccinenation.org/tag/manufacture/)
- [process](https://vaccinenation.org/tag/process/)
- [women](https://vaccinenation.org/tag/women/)
- [wef](https://vaccinenation.org/tag/wef/)
- [mckinsey](https://vaccinenation.org/tag/mckinsey/)
- [female](https://vaccinenation.org/tag/female/)
- [economy](https://vaccinenation.org/tag/economy/)
- [report](https://vaccinenation.org/tag/report/)
- [gender](https://vaccinenation.org/tag/gender/)
- [investment](https://vaccinenation.org/tag/investment/)
- [sepsis](https://vaccinenation.org/tag/sepsis/)
- [neonatal](https://vaccinenation.org/tag/neonatal/)
- [maternal](https://vaccinenation.org/tag/maternal/)
- [pregnancy](https://vaccinenation.org/tag/pregnancy/)
- [measles](https://vaccinenation.org/tag/measles/)
- [mmr](https://vaccinenation.org/tag/mmr/)
- [ukhsa](https://vaccinenation.org/tag/ukhsa/)
- [immunisation](https://vaccinenation.org/tag/immunisation/)
- [childhood](https://vaccinenation.org/tag/childhood/)
- [oral](https://vaccinenation.org/tag/oral/)
- [pill](https://vaccinenation.org/tag/pill/)
- [africa](https://vaccinenation.org/tag/africa/)
- [network](https://vaccinenation.org/tag/network/)
- [pandemic preparedness](https://vaccinenation.org/tag/pandemic-preparedness/)
- [100 days mission](https://vaccinenation.org/tag/100-days-mission/)
- [serum institute india](https://vaccinenation.org/tag/serum-institute-india/)
- [hpv](https://vaccinenation.org/tag/hpv/)
- [thermostable](https://vaccinenation.org/tag/thermostable/)
- [vaccine technology](https://vaccinenation.org/tag/vaccine-technology/)
- [ensilitech](https://vaccinenation.org/tag/ensilitech/)
- [afrigen](https://vaccinenation.org/tag/afrigen/)
- [emervax](https://vaccinenation.org/tag/emervax/)
- [mRNA](https://vaccinenation.org/tag/mrna/)
- [hiv](https://vaccinenation.org/tag/hiv/)
- [adenovirus](https://vaccinenation.org/tag/adenovirus/)
- [iavi](https://vaccinenation.org/tag/iavi/)
- [corbevax](https://vaccinenation.org/tag/corbevax/)
- [approval](https://vaccinenation.org/tag/approval/)
- [toxic shock](https://vaccinenation.org/tag/toxic-shock/)
- [genomics](https://vaccinenation.org/tag/genomics/)
- [strategy](https://vaccinenation.org/tag/strategy/)
- [RNA](https://vaccinenation.org/tag/rna/)
- [partntership](https://vaccinenation.org/tag/partntership/)
- [circular RNA](https://vaccinenation.org/tag/circular-rna/)
- [circRNA](https://vaccinenation.org/tag/circrna/)
- [bowel](https://vaccinenation.org/tag/bowel/)
- [neonate](https://vaccinenation.org/tag/neonate/)
- [ai](https://vaccinenation.org/tag/ai/)
- [artificial intelligence](https://vaccinenation.org/tag/artificial-intelligence/)
- [antigen](https://vaccinenation.org/tag/antigen/)
- [evaxion](https://vaccinenation.org/tag/evaxion/)
- [ntd](https://vaccinenation.org/tag/ntd/)
- [neglected tropical disease](https://vaccinenation.org/tag/neglected-tropical-disease/)
- [innovation](https://vaccinenation.org/tag/innovation/)
- [bio](https://vaccinenation.org/tag/bio/)
- [industry](https://vaccinenation.org/tag/industry/)
- [prophylactic](https://vaccinenation.org/tag/prophylactic/)
- [hepatitis e](https://vaccinenation.org/tag/hepatitis-e/)
- [hepatitis](https://vaccinenation.org/tag/hepatitis/)
- [emergency](https://vaccinenation.org/tag/emergency/)
- [outbreak](https://vaccinenation.org/tag/outbreak/)
- [msf](https://vaccinenation.org/tag/msf/)
- [south sudan](https://vaccinenation.org/tag/south-sudan/)
- [uvax](https://vaccinenation.org/tag/uvax/)
- [equity](https://vaccinenation.org/tag/equity/)
- [equality](https://vaccinenation.org/tag/equality/)
- [global health](https://vaccinenation.org/tag/global-health/)
- [eu](https://vaccinenation.org/tag/eu/)
- [prevention](https://vaccinenation.org/tag/prevention/)
- [one health](https://vaccinenation.org/tag/one-health/)
- [veterinary](https://vaccinenation.org/tag/veterinary/)
- [animal](https://vaccinenation.org/tag/animal/)
- [poultry](https://vaccinenation.org/tag/poultry/)
- [farm](https://vaccinenation.org/tag/farm/)
- [dna](https://vaccinenation.org/tag/dna/)
- [vlp](https://vaccinenation.org/tag/vlp/)
- [cancer vaccine](https://vaccinenation.org/tag/cancer-vaccine/)
- [lung](https://vaccinenation.org/tag/lung/)
- [breast](https://vaccinenation.org/tag/breast/)
- [safety](https://vaccinenation.org/tag/safety/)
- [adverse events](https://vaccinenation.org/tag/adverse-events/)
- [VAERS](https://vaccinenation.org/tag/vaers/)
- [trust](https://vaccinenation.org/tag/trust/)
- [treatment](https://vaccinenation.org/tag/treatment/)
- [moderna](https://vaccinenation.org/tag/moderna/)
- [tumour](https://vaccinenation.org/tag/tumour/)
- [combination](https://vaccinenation.org/tag/combination/)
- [vaxxinity](https://vaccinenation.org/tag/vaxxinity/)
- [development](https://vaccinenation.org/tag/development/)
- [neurodegenerative](https://vaccinenation.org/tag/neurodegenerative/)
- [parkinson's](https://vaccinenation.org/tag/parkinsons/)
- [alzheimer's](https://vaccinenation.org/tag/alzheimers/)
- [novavax](https://vaccinenation.org/tag/novavax/)
- [r21](https://vaccinenation.org/tag/r21/)
- [collaboration](https://vaccinenation.org/tag/collaboration/)
- [african swine fever](https://vaccinenation.org/tag/african-swine-fever/)
- [asf](https://vaccinenation.org/tag/asf/)
- [vaccines](https://vaccinenation.org/tag/vaccines/)
- [infectious disease](https://vaccinenation.org/tag/infectious-disease/)
- [policy](https://vaccinenation.org/tag/policy/)
- [plant](https://vaccinenation.org/tag/plant/)
- [dengue](https://vaccinenation.org/tag/dengue/)
- [lassa](https://vaccinenation.org/tag/lassa/)
- [lassa fever](https://vaccinenation.org/tag/lassa-fever/)
- [genetics](https://vaccinenation.org/tag/genetics/)
- [patient](https://vaccinenation.org/tag/patient/)
- [sanofi](https://vaccinenation.org/tag/sanofi/)
- [cmv](https://vaccinenation.org/tag/cmv/)
- [newborn](https://vaccinenation.org/tag/newborn/)
- [cytomegalovirus](https://vaccinenation.org/tag/cytomegalovirus/)
- [pfizer](https://vaccinenation.org/tag/pfizer/)
- [BioNTech](https://vaccinenation.org/tag/biontech/)
- [MHRA](https://vaccinenation.org/tag/mhra/)
- [death](https://vaccinenation.org/tag/death/)
- [rts](https://vaccinenation.org/tag/rts/)
- [routine immunisation](https://vaccinenation.org/tag/routine-immunisation/)
- [off-the-shelf](https://vaccinenation.org/tag/off-the-shelf/)
- [ebola](https://vaccinenation.org/tag/ebola/)
- [ebolavirus](https://vaccinenation.org/tag/ebolavirus/)
- [zaire](https://vaccinenation.org/tag/zaire/)
- [communication](https://vaccinenation.org/tag/communication/)
- [MERS](https://vaccinenation.org/tag/mers/)
- [coronavirus](https://vaccinenation.org/tag/coronavirus/)
- [zoonotic](https://vaccinenation.org/tag/zoonotic/)
- [human](https://vaccinenation.org/tag/human/)
- [epidemic](https://vaccinenation.org/tag/epidemic/)
- [cholera](https://vaccinenation.org/tag/cholera/)
- [shortage](https://vaccinenation.org/tag/shortage/)
- [stockpile](https://vaccinenation.org/tag/stockpile/)
- [herpes](https://vaccinenation.org/tag/herpes/)
- [adult](https://vaccinenation.org/tag/adult/)
- [belief](https://vaccinenation.org/tag/belief/)
- [attitude](https://vaccinenation.org/tag/attitude/)
- [doctor](https://vaccinenation.org/tag/doctor/)
- [rabies](https://vaccinenation.org/tag/rabies/)
- [self-replicating](https://vaccinenation.org/tag/self-replicating/)
- [srRNA](https://vaccinenation.org/tag/srrna/)
- [cold chain](https://vaccinenation.org/tag/cold-chain/)
- [supply](https://vaccinenation.org/tag/supply/)
- [logistics](https://vaccinenation.org/tag/logistics/)
- [distribution](https://vaccinenation.org/tag/distribution/)
- [sarbecovirus](https://vaccinenation.org/tag/sarbecovirus/)
- [SARS-CoV-2](https://vaccinenation.org/tag/sars-cov-2/)
- [cholesterol](https://vaccinenation.org/tag/cholesterol/)
- [ldl-c](https://vaccinenation.org/tag/ldl-c/)
- [heart](https://vaccinenation.org/tag/heart/)
- [heart disease](https://vaccinenation.org/tag/heart-disease/)
- [cardiovascular](https://vaccinenation.org/tag/cardiovascular/)
- [adjuvant](https://vaccinenation.org/tag/adjuvant/)
- [saponin](https://vaccinenation.org/tag/saponin/)
- [market](https://vaccinenation.org/tag/market/)
- [vaccine safety](https://vaccinenation.org/tag/vaccine-safety/)
- [gbs](https://vaccinenation.org/tag/gbs/)
- [pericarditis](https://vaccinenation.org/tag/pericarditis/)
- [myocarditis](https://vaccinenation.org/tag/myocarditis/)
- [influneza](https://vaccinenation.org/tag/influneza/)
- [infectious](https://vaccinenation.org/tag/infectious/)
- [paediatric](https://vaccinenation.org/tag/paediatric/)
- [unicef](https://vaccinenation.org/tag/unicef/)
- [rubella](https://vaccinenation.org/tag/rubella/)
- [vaccine delivery](https://vaccinenation.org/tag/vaccine-delivery/)
- [delivery](https://vaccinenation.org/tag/delivery/)
- [zero dose](https://vaccinenation.org/tag/zero-dose/)
- [children](https://vaccinenation.org/tag/children/)
- [clinical](https://vaccinenation.org/tag/clinical/)
- [allergies](https://vaccinenation.org/tag/allergies/)
- [allergy](https://vaccinenation.org/tag/allergy/)
- [immunotherapy](https://vaccinenation.org/tag/immunotherapy/)
- [africa cdc](https://vaccinenation.org/tag/africa-cdc/)
- [manufacturing](https://vaccinenation.org/tag/manufacturing/)
- [procurement](https://vaccinenation.org/tag/procurement/)
- [mesothelioma](https://vaccinenation.org/tag/mesothelioma/)
- [ema](https://vaccinenation.org/tag/ema/)
- [fda](https://vaccinenation.org/tag/fda/)
- [ultimovacs](https://vaccinenation.org/tag/ultimovacs/)
- [orphan drug](https://vaccinenation.org/tag/orphan-drug/)
- [polio](https://vaccinenation.org/tag/polio/)
- [poliovirus](https://vaccinenation.org/tag/poliovirus/)
- [oral vaccine](https://vaccinenation.org/tag/oral-vaccine/)
- [public health](https://vaccinenation.org/tag/public-health/)
- [mandate](https://vaccinenation.org/tag/mandate/)
- [law](https://vaccinenation.org/tag/law/)
- [uptake](https://vaccinenation.org/tag/uptake/)
- [anti](https://vaccinenation.org/tag/anti/)
- [cdc](https://vaccinenation.org/tag/cdc/)
- [attitudes](https://vaccinenation.org/tag/attitudes/)
- [booster](https://vaccinenation.org/tag/booster/)
- [liver cancer](https://vaccinenation.org/tag/liver-cancer/)
- [bcg](https://vaccinenation.org/tag/bcg/)
- [shigellosis](https://vaccinenation.org/tag/shigellosis/)
- [antimicrobial resistance](https://vaccinenation.org/tag/antimicrobial-resistance/)
- [typhoid](https://vaccinenation.org/tag/typhoid/)
- [fever](https://vaccinenation.org/tag/fever/)
- [climate change](https://vaccinenation.org/tag/climate-change/)
- [prequalification](https://vaccinenation.org/tag/prequalification/)
- [ivi](https://vaccinenation.org/tag/ivi/)
- [algorithm](https://vaccinenation.org/tag/algorithm/)
- [start-up](https://vaccinenation.org/tag/start-up/)
- [avian influenza](https://vaccinenation.org/tag/avian-influenza/)
- [bird flu](https://vaccinenation.org/tag/bird-flu/)
- [takeda](https://vaccinenation.org/tag/takeda/)
- [endemic](https://vaccinenation.org/tag/endemic/)
- [hexaplex](https://vaccinenation.org/tag/hexaplex/)
- [surveillance](https://vaccinenation.org/tag/surveillance/)
- [preparedness](https://vaccinenation.org/tag/preparedness/)
- [hepatitis b](https://vaccinenation.org/tag/hepatitis-b/)
- [hbv](https://vaccinenation.org/tag/hbv/)
- [liver](https://vaccinenation.org/tag/liver/)
- [herpes zoster](https://vaccinenation.org/tag/herpes-zoster/)
- [nhs](https://vaccinenation.org/tag/nhs/)
- [security](https://vaccinenation.org/tag/security/)
- [nipah virus](https://vaccinenation.org/tag/nipah-virus/)
- [response](https://vaccinenation.org/tag/response/)
- [mpox](https://vaccinenation.org/tag/mpox/)
- [marburg](https://vaccinenation.org/tag/marburg/)
- [enterococcus](https://vaccinenation.org/tag/enterococcus/)
- [efficacy](https://vaccinenation.org/tag/efficacy/)
- [results](https://vaccinenation.org/tag/results/)
- [environment](https://vaccinenation.org/tag/environment/)
- [nature](https://vaccinenation.org/tag/nature/)
- [quadripartite](https://vaccinenation.org/tag/quadripartite/)
- [storage](https://vaccinenation.org/tag/storage/)
- [transport](https://vaccinenation.org/tag/transport/)
- [freeze](https://vaccinenation.org/tag/freeze/)
- [temperature](https://vaccinenation.org/tag/temperature/)
- [machine learning](https://vaccinenation.org/tag/machine-learning/)
- [swine fever](https://vaccinenation.org/tag/swine-fever/)
- [antivaccine](https://vaccinenation.org/tag/antivaccine/)
- [head and neck](https://vaccinenation.org/tag/head-and-neck/)
- [vaccine therapy](https://vaccinenation.org/tag/vaccine-therapy/)
- [individualised](https://vaccinenation.org/tag/individualised/)
- [personalised](https://vaccinenation.org/tag/personalised/)
- [zika](https://vaccinenation.org/tag/zika/)
- [child](https://vaccinenation.org/tag/child/)
- [e.coli](https://vaccinenation.org/tag/e-coli/)
- [hypervaccination](https://vaccinenation.org/tag/hypervaccination/)
- [immune system](https://vaccinenation.org/tag/immune-system/)
- [immunity](https://vaccinenation.org/tag/immunity/)
- [astrazeneca](https://vaccinenation.org/tag/astrazeneca/)
- [life sciences](https://vaccinenation.org/tag/life-sciences/)
- [cervical cancer](https://vaccinenation.org/tag/cervical-cancer/)
- [elimination](https://vaccinenation.org/tag/elimination/)
- [gates](https://vaccinenation.org/tag/gates/)
- [girls](https://vaccinenation.org/tag/girls/)
- [cervical](https://vaccinenation.org/tag/cervical/)
- [self-amplifying](https://vaccinenation.org/tag/self-amplifying/)
- [trans-amplifying](https://vaccinenation.org/tag/trans-amplifying/)
- [pertussis](https://vaccinenation.org/tag/pertussis/)
- [whooping cough](https://vaccinenation.org/tag/whooping-cough/)
- [cancer therapy](https://vaccinenation.org/tag/cancer-therapy/)
- [melanoma](https://vaccinenation.org/tag/melanoma/)
- [spike protein](https://vaccinenation.org/tag/spike-protein/)
- [subunit](https://vaccinenation.org/tag/subunit/)
- [sudan](https://vaccinenation.org/tag/sudan/)
- [needle-free](https://vaccinenation.org/tag/needle-free/)
- [mucosal](https://vaccinenation.org/tag/mucosal/)
- [human challenge studies](https://vaccinenation.org/tag/human-challenge-studies/)
- [australia](https://vaccinenation.org/tag/australia/)
- [community](https://vaccinenation.org/tag/community/)
- [information](https://vaccinenation.org/tag/information/)
- [pneumococcal](https://vaccinenation.org/tag/pneumococcal/)
- [streptococcus](https://vaccinenation.org/tag/streptococcus/)
- [sdg](https://vaccinenation.org/tag/sdg/)
- [un](https://vaccinenation.org/tag/un/)
- [henipavirus](https://vaccinenation.org/tag/henipavirus/)
- [broad](https://vaccinenation.org/tag/broad/)
- [smallpox](https://vaccinenation.org/tag/smallpox/)
- [last mile](https://vaccinenation.org/tag/last-mile/)
- [lmic](https://vaccinenation.org/tag/lmic/)
- [monoclonal antibody](https://vaccinenation.org/tag/monoclonal-antibody/)
- [monoclonal antibodies](https://vaccinenation.org/tag/monoclonal-antibodies/)
- [mAbs](https://vaccinenation.org/tag/mabs/)
- [fungus](https://vaccinenation.org/tag/fungus/)
- [precision](https://vaccinenation.org/tag/precision/)
- [origami](https://vaccinenation.org/tag/origami/)
- [neurological](https://vaccinenation.org/tag/neurological/)
- [care](https://vaccinenation.org/tag/care/)
- [virtual reality](https://vaccinenation.org/tag/virtual-reality/)
- [bioprocess](https://vaccinenation.org/tag/bioprocess/)
- [elephantiasis](https://vaccinenation.org/tag/elephantiasis/)
- [neglected](https://vaccinenation.org/tag/neglected/)
- [parasite](https://vaccinenation.org/tag/parasite/)
- [mosquito](https://vaccinenation.org/tag/mosquito/)
- [mosquito-borne](https://vaccinenation.org/tag/mosquito-borne/)
- [nih](https://vaccinenation.org/tag/nih/)
- [agreement](https://vaccinenation.org/tag/agreement/)
- [autoimmune disease](https://vaccinenation.org/tag/autoimmune-disease/)
- [multiple sclerosis](https://vaccinenation.org/tag/multiple-sclerosis/)
- [platform](https://vaccinenation.org/tag/platform/)
- [south africa](https://vaccinenation.org/tag/south-africa/)
- [gsk](https://vaccinenation.org/tag/gsk/)
- [vaccine-preventable](https://vaccinenation.org/tag/vaccine-preventable/)
- [yellow fever](https://vaccinenation.org/tag/yellow-fever/)
- [arbovirus](https://vaccinenation.org/tag/arbovirus/)
- [medicine](https://vaccinenation.org/tag/medicine/)
- [disinformation](https://vaccinenation.org/tag/disinformation/)
- [regulatory](https://vaccinenation.org/tag/regulatory/)
- [lung cancer](https://vaccinenation.org/tag/lung-cancer/)
- [confidence](https://vaccinenation.org/tag/confidence/)
- [england](https://vaccinenation.org/tag/england/)
- [parents](https://vaccinenation.org/tag/parents/)
- [water](https://vaccinenation.org/tag/water/)
- [water-borne](https://vaccinenation.org/tag/water-borne/)
- [conjugate](https://vaccinenation.org/tag/conjugate/)
- [stability](https://vaccinenation.org/tag/stability/)
- [laser](https://vaccinenation.org/tag/laser/)
- [h5n1](https://vaccinenation.org/tag/h5n1/)
- [us](https://vaccinenation.org/tag/us/)
- [spray](https://vaccinenation.org/tag/spray/)
- [uti](https://vaccinenation.org/tag/uti/)
- [immunosenescence](https://vaccinenation.org/tag/immunosenescence/)
- [aging](https://vaccinenation.org/tag/aging/)
- [old](https://vaccinenation.org/tag/old/)
- [multivalent](https://vaccinenation.org/tag/multivalent/)
- [protozoa](https://vaccinenation.org/tag/protozoa/)
- [chagas](https://vaccinenation.org/tag/chagas/)
- [unmet need](https://vaccinenation.org/tag/unmet-need/)
- [diagnosis](https://vaccinenation.org/tag/diagnosis/)
- [hepatitis c](https://vaccinenation.org/tag/hepatitis-c/)
- [viral](https://vaccinenation.org/tag/viral/)
- [chronic](https://vaccinenation.org/tag/chronic/)
- [coverage](https://vaccinenation.org/tag/coverage/)
- [paho](https://vaccinenation.org/tag/paho/)
- [awareness](https://vaccinenation.org/tag/awareness/)
- [epi](https://vaccinenation.org/tag/epi/)
- [interview](https://vaccinenation.org/tag/interview/)
- [ecosystem](https://vaccinenation.org/tag/ecosystem/)
- [sustainability](https://vaccinenation.org/tag/sustainability/)
- [economist impact](https://vaccinenation.org/tag/economist-impact/)
- [readiness](https://vaccinenation.org/tag/readiness/)
- [wvc](https://vaccinenation.org/tag/wvc/)
- [apiject](https://vaccinenation.org/tag/apiject/)
- [injection](https://vaccinenation.org/tag/injection/)
- [non-specific effects](https://vaccinenation.org/tag/non-specific-effects/)
- [hic](https://vaccinenation.org/tag/hic/)
- [ecdc](https://vaccinenation.org/tag/ecdc/)
- [hvivo](https://vaccinenation.org/tag/hvivo/)
- [service](https://vaccinenation.org/tag/service/)
- [solutions](https://vaccinenation.org/tag/solutions/)
- [q2 solutions](https://vaccinenation.org/tag/q2-solutions/)
- [travel](https://vaccinenation.org/tag/travel/)
- [vector](https://vaccinenation.org/tag/vector/)
- [barda](https://vaccinenation.org/tag/barda/)
- [patch](https://vaccinenation.org/tag/patch/)
- [microneedle](https://vaccinenation.org/tag/microneedle/)
- [infrastructure](https://vaccinenation.org/tag/infrastructure/)
- [adjuvants](https://vaccinenation.org/tag/adjuvants/)
- [msd](https://vaccinenation.org/tag/msd/)
- [solution](https://vaccinenation.org/tag/solution/)
- [allucent](https://vaccinenation.org/tag/allucent/)
- [cro](https://vaccinenation.org/tag/cro/)
- [biotech](https://vaccinenation.org/tag/biotech/)
- [valneva](https://vaccinenation.org/tag/valneva/)
- [medical need](https://vaccinenation.org/tag/medical-need/)
- [chikungunya](https://vaccinenation.org/tag/chikungunya/)
- [lyme](https://vaccinenation.org/tag/lyme/)
- [bluetongue](https://vaccinenation.org/tag/bluetongue/)
- [authorisation](https://vaccinenation.org/tag/authorisation/)
- [hpai](https://vaccinenation.org/tag/hpai/)
- [WOAH](https://vaccinenation.org/tag/woah/)
- [assay](https://vaccinenation.org/tag/assay/)
- [mabtech](https://vaccinenation.org/tag/mabtech/)
- [microarray](https://vaccinenation.org/tag/microarray/)
- [universal](https://vaccinenation.org/tag/universal/)
- [oncology](https://vaccinenation.org/tag/oncology/)
- [glioblastoma](https://vaccinenation.org/tag/glioblastoma/)
- [legal](https://vaccinenation.org/tag/legal/)
- [crisis](https://vaccinenation.org/tag/crisis/)
- [vaccinology](https://vaccinenation.org/tag/vaccinology/)
- [economic](https://vaccinenation.org/tag/economic/)
- [fatigue](https://vaccinenation.org/tag/fatigue/)
- [aids](https://vaccinenation.org/tag/aids/)
- [syphilis](https://vaccinenation.org/tag/syphilis/)
- [infant](https://vaccinenation.org/tag/infant/)
- [LNP](https://vaccinenation.org/tag/lnp/)
- [marketing authorisation](https://vaccinenation.org/tag/marketing-authorisation/)
- [tts](https://vaccinenation.org/tag/tts/)
- [ac immune](https://vaccinenation.org/tag/ac-immune/)
- [integrum](https://vaccinenation.org/tag/integrum/)
- [rift valley fever](https://vaccinenation.org/tag/rift-valley-fever/)
- [serum](https://vaccinenation.org/tag/serum/)
- [implementation](https://vaccinenation.org/tag/implementation/)
- [merck](https://vaccinenation.org/tag/merck/)
- [brazil](https://vaccinenation.org/tag/brazil/)
- [protein](https://vaccinenation.org/tag/protein/)
- [design](https://vaccinenation.org/tag/design/)
- [emerging](https://vaccinenation.org/tag/emerging/)
- [re-emerging](https://vaccinenation.org/tag/re-emerging/)
- [icosavax](https://vaccinenation.org/tag/icosavax/)
- [routine](https://vaccinenation.org/tag/routine/)
- [priority](https://vaccinenation.org/tag/priority/)
- [bacterial](https://vaccinenation.org/tag/bacterial/)
- [cryptosporidium](https://vaccinenation.org/tag/cryptosporidium/)
- [sanitation](https://vaccinenation.org/tag/sanitation/)
- [crimean-congo haemorrhagic fever](https://vaccinenation.org/tag/crimean-congo-haemorrhagic-fever/)
- [replicating](https://vaccinenation.org/tag/replicating/)
- [glioma](https://vaccinenation.org/tag/glioma/)
- [chlamydia](https://vaccinenation.org/tag/chlamydia/)
- [reverse vaccinology](https://vaccinenation.org/tag/reverse-vaccinology/)
- [clinical trials](https://vaccinenation.org/tag/clinical-trials/)
- [epstein-barr virus](https://vaccinenation.org/tag/epstein-barr-virus/)
- [japanese encephalitis](https://vaccinenation.org/tag/japanese-encephalitis/)
- [long COVID](https://vaccinenation.org/tag/long-covid/)
- [t cell](https://vaccinenation.org/tag/t-cell/)
- [tdap](https://vaccinenation.org/tag/tdap/)
- [resilience](https://vaccinenation.org/tag/resilience/)
- [scale](https://vaccinenation.org/tag/scale/)
- [bavarian nordic](https://vaccinenation.org/tag/bavarian-nordic/)
- [cancer research](https://vaccinenation.org/tag/cancer-research/)
- [omicron](https://vaccinenation.org/tag/omicron/)
- [infodemic](https://vaccinenation.org/tag/infodemic/)
- [facebook](https://vaccinenation.org/tag/facebook/)
- [autism](https://vaccinenation.org/tag/autism/)
- [h5n2](https://vaccinenation.org/tag/h5n2/)
- [recombinant](https://vaccinenation.org/tag/recombinant/)
- [polysaccharide](https://vaccinenation.org/tag/polysaccharide/)
- [elderly](https://vaccinenation.org/tag/elderly/)
- [cost](https://vaccinenation.org/tag/cost/)
- [lipid nanoparticle](https://vaccinenation.org/tag/lipid-nanoparticle/)
- [side effects](https://vaccinenation.org/tag/side-effects/)
- [reactogenicity](https://vaccinenation.org/tag/reactogenicity/)
- [antibody](https://vaccinenation.org/tag/antibody/)
- [antibodies](https://vaccinenation.org/tag/antibodies/)
- [next generation](https://vaccinenation.org/tag/next-generation/)
- [intranasal](https://vaccinenation.org/tag/intranasal/)
- [award](https://vaccinenation.org/tag/award/)
- [serotype](https://vaccinenation.org/tag/serotype/)
- [analysis](https://vaccinenation.org/tag/analysis/)
- [cattle](https://vaccinenation.org/tag/cattle/)
- [cow](https://vaccinenation.org/tag/cow/)
- [tick](https://vaccinenation.org/tag/tick/)
- [eradication](https://vaccinenation.org/tag/eradication/)
- [inactivated](https://vaccinenation.org/tag/inactivated/)
- [clinical trial](https://vaccinenation.org/tag/clinical-trial/)
- [ovarian](https://vaccinenation.org/tag/ovarian/)
- [covid19](https://vaccinenation.org/tag/covid19/)
- [menstruation](https://vaccinenation.org/tag/menstruation/)
- [production](https://vaccinenation.org/tag/production/)
- [biosecurity](https://vaccinenation.org/tag/biosecurity/)
- [vaccine hesitancy](https://vaccinenation.org/tag/vaccine-hesitancy/)
- [pharmajet](https://vaccinenation.org/tag/pharmajet/)
- [nasal](https://vaccinenation.org/tag/nasal/)
- [herpes simplex](https://vaccinenation.org/tag/herpes-simplex/)
- [arenavirus](https://vaccinenation.org/tag/arenavirus/)
- [norovirus](https://vaccinenation.org/tag/norovirus/)
- [device](https://vaccinenation.org/tag/device/)
- [std](https://vaccinenation.org/tag/std/)
- [sabin](https://vaccinenation.org/tag/sabin/)
- [government](https://vaccinenation.org/tag/government/)
- [spillover](https://vaccinenation.org/tag/spillover/)
- [chandipura](https://vaccinenation.org/tag/chandipura/)
- [technology transfer](https://vaccinenation.org/tag/technology-transfer/)
- [dementia](https://vaccinenation.org/tag/dementia/)
- [immunology](https://vaccinenation.org/tag/immunology/)
- [brain](https://vaccinenation.org/tag/brain/)
- [dendritic cell](https://vaccinenation.org/tag/dendritic-cell/)
- [endometrial](https://vaccinenation.org/tag/endometrial/)
- [nanoparticle](https://vaccinenation.org/tag/nanoparticle/)
- [immunogenicity](https://vaccinenation.org/tag/immunogenicity/)
- [contract](https://vaccinenation.org/tag/contract/)
- [bladder](https://vaccinenation.org/tag/bladder/)
- [challenge](https://vaccinenation.org/tag/challenge/)
- [animal health](https://vaccinenation.org/tag/animal-health/)
- [livestock](https://vaccinenation.org/tag/livestock/)
- [pheic](https://vaccinenation.org/tag/pheic/)
- [immunocompromised](https://vaccinenation.org/tag/immunocompromised/)
- [rollout](https://vaccinenation.org/tag/rollout/)
- [vaccinia](https://vaccinenation.org/tag/vaccinia/)
- [live](https://vaccinenation.org/tag/live/)
- [effective](https://vaccinenation.org/tag/effective/)
- [needle](https://vaccinenation.org/tag/needle/)
- [transmission](https://vaccinenation.org/tag/transmission/)
- [healthcare](https://vaccinenation.org/tag/healthcare/)
- [bovine](https://vaccinenation.org/tag/bovine/)
- [adolescent](https://vaccinenation.org/tag/adolescent/)
- [education](https://vaccinenation.org/tag/education/)
- [tolerability](https://vaccinenation.org/tag/tolerability/)
- [accessibility](https://vaccinenation.org/tag/accessibility/)
- [plan](https://vaccinenation.org/tag/plan/)
- [deployment](https://vaccinenation.org/tag/deployment/)
- [campaign](https://vaccinenation.org/tag/campaign/)
- [supply chain](https://vaccinenation.org/tag/supply-chain/)
- [effectiveness](https://vaccinenation.org/tag/effectiveness/)
- [america](https://vaccinenation.org/tag/america/)
- [acceptance](https://vaccinenation.org/tag/acceptance/)
- [countermeasures](https://vaccinenation.org/tag/countermeasures/)
- [diagnostics](https://vaccinenation.org/tag/diagnostics/)
- [congenital](https://vaccinenation.org/tag/congenital/)
- [leptospirosis](https://vaccinenation.org/tag/leptospirosis/)
- [acess](https://vaccinenation.org/tag/acess/)
- [multiple myeloma](https://vaccinenation.org/tag/multiple-myeloma/)
- [cdmo](https://vaccinenation.org/tag/cdmo/)
- [progress](https://vaccinenation.org/tag/progress/)
- [meningitis](https://vaccinenation.org/tag/meningitis/)
- [finance](https://vaccinenation.org/tag/finance/)
- [tcv](https://vaccinenation.org/tag/tcv/)
- [asia](https://vaccinenation.org/tag/asia/)
- [grant](https://vaccinenation.org/tag/grant/)
- [roadmap](https://vaccinenation.org/tag/roadmap/)
- [sars](https://vaccinenation.org/tag/sars/)
- [viral vector](https://vaccinenation.org/tag/viral-vector/)
- [diversity](https://vaccinenation.org/tag/diversity/)
- [speed](https://vaccinenation.org/tag/speed/)
- [fast track](https://vaccinenation.org/tag/fast-track/)